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Abstract	
Fragment-based drug design (FBDD) has been rapidly gaining traction in the drug 
discovery process. A central tenant of fragment-based molecular screening is to use less 
sophisticated small molecules to sample chemical space more efficiently. With 
Vemurafenib and Venetoclax as FDA approved therapeutics from FBDD and several 
others in Phase III clinical trials, FBDD is becoming a validated technique for drug 
discovery. However, because of their small size these fragments are likely to bind to their 
target with a low affinity, necessitating more sensitive methods to detect protein-ligand 
interactions during a screen. Nuclear magnetic resonance spectroscopy has emerged as 
one of several powerful biophysical techniques for conducting fragment screens. In this 
thesis, a 19F protein-observed NMR method for detecting bromodomain−ligand 
interactions using fluorine-labeled aromatic amino acids due to the conservation of 
aromatic residues in the bromodomain binding site is described. Therein, we test the 
sensitivity, accuracy, and speed of this method with small molecule ligands. Experiment 
times on the order of a few minutes and the simplicity of the NMR spectra obtained make 
this approach well-suited to the investigation of small- to medium-sized proteins, as well 
as the screening of multiple proteins in the same experiment. Simplified 19F NMR spectra 
allowed for simultaneous testing of multiple bromodomains to assess selectivity and 
identification of a new BPTF ligand. Fluorine labeling only modestly affected the Brd4 
structure and function assessed by isothermal titration calorimetry, circular dichroism, 
and X-ray crystallography.  To benchmark its potential as a ligand discovery tool, we 
compare the protein-observed 19F NMR screening method with the well-characterized 
ligand-observed 1H CPMG NMR screen. We selected the first bromodomain of Brd4 as a 
model system because of the high ligandability of Brd4 and the need for small molecule 
inhibitors of related epigenetic regulatory proteins. We conclude that for the protein class 
understudy here, protein-observed 19F NMR and 1H CPMG have similar sensitivity, with 
both being effective tools for ligand discovery. The speed, ease of interpretation, and low 
  iii 
concentration of protein needed for binding experiments affords a new method to 
discover and characterize both native and new ligands. 
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Preface	
Chapter 1 of this dissertation provides a background on the biological motivations 
of the project, as well as the various biophysical methods utilized. Bromodomains were 
chosen due to the availability of the well-characterized bromodomain of Brd4 coupled 
with the need for chemical probes for the majority of the other bromodomains. In order to 
study these proteins, various biophysical methods to assess structure and function of the 
bromodomains were utilized such as circular dichroism, x-ray crystallography, nuclear 
magnetic resonance spectroscopy (NMR), and others. 
In Chapter 2 of this thesis, a 19F NMR method for detecting bromodomain−ligand 
interactions using fluorine-labeled aromatic amino acids due to the conservation of 
aromatic residues in the bromodomain binding site is described. Therein, we test the 
sensitivity, accuracy, and speed of this method with small molecule ligands (+)-JQ1, 
BI2536, Dinaciclib, TG101348, and acetaminophen using three bromodomains Brd4, 
BrdT, and BPTF. Simplified 19F NMR spectra allowed for simultaneous testing of 
multiple bromodomains to assess selectivity and identification of a new BPTF ligand. 
Fluorine labeling only modestly affected the Brd4 structure and function assessed by 
isothermal titration calorimetry, circular dichroism, and X-ray crystallography. The 
speed, ease of interpretation, and low concentration of protein needed for binding 
experiments affords a new method to discover and characterize both native and new 
ligands. 
The protocol in Chapter 3 describes the sequence-selective labeling of three 
proteins (the first bromodomains of Brd4 and BrdT, and the KIX domain of the CREB-
binding protein) using commercially available fluorinated aromatic amino acids and 
fluorinated precursors as example applications of the method developed by our research 
group. NMR spectroscopy can be used to quantify the binding affinity between proteins 
and low-complexity molecules, termed ‘fragments’; this versatile screening approach 
allows researchers to assess the druggability of new protein targets. Protein-observed 19F-
NMR (PrOF NMR) using 19F-labeled amino acids generates relatively simple spectra that 
  xvii 
are able to provide dynamic structural information toward understanding protein folding 
and function. Changes in these spectra upon the addition of fragment molecules can be 
observed and quantified. Fragment-screening approaches are discussed, as well as Kd 
determination, ligand-efficiency calculations and druggability assessment, i.e., the ability 
to target these proteins using small-molecule ligands. Experiment times on the order of a 
few minutes and the simplicity of the NMR spectra obtained make this approach well-
suited to the investigation of small- to medium-sized proteins, as well as the screening of 
multiple proteins in the same experiment. To further decrease the time of PrOF NMR 
experiments, paramagnetic relaxation enhancement through the addition of chelated 
Ni(II) can be used to shorten longitudinal relaxation time. Enhancing relaxation time 
leads to shorter experiments without perturbing the binding of low- or high- affinity 
ligands. This method allows for time-efficient screening of potential ligands for a wide 
variety of proteins in the growing field of fragment-based ligand discovery. 
Selective inhibition of bromodomain function is a newly proposed therapeutic 
strategy. In Chapter 4, a 19F NMR dual screening method for small molecule discovery 
using fluorinated tryptophan resonances on two bromodomain-containing proteins is 
described. The chemical shift dispersion of 19F resonances within fluorine-labeled 
proteins enables the simultaneous analysis of two fluorinated bromodomains by NMR. A 
library of 229 small molecules was screened against the first bromodomain of Brd4 and 
the BPTF bromodomain. We report the first small molecule selective for BPTF over 
Brd4, termed AU1. The Kd = 2.8 µM for AU1, which is active in a cell-based reporter 
assay. No binding is detected with Brd4. Three new Brd4 inhibitors with submicromolar 
affinity were also discovered. Brd4 hits were validated in a thermal stability assay and 
potency determined via fluorescence anisotropy. The speed, ease of interpretation, and 
low protein concentration needed for protein-observed 19F NMR experiments in a 
multiprotein format offers a new method to discover and characterize selective ligands 
for bromodomain-containing proteins. 
In Chapter 5, to evaluate its potential as a ligand discovery tool, we compare a 
newly developed 1D protein-observed fluorine NMR screening method with the well-
  xviii 
characterized ligand-observed 1H Carr-Purcell-Meiboom-Gill (CPMG) NMR screen. We 
selected the first bromodomain of Brd4 as a model system to benchmark PrOF NMR 
because of the high ligandability of Brd4 and the need for small molecule inhibitors of 
related epigenetic regulatory proteins. We compare the two methods’ hit sensitivity, 
triaging ability, experiment speed, material consumption, and the potential for false 
positives and negatives. To this end, we screened 930 fragment molecules against Brd4 in 
mixtures of five and followed up these studies with mixture deconvolution and affinity 
characterization of the top hits. In selected examples, we also compare the environmental 
responsiveness of the 19F chemical shift to 1H in 1D-protein observed 1H NMR 
experiments. To address concerns of perturbations from fluorine incorporation, ligand 
binding trends and affinities were verified via thermal shift assays and isothermal titration 
calorimetry. We conclude that for the protein understudy here, PrOF NMR and 1H 
CPMG have similar sensitivity, with both being effective tools for ligand discovery. In 
cases where an unlabeled protein can be used, 1D protein- observed 1H NMR may also be 
effective; however, the 19F chemical shift remains significantly more responsive. 
A key necessity of PrOF NMR, is resonance assignment of the protein’s 19F NMR 
spectrum for structural analysis. In Chapter 6, a quantum chemical method has been 
developed as an initial approach to facilitate the assignment of a fluorinated protein’s 19F 
NMR spectrum. The epigenetic “reader” domain of protein Brd4 was taken as a case 
study to assess the strengths and limitations of the method. The overall modeling protocol 
predicts chemical shifts for residues in rigid proteins with good accuracy; proper 
accounting for explicit solvation of fluorinated residues by water is critical. 
Together these initial findings in this thesis describe my contributions to the field 
of fragment-based ligand discovery through development of a new protein-based 19F 
NMR biophysical technique. 
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Chapter	1. Introduction	
1.1 Epigenetics 
Epigenetics is the study of mitotically and meiotically heritable changes in gene 
function that are not solely-dependent on DNA sequence.1 Every cell in a human body 
contains the same DNA sequence in the nucleus, but each can exhibit different 
phenotypic properties. These differences are in part due to epigenetic factors, and so the 
ability to modulate these factors bestows control over biological systems. Dysregulation 
of these factors is frequently implicated in disease, such as cancer,2 heart disease,3 and 
inflammation4. Epigenetic mechanisms include RNA transcription, nucleosome 
positioning, DNA modification independent of nucleotide sequence, and covalent 
chromosomal modifications. The biological motivations of this work focus primarily on 
covalent chromosomal modifications. 
A critical factor in determining whether DNA is expressed or not is the 
accessibility of the chromatin environment.5 Euchromatic environments, where DNA is 
not coiled around histone proteins, are generally accessible while heterochromatic 
environments, where DNA is coiled around histone proteins, are generally inaccessible. 
To compact DNA sufficiently to fit within the nucleus of a cell, DNA is tightly folded 
and constrained by histone and nonhistone proteins in a dynamic polymer called 
chromatin. Chromatin organization is dependent on higher order structure with the basic 
repeating unit of nucleosomes. Each nucleosome is roughly two superhelical turns of 
DNA wrapped around an octamer core of histone proteins. While wrapped in the 
chromatin and nucleosome complex, DNA is transcriptionally inert.6 In order to regulate 
whether or not DNA is accessible, and consequently whether portions of DNA are 
expressed, amino acid side-chains of histones can be covalently modified. Such 
modifications include acetylation, methylation, phosphorylation, glycosylation, 
crotonylation, and citrullination, among others (Figure 1.1).7 Modification of these tails is 
highly selective for specific amino acid sequences.8,9 Heritable and reversible changes to 
histone tails have also been observed to occur.10 
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Figure 1.1 Example posttranslational modifications of lysine. 
 
The mechanism of histone modifications regulating DNA expression has been 
termed the Histone Code Hypothesis.11 The installation, removal, and recognition of 
histone modifications is facilitated by the colloquially termed “writers”, “readers”, and 
“erasers”. A small subset of these regulatory proteins work with acetylation and 
methylation of lysine sidechains. Writers, such as histone acetyltransferases (HATs), and 
histone methyltransferases (HMTs), post-translationally modify histones with functional 
groups such as methyl or acetyl groups. Readers, such as bromodomains and 
chromodomains, recognize the post-translational modifications made by the writers, and 
moderate DNA transcription. Erasers, such as histone deacetylase (HDAC) and histone 
demethylase (HMD) remove the marks made by HATs and HMTs respectively.11 
1.2 Bromodomains 
Bromodomains act as readers of acetylated-lysines of histones, playing an integral 
role in DNA transcription. There are 46 distinct human proteins containing a total of 61 
bromodomains (Figure 1.2).12 All bromodomain modules share a conserved fold 
comprising a left-handed bundle of four α-helices (αZ, αA, αB, αC) linked by loop regions 
(ZA and BC loops) that contribute to substrate specificity. X-ray co-crystal structures 
with peptides containing acetylated-lysine residues show that the binding site is a central 
hydrophobic cavity with the acetylated-lysine anchored with a hydrogen bond to a highly 
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conserved asparagine residue (e.g, N140 of Brd4, Figure 1.3). The loop regions 
surrounding the acetylated lysine binding site are shown to have high conformational 
flexibility by computational dynamics studies.13 Despite the highly conserved fold of the 
bromodomains, their surface properties around the acetylated-lysine binding site are 
highly diverse. The electrostatic potential of the surface area around the binding site 
ranges from highly positively charged (+10 kT/e (electrostatic potential; k ≡ Boltzmann’s 
constant, T ≡ temperature, e ≡ charge of an electron)) to strongly negatively charged (-10 
kT/e).12 Often the bromodomain motif is flanked by other epigenetic regulatory proteins, 
including plant homeodomains (PHD), other bromodomains, and even histone 
acetyltransferases. 
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Figure 1.2 A phylogenetic tree of the 61 human bromodomains. 
This plot clusters proteins by sequence similarity. The primary proteins under study in 
this dissertation are highlighted with stars. Bromodomains with a chemical probe (potent, 
selective, and cell active) with an IC50/Kd/Ki < 0.5 µM are highlighted with a square. This 
figure was generated using ChromoHub.14 
 
 
 
 	
  5 
 
Figure 1.3 The first bromodomain of Brd4.  
This is an x-ray structure of the first bromodomain of Brd4 bound with a histone peptide 
containing an acetylated lysine. Various structural areas are labeled. PDB ID: 3UVW 
 
Bromodomains have been evidenced to play a role in inflammation, obesity, and 
cancer.15 They were long viewed as undruggable, as were most protein-protein 
interactions due to the interface being large, featureless, and lacking an initial natural 
substrate as a starting place.16 DMSO also binds in the acetylated-lysine binding site 
which would convolute high throughput screens in which the molecules are dissolved in 
DMSO stocks. Despite this view, in 2010 two BET bromodomain inhibitors were 
developed, JQ1 (Kd= 50 nM)13 and I-BET (Kd= 55.2 nM)17. The molecule JQ1 has been 
used to study the BET (Bromodomain and extraterminal) bromodomains, but it does not 
have high specificity toward any one BET bromodomain. It cannot yet be unambiguously 
determined which bromodomain interaction is leading to specific phenotypes because an 
inhibitor that only targets a single bromodomain has not been disclosed. Of the 46 
bromodomain containing proteins, 14 have been targeted with modest degrees of affinity 
and selectivity, (CBP, Brd2(1), Brd2(2), Brd3(1), Brd3(2), Brd4(1), Brd4(2), BrdT(1), 
BrdT(2), BPTF, Brd7, Brd9, BAZ2B, EP300).18 Chemical probes that target a specific 
BET bromodomain, as well as probes to target the rest of the 61 bromodomains, are 
needed. Despite the few small-molecule inhibitors known for bromodomains at the time, 
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analysis using Schrödinger’s SiteMap by Vidler et al. suggested that thirteen 
bromodomains are characterized with high druggability, with five more being suggested 
as moderately druggable.19 The BET bromodomains are included in the category of being 
druggable, which fits with the SiteMap analysis because small-molecule inhibitors have 
been found for these bromodomains. Other bromodomains, such as the BPTF 
bromodomain (also known as fetal Alz-50 clone 1 protein (FALZ)), were predicted to be 
highly druggable. This lack of inhibitors motivated us to choose the bromodomain of 
BPTF as our protein target as described further in Chapter 4. 
Structural biology efforts by both NMR and x-ray crystallography have provided 
detailed atomic level information for guiding designs of small molecules inhibitors as 
well as a characterize native histone interactions. As mentioned previously, the 
bromodomains contain a hydrophobic pocket to recognize acetylated lysines which can 
vary substantially in composition.20 Using NMR structural analysis, the seminal study by 
Dhalluin et al. concluded that ligands binding to the bromodomain of PCAF (a 
bromodomain part of the same family as BPTF) frequently make significant contact with 
the side chains of three tyrosine residues in the binding site (Y809, Y802, Y760).20 The 
acetylated-lysine of the ligand forms a water-mediated hydrogen bond with a highly 
conserved asparagine residue (N803),19  results which were further confirmed by x-ray 
crystallography (Figure 1.4).21 All of these residues are highly conserved across 
bromodomains, making fluorinated tyrosine residues an appealing target for binding 
analysis by PrOF NMR as described in Chapter 2. While the inner regions of the 
acetylated-lysine binding pocket are largely hydrophobic, the electrostatics of the surface 
vary among bromodomains. As such, the surface surrounding the pocket of the 
acetylated-lysine binding site is postulated to be the ideal area to target to affect 
selectivity between the various bromodomains.22 
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Figure 1.4 Tyrosine and tryptophan residues in the binding site of Brd4. 
The percentages represent the conservation of aromatic amino acids at the homologous 
position in the bromodomain family. 
 
The surface of the acetylated-lysine binding pocket contains a tryptophan-proline-
phenylalanine sequence, known as the WPF shelf. This shelf is present in many 
bromodomains, including Brd4 and BPTF, and is always near the acetyl-lysine binding 
site, though does vary in that distance between different bromodomains. In Brd4, the 
WPF shelf is within 7 Å of the acetylated lysine itself, but being near the opening of the 
binding site, it is frequently under 4 Å from a heavy atom in a binding ligand. 
Additionally, b-factor analysis of x-ray crystal structures of BPTF indicate greater 
dynamics and flexibility of the WPF shelf tryptophan, indicating that it is likely closer to 
the binding site at times than the static structure would indicate. The WPF shelf has been 
known to also participate in dual binding of acetylated-lysine ligands, wherein one 
acetylated-lysine binds in the standard binding pocket, while one will bind to the 
tryptophan residue on the WPF shelf (Figure 1.5).23 
  8 
 
Figure 1.5 The bromodomains of BPTF (Left) and Brd4 (Right) colored by b-factor. 
More red indicates greater flexibility while more blue indicates greater rigidity. The 
explicitly shown tryptophan residues have a higher b-factor, indicated greater dynamics 
of that sidechain than the amide backbone of the protein. The spheres indicate the 
acetylated-lysine binding site. 
 
1.2.1 The bromodomain of Brd4 
Bromodomain containing protein 4 (Brd4) is a BET bromodomain, dysregulation 
of which has been linked with various diseases. It contains two bromodomains, BD1 and 
BD2. It was initially identified in purifications of mammalian Mediator complex, which 
links transcription factors to the Pol II C-terminal domain.24 Brd4 has been found to be 
overexpressed in breast cancer biopsies, with Brd4 transcriptional signatures directly 
correlating to the rate of disease progression.25 Brd4 dysregulation has also been 
implicated in nuclear protein in testis (NUT) midline carcinoma.26 Consistent with these 
observations, JQ1 treatment significantly inhibited tumor growth in mice in two models 
of NUT midline carcinoma.13 Additionally, a small hairpin RNA screen identified Brd4 
as playing an essential role in leukemia.27 
Molecules repurposed from the kinase inhibitor field were found to act as 
privileged scaffolds for bromodomain inhibition. Dinaciclib was the first disclosed kinase 
inhibitor with activity toward Brd4,28 followed up by several more extensive studies that 
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found many kinase inhibitor and kinase-inhibitor-like molecules with activity toward 
bromodomains.29,30 Though there are currently no published small molecules that are 
selective for Brd4 exhibiting submicromolar potency, there are many molecules that 
target the general BET-family. Such structures include isoxazoles,31 triazoles,13,17 
amidines,32 ureas,32,33 and oxadiazoles.32 Additionally, because the natural substrate of 
Brd4 is acetylated-lysine residues on histone tails, histone peptides containing acetylated-
lysine also bind Brd4 with appreciable affinity (Table 1.1). The more acetylated-lysines 
the histone peptides contain, the tighter the affinity tends to be with the bromodomain of 
Brd4. 
Table 1.1 Peptide Mimetic Binders for Brd4-BD1 
Histone	Mimic	
Kd	(μM)	for	
Brd4-BD1	 Full	Sequence	 Method	
H4K5/8/12/16	 2.8	±	0.2	 YSGRGKacGGKacGLGKacGGAKacRHRK	 ITC34	
H4K12/16/20	 20.4	±	0.8	 GKacGGAKacRHRKacV	 ITC34	
H4K8/12	 27.4	±	0.9	 GKacGLGKacGGAKR	 ITC34	
H4K5/8	 38	±	3.7	 GRGKacGGKacGLGKG	 ITC35	
H4K12/16	 46.1	±	0.9	 GKacGGAKacRHRKV	 ITC34	
H4K8	 84.7	±	9.2	 RGKGGKacGLGKGY	 ITC12	
H3K14	 118	±	28	 GGKacAPRKQ	 ITC35	
H3K9	 301	±	40.9	 KQTARKacSTGGKY	 ITC12	
H4K12	 650	±	11	 SGRGKGGKGLGKacGGAK	 NMR12	
H4K5	 810	±	57	 SGRGKacGGKGLGKGGAK	 NMR34	
 
1.2.2 BPTF 
Bromodomain PHD finger transcription factor (BPTF) is a protein that contains 
both a bromodomain and a planthomeo domain (PHD) finger, for which no small 
molecule inhibitors were known prior to our study. Originally isolated in Drosophila, 
BPTF is the largest member of the Nucleosome Remodeling Factor complex (NURF), 
which was shown through in vivo whole genome expression studies to regulate 
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transcription of several hundred Drosophila genes.36 Human NURF contains homologues 
of three of the four NURF components in Drosophila, including BPTF.37 It has also been 
found that BPTF is overexpressed in various human tumors, such as lung cancers. 
Knockdown of BPTF production resulted in reduced embryonic lung cancer cell 
proliferation.38 Since then, BPTF has been correlated with various disease states, 
including heart disease, melanoma,39 lung cancer,38 Alzheimer’s,40 gastric and colorectal 
cancers41 (Figure 1.7). While the direct role of BPTF in cancer has not been 
unambiguously elucidated, Real et al. has shown that BPTF is required for c-myc 
transcriptional activity in tumor cells.42 Additionally, BPTF has been correlated to roles 
in spermatogenesis,43 hematopoiesis,44 and essential roles in mouse embryonic 
development45.  
 
Figure 1.6 Bar representation of the BPTF protein. 
The bromodomain and PHD fingers are explicitly shown. The bromodomain is a small 
fraction of the overall protein. The entire BPTF protein weighs 338 kDa, with the 
bromodomain portion weighing 14 kDa (4% of total protein weight). 
 
Because BPTF contains a PHD finger, studies involving gene knockdown of 
BPTF do not offer specific information as to whether the PHD finger or the 
bromodomain of BPTF is responsible for any phenotypic changes resulting from the 
knockdown of BPTF.  A selective inhibitor of the acetylated-lysine binding site of the 
BPTF bromodomain would allow for greater elucidation into the specific rolls BPTF 
plays in various diseases, including lung cancer. 
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Figure 1.7 A timeline of BPTF research. 
1.2.3 Targeting bromodomain protein-protein interactions 
The Histone Code Hypothesis, along with other epigenetic and biological aspects, 
involves protein-protein interactions (PPIs). There are an estimated 650,000 protein-
protein interactions in the human body,46 with an estimated 23,000 proteins encoded in 
human DNA. This means each protein is involved with an average of 27 protein-protein 
interactions. PPIs are challenging drug targets, often characterized as large, featureless, 
and shallow interfaces. Nevertheless, there are sometimes hotspot amino acids involved 
in PPIs that contribute large fractions (usually greater than 1.0 kcal/mol) to the Gibb’s 
Free Energy of a binding interaction.47 Normalizing for the natural abundance of amino 
acids in proteins, the tryptophan, tyrosine, and arginine are the most likely residues to be 
at a protein-protein interface.48 The aromatic amino acids are also the most likely to act as 
hotspots in α-helical peptide-protein interactions, often contributing ~3.0 kcal/mol to the 
binding energy.49  
Despite their challenging nature, small molecules have been successfully used to 
modulate PPIs. Nutlin-3 is one of the more prominent examples, successfully binding 
mouse double minute 2 homolog (MDM2) to activate the p53 pathway in cancer cells.50 
Recently, the AbbVie compound Venetoclax was approved by the FDA and is the first 
small molecule by which the primary mechanism is inhibition of a protein-protein 
interaction involving Bcl-2.51 PPIs represent valuable therapeutic targets, but there are 
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many PPIs that do not yet have known small molecule binders due to the inherent 
difficulty of finding a small molecule that can mimic a protein. It is challenging to 
configure assays that effectively identify inhibitors of PPIs, requiring new technologies 
and screening methodologies to better enable the discovery of new drugs to modulate 
PPIs, including bromodomains.52 
Because until 2010 there were no potent (i.e., submicromolar Kd) known small-
molecule inhibitors for bromodomains, there were limited biophysical assays available 
with which to assess bromodomain-ligand interactions. Methods that rely on competitors, 
such as fluorescence polarization or “spy” based NMR experiments, were not useful for 
this target class due to not having potent small-molecule inhibitors. Jay Bradner disclosed 
JQ1, with off-target effects to other bromodomains assessed by thermal shift assays and 
α-screen. Thermal shift assays measure the melting temperature of a protein in presence 
and absence of ligand, and assume that the favorable binding energy of a ligand will 
increase the required temperature to denature the protein. While thermal shift assays tend 
to be poor at rank-ordering affinities among different ligands, for bromodomains the 
correlation tends to be modestly high. An α-screen assay attaches protein and a known 
ligand to separate beads which fluoresce when near each other. If an added molecule 
displaces the control ligand, the beads move away from each other and the decrease in 
fluorescence can be measured. The α-screen assays were enabled by using a truncated 
histone tail containing acetylated-lysine, the natural substrate of bromodomains. While 
the affinity for the histone tails is low, the high density of histone tail peptides on the 
beads allows for an avidity effect, heightening the sensitive of the assay. Thus, α-screen 
was still useful as a basic competition experiment. Direct binding was then verified and 
quantified by isothermal titration calorimetry.13 
Due to the increased efforts to inhibit bromodomains in the past several years, 
there are now many inhibitors available for several different bromodomains. 
Bromosporine offers a general bromodomain inhibitor, potentially allowing general 
access to competition experiments for various biophysical assays such as fluorescence 
polarization as well as competition NMR experiments (Figure 1.8).53 
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Figure 1.8 Chemical structures of bromodomain binders (+)-JQ1 and 
bromosporine. 
 
1.3 Fragment-based drug design 
The principle purpose of drug discovery and development is to identify molecules 
that interact strongly with biomolecules to produce a desired biological response.54 This 
initially took the form of phenotypic drug discovery, which requires no prior knowledge 
of the desired biological target nor its function. The majority of current drug targets are 
G-protein-coupled receptors, nuclear receptors, ion channels, and enzymes; all of which 
were initially targets of phenotypic drug discovery approaches. With the advent of 
genomics and proteomics, biological target identification has been greatly accelerated. 
The opportunity is now present to efficiently interrogate the role of certain proteins in a 
given disease state, and better allows for a target-first strategy of drug design. New 
approaches to target-first drug discovery often take the forms of structure-based drug 
design, or fragment-based drug discovery. 
Over the last 20 years, fragment-based drug discovery has been gaining increasing 
traction in the pharmaceutical industry. Over 30 drug candidates derived from fragments 
have entered the clinic, with two approved and several currently in advanced clinical 
trials.55–57 Fragment based drug discovery offers a method to sample a broader area of 
chemical space, compared with high throughput drug screening. A report in Medicinal 
Research Reviews states the total possible combination of small drug-like molecules (<31 
atoms with only C, N, O, S, and H) is 1063; as such, sampling a substantial fraction of that 
space is extremely challenging.58–60 High-throughput screens sometimes test up to two 
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million compounds.61 Even large screens such as these result in only a small percentage 
(10-52) of chemical space being sampled. Indeed, despite the ability to screen millions of 
compounds, high-throughput screens will at times yield very few hits, or actives that are 
false positives.62 While the space tested can be made more effective by rationally 
choosing categories of molecules (i.e. privileged scaffolds), in combination with 
computational docking studies, serendipity is still a substantial factor in whether or not a 
useful molecule is screened. A more effective way to increase the amount of chemical 
space being sampled is to screen with less complex molecules; fragments.63 A fragment 
screen will sample a greater amount of potential chemical space with each compound 
than the more complex, and consequently more specific molecules utilized in a high-
throughput screen. Molecular weight is often a proxy for complexity, so fragment 
libraries tend to contain molecules with a weight < 300 g/mol. This is encompassed in the 
fragment “Rule of three”  which specifies molecular weight < 300, the number of 
hydrogen bond donors is ≤ 3, the number of hydrogen bond acceptors is ≤ 3, and clogP 
(computational derived octanol-water partition coefficient) is ≤ 3.64 Of particular 
importance for fragments due to their likely low affinity for targets is high water 
solubility to enable high screening concentrations. Additionally, a strong advantage of 
fragment screening over high-throughput screening is that due to the simplicity of the 
molecules being screened, there is lower probability that a specific steric interaction will 
prevent an otherwise favorable molecule from binding to the desired binding site. 
Fragments are less sophisticated than the compounds utilized in high-throughput 
screening, and bind more weakly than compounds used in high-throughput screening. 
Thus, fragment screening requires more lead optimization, as the hits from such a screen 
will have low dissociation constants initially (typically between 50 µM and 1 mM)65, 
requiring a substantial amount of work to modify the hits into a molecule that binds with 
high affinity.66 
The two FDA approved therapeutics derived from fragment based drug design are 
Vemurafenib55 and Venetoclax56 (Figure 1.9). Vemurafenib targets BRAF and is a 
treatment for melanoma, and is elaborated from an initially identified azaindole fragment. 
Venetoclax is the result of the seminal work in protein-observed NMR screening 
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disseminated by Abbott Laboratories, and targets BCL-2 to treat lymphoma.67 A linking 
strategy between two fragments was used to develop Venetoclax, and 20 years passed 
between initial discovery of the fragments and FDA approval. The substantial time 
required casts doubt on the efficacy of linking fragments to develop high-affinity 
inhibitors, and consequently compound elaboration continues to be the more common 
method to develop lead compounds from fragment hits. 
 
Figure 1.9 Structures of the two FDA approved drugs derived from fragments. 
1.4 The role of biophysical assays in FBDD 
One of the major disadvantages of fragment screening compared with high-
throughput screening is the increased sensitivity of detectors required for sufficient 
analysis. Because of this, traditional phenotypic screens as well as biochemical screens 
frequently lack the required sensitivity to effectively conduct a fragment screen. 
Biophysical assays satisfy these increased requirements for sensitivity, and have been 
rapidly adapted to allow for increasing automation for use in screen. The classical 
fragment screening methods are NMR spectroscopy, surface plasmon resonance (SPR), 
and x-ray crystallography. Recent developments such as thermal shift assays (TSA) and 
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microscale thermophoresis (MST), have successfully been used to analyze fragment 
binding and are also amiable for screening. 
1.4.1 NMR spectroscopy 
 
Due to the high-responsiveness of NMR spectroscopy, NMR experiments were 
the first methods utilized for fragment screening. Since the initial reports from Abbott 
Laboratories, NMR has become increasingly utilized in the drug discovery process as 
both a primary screening technique and as a follow-up assay.67 The wealth of information 
provided, as well as the ability to perform both protein- and ligand-observed experiments 
make NMR an incredibly versatile tool in the drug discovery process. The recent advent 
of cryo-probe technology has allowed NMR screening to be a realized technique, with the 
capability to conduct protein-observed NMR experiments at modest concentrations (< 70 
µM) in under ten minutes.68 As the low-hanging fruit in the realm of drug discovery 
grows increasingly barren, techniques with greater response are required to enable 
screening of different libraries. Ligand- and protein-observed NMR techniques rank 
among the most responsive biophysical assays currently available.69 
Ligand-observed NMR experiments have been widely used in both academics and 
the pharmaceutical industry as a rapid screening technique. These methods take two 
forms, observing the ligands directly, and observing a bound ligand’s displacement as a 
competition experiment (the “spy” molecule approach).70 The ligand-observed CPMG 
method detects ligand-binding interactions as a function of drop in signal intensity 
(Figure 1.10). While any nucleus present in the molecules in the library can theoretically 
be observed, this most often takes the form of 19F CPMG or 1H CPMG. Fluorine CPMG 
is widely used and effective, but a disadvantage is the requirement that fluorine be 
present in the ligands used for the screen, reducing the span of chemical space that can be 
sampled. Proton CPMG can be used to overcome this shortfall, with the disadvantage that 
fragment molecules will usually have many more protons than fluorine nuclei, increasing 
the difficulty of data interpretation and likelihood of ligand signals overlapping. Due to 
the hyper-responsiveness of the 19F chemical shift to changes in the atom’s local 
chemical environment, in some cases a simple 1-dimensional ligand-observed NMR 
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experiment is sufficient to assess target engagement. A recent report from Amgen 
describes a 19F NMR screen against β-secretase that resulted in significant ligand 
resonance broadening upon interaction with the BACE protein.71 
 
Figure 1.10 A diagram of a CPMG screen. 
Because the ligand resonances are observed it is immediately known which ligand is 
responsible for the binding interaction. 
 
The two other common ligand-observed NMR screening methods are saturation 
transfer difference (STD), and WaterLOGSY.72 Both techniques are based on 
intermolecular nuclear Overhauser effects (NOEs) to transiently bound 1H atoms. 
WaterLOGSY excites bulk water and transfers the magnetization to bound water, and 
then to bound ligand. STD selectively excites the protein (usually irradiating upfield of 0 
ppm), saturating the bound ligand due to the effective spin diffusion across large 
molecules (Table 1.2). These methods also allow for epitope mapping, as 1H resonances 
from atoms that interact with the ligand should be effected more than those farther 
away.73 A distinct advantage of STD and WaterLOGSY over CPMG is that the first two 
methods can be accomplished in a single NMR tube with no follow-up experiments. With 
CPMG, after the initial spectrum is collected protein must then be added, and a 
subsequent spectrum acquired. CPMG tends to be more sensitive, but the additional steps 
slow the time of screening and adds additional labor time as liquid handling capabilities 
for the protein addition are less common. 
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Protein-observed NMR methods have become valued for the ability to quantify 
binding interactions over a wide range of affinities, including particularly weak ligands. 
While protein-observed 1H-15N HSQC methods are limited by protein size (generally < 
40 kDa),74 pulse sequences such as TROSY have increased this limit to greater than 100 
kDa when using high-field magnets,75 although a deuterated protein is typically 
employed. With protein-observed NMR techniques a perturbation of protein NMR 
resonance is observed between the bound and unbound state, thus allowing a dissociation 
constant to be determined using protein-observed methods if the interaction exhibits a 
fast chemical exchange rate, commonly found for low affinity ligands.  Protein-based 
methods using labeled amides (e.g., 1H−15N HSQC) provide additional structural 
information for developing small molecules; however, the experiment can be material-
intensive and time-consuming. A valuable strength of protein-observed NMR is the 
ability to obtain accurate dissociation constants of low-affinity ligands by ligand titration 
while monitoring the dose dependent perturbation of protein resonances. Additionally, 
the chemical shifts of the protein resonances allow for additional structural assessments. 
In this context, well-dispersed resonances provide an indication that the protein is in 
solution and not aggregated. The location of the resonances can offer a “fingerprint” of 
the protein, and substantial resonance deviation from this fingerprint can indicate large 
conformational changes. This serves to act as an in situ quality control for the protein 
NMR assays, reducing false positives and negatives. 
Structure-activity relationship (SAR) by NMR is a method for monitoring binding 
interactions utilizing NMR techniques. Traditional SAR by NMR involves the 2D 
technique heteronuclear single quantum correlation (HSQC) to monitor the changes in 
chemical shifts of the amide backbone of proteins, and was initially described in the 
seminal SAR by NMR paper from Abbott Laboratories.67 When the chemical 
environment of the amides in a protein change, different resonances result from the 
amides, producing different 2D NMR spectra and providing binding information. Using a 
least squares analysis determines the degree of difference between the two spectra, 
presumably bound and unbound. Additional information can be gleaned from the spectra 
by assigning each resonance, and then determining specifically which amides within the 
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protein are experiencing a difference in chemical environment upon binding. This method 
will help determine how the protein changes as a function of binding, but does not 
unambiguously identify the location of the binding site. The amide resonances can shift 
due to a nearby binding interaction, but can also shift if that binding interaction is 
inducing a change in the conformation of the protein away from the binding site. A 
disadvantage of SAR by NMR is that it is slow, reducing its utility in screening 
techniques.66 
 
Table 1.2 A table comparing the different NMR screening methods. 
Method Parameter 
observed 
Physical cause 
Protein-observed 
NMR 
Chemical shift 
perturbation 
Perturbation to local chemical 
environment 
CPMG Decrease in bound 
ligand resonance 
intensity 
Ligand exhibiting rotational correlation 
time corresponding to the protein 
STD Ligand resonance 
intensity correlates 
with distance to the 
protein surface 
NOE transferred from protein to bound 
ligand 
WaterLOGSY Phase inversion of 
bound ligand 
resonances 
NOE transferred from bulk water to 
protein-bound water to bound ligand 
 
1.4.2 Surface plasmon resonance 
 
Surface plasmon resonance (SPR) is the other most widely used technique for 
fragment screening.76 SPR requires immobilization of the target protein to a sensor chip, 
often achieved by either bioconjugation reactions or by affinity tags. Because the protein 
is immobilized, very little protein is consumed during an SPR screen. Changes in mass at 
the interface of the chip are detected by changes in the angle of incidence from plane-
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polarized light. While the mass fraction difference used to be limiting, modern SPR 
instruments have no restriction on ligand size for analysis. 
SPR techniques are unique in that they allow monitoring of protein-ligand 
interactions in real-time, and thus SPR is one of the few methods by which binding 
kinetics can be elucidated. While measuring kinetics in principle allows determination of 
affinity, in practice kinetics on the order of the rate of diffusion (1 x 108 M/s) are 
challenging to detect. Due to this limitation, a titration experiment will often be used with 
fragments to determine a dissociation constant. 
1.4.3 X-ray crystallography 
 
Though x-ray crystallography is primarily viewed as a technique for structure 
determination, the high solubility of fragments frequently enables a soaking system to 
generate co-crystals of protein and ligand. Fragment screening by x-ray crystallography 
was pioneered by Astex Pharmaceuticals.77 A key advantage of crystallographic 
screening is that necessarily a crystal structure is obtained, allowing rational design for 
further fragment elaborations as well as verification of the binding site. However, x-ray 
crystallography provides no indication of binding affinity, substantially reducing the 
ability to triage actives. The active rate of crystallographic screening is also limited to 
proteins that crystallize readily, and will frequently have lower active rates than other 
biophysical techniques. However, while crystallographic screening frequently results in 
false negatives, it is exceptional at avoiding false positives because the presence of 
electron density corresponding to the ligand unambiguously verifies that the ligand bound 
in an organized manner. 
1.4.4 Thermal shift assays for fragment screening 
 
Thermal shift assays take advantage of the principle that favorable binding 
interactions tend to require greater energy to disrupt. The temperature at which a protein 
denatures will be increased due to the favorable binding interaction, allowing rank-
ordering of ligands by the degree to which they stabilize the protein. While differential 
scanning calorimetry (DSC) offers a label-free technique to assess melting temperature as 
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well as derive thermodynamic parameters, the throughput of DSC precludes it from 
effective fragment screening. Differential scanning fluorimetry (DSF) dramatically 
increases the throughput of the assay, allowing thousands of compounds to be screened in 
a day with minimal protein consumption. DSF involves the incorporation of a fluorescent 
dye such as Sypro-Orange. An effective DSF dye will undergo fluorescence quenching in 
the presence of water, and also bind to the accessible hydrophobic patches of a denatured 
protein. When the protein is thermally denatured, the fluorescent dye will interact with 
the protein and consequently be less solvated by water, which will reduce the 
fluorescence quenching and result in an increase in fluorescence. 
Despite being a label-free technique, fluorescent dyes have been reported to 
interact with proteins, ligands, and surfactants.78 Dye interaction with the protein can 
stabilize either the folded or thermally-denatured form, potentially shifting the melting 
temperature in either direction. Dye interaction with the ligand will usually preclude 
ligand binding, and interaction with surfactant will result in very high background signal. 
Additionally, a given ligand can interact with the thermally-denatured protein, resulting 
in a decrease in the melting temperature. All of these phenomenon make DSF very prone 
to false-positives and false-negatives. Rank-ordering by DSF can also be problematic. 
The degree of binding is determined at the melting temperature of the protein, usually 
higher than relevant biological temperatures. The entropic nature of the binding 
interaction also plays a greater role in melting temperature than the enthalpic portion.79 
Nonetheless, for certain classes of proteins DSF works very well and effectively rank-
orders ligands, and has the highest throughput of the modern fragment screening 
techniques. 
1.4.5 Microscale thermophoresis 
 
Microscale thermophoresis (MST) is an emerging fragment screening technique, 
first being described to assess ligand binding in 2012.80 The movement of molecules in a 
temperature gradient is dependent on size, charge, and solvation entropy. Microscale 
thermophoresis exploits this phenomenon by heating a small portion of the sample with 
an infrared laser, and measure the rate of diffusion by monitoring fluorescence. The 
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fluorescent signal can either be from the intrinsic fluorescence of one or more tryptophan 
residues, or from an attached fluorophore. Because the primary signal is fluorescence, 
very low concentrations of protein can be used (< 1 µM). Due to the low concentrations 
allowed, problems arising due to solubility or aggregation of the protein or ligand can 
generally be avoided with MST. Accurate dissociation constants can be rapidly 
determined with a serial dilution of ligand, and aggregation of either ligand or protein can 
be readily observed in the thermophoresis signal.81 
1.5 Protein-observed Fluorine NMR 
Both the ligand and drug discovery fields have been increasingly taking 
advantage of 19F NMR as a biophysical technique for exploring perturbations to protein 
structure as well as characterizing protein-ligand and protein-protein interactions. The 
organic fluorine has been eloquently entitled the “odd man out” from the rest of the 
organic compounds.82 While the most abundant halogen in the earth’s crust, fluorine is 
rarely found in biological systems. The fluoride ion has a very high redox potential, and 
many fluorine-containing minerals are insoluble in water, reducing the ability of fluorine 
to be present in living organisms.83 It is estimated that there are between six84 and one-
hundred83 known natural products that contain fluorine.  Because of this, fluorine is an 
ideal atom to use as an NMR probe when studying biomolecules because there are no 
background signals from the biologics under study, and common buffer additives such as 
detergents generally do not contain fluorine. 
Nuclear magnetic resonance of fluorine nuclei offers a highly sensitive method 
for observing changes in chemical environment due to a binding interaction. The NMR 
active 19F atom is the only stable isotope of fluorine, simplifying incorporation because 
low abundance isotopes are not necessary for this NMR analysis. Additionally, fluorine 
has the third highest gyromagnetic ratio of the NMR active nuclei, exceeded only by 
proton and tritium (Table 1.3). Fluorine signals appear as singlets when a proton 
decoupling sequence is utilized, so if need be, this can be utilized to further increase 
signal intensity when working with small molecules.70 These factors, coupled with the 
newly acquired cryo-prodigy probe allow for rapid (less than 5 minutes) acquisition of 
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PrOF NMR spectra (Figure 1.11). Because the method of observing binding interactions 
or conformational changes is generally based on chemical shift, a reduced signal to noise 
ratio is required compared to integration based analysis. This is explained further in 
Chapter 5. 
 
Figure 1.11 19F NMR spectra of 5FW-Brd4 taken at various experiment times.	
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Table 1.3 Properties of NMR Nuclei85 
Nucleus Gyromagnetic Ratio (MHz/T) Natural 
Abundance 
3H 45.557 trace 
1H 42.577 99.98% 
19F 40.053 100% 
31P 17.235 100% 
13C 10.705 1.11% 
17O 5.772 0.0373% 
15N -4.316 0.37% 
 
The resonances of fluorine are highly sensitive to changes in chemical 
environment, with a range of chemical shifts spanning over 300 ppm.85 Such a large 
range results in a low probability of overlapping peaks, simplifying interpretation of 
NMR spectra. Additionally, the resonances corresponding to fluorinated tryptophan, 
tyrosine, and phenylalanine, are all predominantly located in different regions of the 
spectrum, allowing labeling with multiple aromatic amino acid types without concern for 
overlapping peaks (Figure 1.12).86 
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Figure 1.12 PrOF NMR spectra of proteins containing fluorinated amino acids. 
The 19F spectra of the different aromatic amino acids appear in distinct regions and do not 
overlap. 
 
PrOF NMR has been used for over 40 years to assess protein conformational 
perturbations, beginning with the seminal work on alkaline phosphatase,87 and even being 
expanded to the 380 kDa ATPase88. Because the side-chains are labeled with fluorine, 
proteins of very large size or restricted mobility are still able to be assessed by PrOF 
NMR. Labeling of the β2-adrenergic receptor, a membrane bound protein, with 2,2,2-
trifluoroethylcysteine disulfide resulted in resolvable resonances that allowed studying of 
conformational changes.89 Despite the responsiveness of fluorine-labeled proteins, until 
very recently PrOF NMR was not utilized for ligand discovery. Only the recent 
developments of cryo-probe technology have enabled sufficiently rapid 19F NMR 
experiments to allow for screening by this method. 
The chemical shifts of fluorine nuclei resonances are primarily controlled by lone-
pair electrons, resulting in a large paramagnetic term in the shielding equation.90 Thus, 
fluorine chemical shifts are particularly sensitive to changes in the local van der Waals 
environment, as well as local electrostatic fields, with surface exposed fluorine atoms on 
proteins being able to detect the differences between H2O and D2O with chemical shift 
perturbations up to 0.2 ppm.86 This sensitivity to local electrostatic environments 
contributes largely to the fluorine atom’s utility for detecting changes in biomolecules.85 
The range of chemical shifts for 19F nuclei is ~100 times larger than 1H nuclei, allowing it 
to be used to monitor weak binding, folding, enzyme kinetics, and conformational 
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change, and consequently the related thermodynamic properties.91–93 Chemical shift 
agents can further broaden these chemical shift differences, separating surface exposed 
residues from those on the interior of the protein. 
The tools to fluorinate proteins are readily available in most biochemistry labs. At 
the most basic level, the lab needs to be set up for standard protein Escherichia coli (E. 
coli) expression. To express proteins with fluorinated tyrosine or phenylalanine, the 
aromatic amino acid biosynthesis pathway must be inhibited, or the bacteria must be 
auxotrophic for the desired amino acids. DL39 cells are auxotrophic for phenylalanine 
and tyrosine, and so are an excellent choice for fluorophenylalanine and fluorotyrosine 
incorporation, and are commonly used in labs for E. coli work. However, since DL39 
cells are not auxotrophic for tryptophan the W3110TrpA33 cell line can be used to 
instead to incorporate fluorinated tryptophan.94,95 Other common methods for fluorine 
incorporation involve inhibiting the aromatic amino acid biosynthesis pathway using 
glyphosate, a somewhat expensive reagent, but a new method reported by Crowley et al. 
exploits the aromatic amino acid biosynthesis pathway, utilizing fluorinated precursors to 
produce fluorinated tryptophan. Consequently, in this method the bacterial strain must 
not be auxotrophic for aromatic amino acids.96 Instead, Crowley utilizes BL21 cells and 
adds 5-fluoroindole, a precursor to tryptophan. Addition of 5-fluoroindole to the media 
used for production of BL21 cells, with removal of natural tryptophan, results in 
incorporation of the bacterial produced 5-fluorotryptophan into the protein of interest. 
PrOF NMR offers a complimentary technique to currently existing techniques for 
assessing protein binding interactions. While PrOF NMR does not provide the same 
information regarding the overall structure of a protein that 1H-15N HSQC NMR can, 
PrOF NMR has the advantage of being simple to interpret because of the low number of 
resonances, while also placing the chemical probe very close to the binding interaction. 
1H-15N HSQC detects the amide backbone of proteins, while PrOF NMR detects fluorine 
resonances that are of the side chains of the amino acids, much closer to the binding 
interaction. Because the dominant isotope of fluorine is NMR active, it is much cheaper 
to incorporate than the rarer 13C or 15N nuclei. 13C labeled tyrosine is ~$850 for 100 mg 
from Sigma-Aldrich, and 13C labeled tryptophan is ~$2000 per 100 mg. By comparison, 
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3-flurotyrosine is ~$84 for 500 mg and 5-fluoroindole is $50 for 1 g. Substituting a 
fluorine atom for a hydrogen atom results in a compound that is sterically similar, with 
fluorine atoms having a van der Waal’s radius of 1.47 Å while hydrogen is 1.20 Å.97 This 
offers a substantial advantage over many labeling technologies, such as fluorophore 
labeling that greatly increase the size of the ligand. 
Fluorine nuclear magnetic resonance spectroscopy (19F NMR) offers a hyper-
responsive method to analyze protein-ligand interactions and is ideally suited to develop 
these probes. Chemical shifts of fluorine nuclei resonances are particularly sensitive to 
changes in chemical environment due to their large number of unpaired electrons, and 
fluorine has a very high gyromagnetic ratio, allowing for rapid acquisition of spectra.85 In 
previous studies, PrOF NMR has been utilized for kinetics experiments, acquiring a 19F 
NMR spectrum in under two seconds.98 Protein-observed fluorine (PrOF) NMR provides 
information regarding binding interactions as a function of chemical shift.99 Aromatic 
amino acids are enriched at protein-protein interfaces,100,48 and therefore fluorinated 
aromatic amino acids offer an efficient way to monitor binding interactions as a function 
of chemical shift of the fluorine resonances. PrOF NMR is an analysis technique that can 
offer great detection of binding interactions because the observed resonances come from 
atoms in close proximity to binding interactions, but other techniques, including FP, ITC, 
and HSQC, are necessary in order to fully understand protein-ligand binding interactions. 
 
1.6 Biophysical techniques to assess structure and function 
Fluorescence anisotropy is affected by the rotational correlation of fluorophores in 
solution. The fluorescence anisotropy is measured by irradiating the solution with 
polarized light, and measuring the anisotropy of the returning fluoresced light. The 
rotational correlation of molecules in solution is proportional to the size of the molecule: 
the larger the molecule is, the more slowly it tumbles, as indicated by a long rotation 
correlation time. FP exploits this relationship by attaching a fluorophore to a small 
molecule that binds to the protein of interest, which results in high anisotropy in the 
bound state and low anisotropy when free in solution (Figure 1.13). Following the change 
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in fluorescence anisotropy as a function of concentration of either the protein or the 
fluorophore allows calculation of the direct dissociation constant (Kd). A disadvantage of 
this technique is that the binding ligand is modified by incorporation of the fluorophore, 
and so measurements of the Kd of the fluorescent ligand may be modified as a result of 
fluorophore incorporation.101 
 
Figure 1.13 Fluorescence anisotropy direct binding with Brd4. 
Direct binding between BODIPY-BI2536 and varying concentrations of Brd4 yields a Ki 
of 50 ± 11 nM.	
 
y = c+ (b− c) (Kd + a+ x)− (Kd + a+ x)
2 − 4ax
2a  
Ki values were obtained using a variant of the Cheng-Prussof equation from Huang et 
al.102 
A common method to avoid only measuring the binding constant of the modified 
fluorophore-containing ligand is to perform a competition assay. In this assay, the 
fluorophore containing ligand is already bound to the protein of interest (ideally only at 
the binding site of interest). The ligand being studied (the one without a fluorophore) is 
then titrated into the mixture, and competes off the fluorophore containing ligand. The 
decrease in fluorescence anisotropy is measured as a function of protein, ligand, and 
fluorophore containing ligand concentration to obtain the IC50, which can be used to 
calculate the indirect dissociation constant (KI). In addition to measuring the binding 
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constant of a ligand unmodified by incorporation of the fluorophore, if the fluorophore 
containing ligand only binds at the binding-site under study, then it can be determined 
whether or not the ligand under study binds to the desired binding site or another site on 
the protein.101 
Isothermal titration calorimetry (ITC) allows very accurate determination of 
binding energies in addition to binding stoichiometry and the thermodynamic properties 
of binding (Figure 1.14). This method works by gradually titrating in a known amount of 
protein or ligand, and measuring the change in heat as a result of the reaction. The change 
in heat is measured indirectly, back calculated as a function of the amount of energy 
required to maintain the solution at a constant temperature.103 A disadvantage of ITC is 
that it provides no structural reference to where the binding event is occurring, and not 
fast enough to be used as an effective screening technique. 
 
Figure 1.14 An example ITC thermogram of BPTF with AU1 (discussed in chapter 
4). 
 
1.7 Preface to this Dissertation 
The follow chapters describe my role in the development of protein-observed 19F 
NMR as a ligand discovery and screening technique. Chapter 2 describes the initial 
application of PrOF NMR to bromodomains, with its sensitivity highlighted by 
uncovering the previously unknown Brd4-acetaminophen interaction and BPTF-BI2536 
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interactions. Chapter 3 is a disclosed protocol to disseminate the technique of making 
fluorinated protein and subsequent NMR analysis, including a brief discussion of using 
paramagnetic relaxation agents to reduce NMR experiment time by ~50%. Chapter 4 
entails the use of a dual PrOF NMR screen to uncover isoform selective binders between 
BPTF and Brd4, resulting the discovery of the first molecule selective for BPTF over 
Brd4. Chapter 5 details a collaboration with Lilly Research Laboratories to compare 
PrOF NMR with the industry standard 1H CPMG ligand observed NMR screening 
technology. Chapter 6 describes the results of a collaboration with William Isley to 
develop a computational method to assign PrOF NMR resonances. 
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Chapter	2. Fluorinated	aromatic	amino	acids	are	sensitive	19F	NMR	
probes	for	bromodomain-ligand	interactions	
 
Reproduced with permission from “Fluorinated Aromatic Amino Acids Are Sensitive 19F 
NMR Probes for Bromodomain-Ligand Interactions,” N. K. Mishra, A. K. Urick, S. W. 
Ember, E. Schönbrunn, W. C. Pomerantz, ACS Chemical Biology 2014, 2755-2760. 
Copyright 2014 American Chemical Society. 
 
Motivation: The purpose of this research was to use the bromodomain of Brd4 as a 
representative protein of this structural class of epigenetic “reader” proteins to validate 
the effectiveness of protein-observed fluorine NMR for characterizing protein-ligand 
interactions. Brd4 represented a good model system as it had structurally characterized 
small-molecule inhibitors at the time we began this work, so good positive controls were 
readily available as well as detailed structural biology data. 
2.1 Introduction 
Bromodomains are epigenetic “reader” proteins that were the first structural 
modules for recognizing the acetylated e-nitrogen of lysine on histones and play essential 
roles in diverse diseases, particularly in cancer.15 Structural biology efforts in NMR104 
and particularly x-ray crystallography have accelerated chemical probe development with 
more than 150 x-ray structures of 43 different bromodomains reported.34 The BET 
(Bromodomain and extraterminal) subfamily of proteins, Brd2, 3, 4, and T are the most 
intensely studied due to the discovery of tool compounds including pan-BET inhibitors 
such as (+)-JQ1, first used to validate Brd4 inhibition for treating NUT midline 
carcinoma (Figure 2.1).13 Selective targeting of BET bromodomains is one of the most 
significant challenges for this emerging therapeutic class.15 Discovery of new binding 
modes can yield insight into selective inhibitor designs. While BET research is 
developing rapidly, the majority of the remaining bromodomains are not as well-
characterized due to a lack of both small molecule inhibitors and optimal screening 
methods.52 Here, we describe a new ligand discovery and characterization method for 
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bromodomains using 19F NMR, and highlight the value of fluorine labeling aromatic 
side-chains for selectivity and binding analyses.  
Protein-observed NMR has proven to be a powerful ligand discovery method 
since the original reports from Abbott labs.67 In these experiments, a protein is labeled 
with NMR active nuclei, typically on the backbone amides. Small molecule induced 
changes in protein chemical shifts are used to characterize a binding event. This method 
can be used to elucidate the binding site, discriminate specific from non-specific 
interactions, and quantify weak affinities of low molecular weight compounds (MW < 
300) termed fragments, commonly used for NMR screening. Fragments can be missed in 
the current ligand discovery methods for bromodomains.33  This is particularly 
challenging in the absence of an initial ligand for competition studies, which is the case 
for many bromodomains.52 However, in amide detected, protein-observed NMR, the need 
for high concentration of protein, detailed resonance assignments, and speed of 
experiment can be limiting.105  
 
Figure 2.1 Aromatic amino acids are close to the bromodomain binding site. 
Ribbon diagram of Brd4(1) bound to (+)-JQ1 (PDB ID 3MXF). The a-carbons of 
tyrosine and tryptophan are indicated as spheres. Y97, Y139, and W81 are within 5 Å and 
Y98 and Y137 are within 10 Å. (Right) (+)-JQ1 and fluorinated amino acids used in this 
study. 
 
We described the use of protein-observed 19F NMR (PrOF NMR) for fragment 
screening using fluorinated aromatic amino acid side chains demonstrated by a 50 
compound fragment pilot screen on a non-bromodomain containing protein.99 Here we 
first test the PrOF NMR approach on the N-terminal bromodomain of Brd4 (Brd4(1)), 
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using known ligands and include a small molecule whose binding affinity was too weak 
to characterize by prior methods. Sequence analyses of 61 bromodomains identified The 
conservation of aromatic amino acids, many positioned near the histone binding site.12 
Aromatic	amino	acid	analysis	across	all	61	Bromodomains	Relative	to	Brd4(1)		
Table 2.1 Conservation of aromatic amino acids within bromodomains at the same 
site as Brd4(1). 
Additional aromatic amino acids are all present in bromodomains but found at sites 
distinct from Brd4(1). (e.g., see the BPTF sequence below). Data was compiled from the 
bromodomain sequence alignments from Filippakopoulos, P et al.  Cell 2012, 149, 214-
231.  Residues near the  histone binding site are highlighted in red. 
Brd4(1) 
Sequence 
# Tyr # Trp # Phe Sum Percent 
Y65 6  2 8 13 
Y97 59   59 97 
Y98 29  2 31 51 
Y118 9  3 12 20 
Y119 59   59 97 
Y137 8 2 1 11 18 
Y139 40  16 56 92 
W75 10 6 4 20 33 
W81  18 1 19 31 
W120  3  3 5 
F79 6  7 13 21 
F83   57 57 93 
F129   13 13 21 
F133   37 37 61 
F157 2  36 38 62 
 
 
For new selectivity studies, we apply this method to a second BET bromodomain 
BrdT, as well as a non-BET BPTF, for which no small molecule probes are known. The 
hyper-responsiveness of the fluorine-chemical shift to ligand binding and simplicity of 
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the rapidly acquired NMR spectrum,99,106 provides the speed and structural information 
necessary for developing potential inhibitors. These studies lead us to propose PrOF 
NMR as a structure-based tool for characterizing new and native ligands for the aromatic-
rich bromodomains. 
 
Figure 2.2 Structure and function of 3FY-Brd4(1). 
A) Cartoon representation of a 3FY-labeled Brd4(1) crystal structure complexed with 
(+)-JQ1. B) Isothermal titration calorimetric analysis of binding of (+) JQ1 binding to 
3FY-Brd4(1) at 25 oC. 
 
2.2 Results and Discussion 
We analyzed the crystal structure of Brd4(1) in complex with inhibitor (+)-JQ1 
(Figure 2.1) to determine a fluorine-labeling strategy. The aromatic side chains of Y97, 
Y139 and W81 are within 3-5 Å of (+)-JQ1. Y98 and Y137 are within 10 Å of the 
thiophene ring of (+)-JQ1. Although W75 is not in close contact, it is located on the 
dynamic Z helix of Brd4(1) (Figure 2.2). Fewer phenylalanine side chains were in close 
proximity. For these reasons, we decided to investigate the ligand detection ability of 
PrOF NMR using either 3-fluorotyrosine (3FY) or 5-fluorotryptophan (5FW)-labeled 
Brd4(1). High labeling efficiency with 3FY and 5FW was achieved (78-90%) with good 
to high protein yields (10-60 mg/L).  
We used circular dichroism (CD), isothermal titration calorimetry (ITC), and x-
ray crystallography to assess the structural and functional effects on fluorine 
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incorporation into Brd4(1). Far UV CD spectra of the fluorinated proteins shows similar 
levels of secondary structure but a slightly lower thermal stability (Tm = 50 °C vs 52 °C) 
(Figure 2.4, Table 2.2). We used ITC to assess how these effects may alter binding. (+)-
JQ1 binds to Brd4(1) with a Kd of 49 nM at 15 oC.13 We detect a similar binding affinity 
of 75 ± 4 nM for our Brd4(1)  and 88 ± 6 nM for 3FY-Brd4(1)  (Figure 2.2, Figure 2.3) at 
25 oC. We solved the crystal structure of 3FY-Brd4(1) bound to (+)-JQ1. Aligning this 
structure onto the unlabeled protein complex with (+)-JQ1 yielded an RMSD of 0.089 Å 
(Figure 2.2).  These results lead us to conclude that fluorine incorporation has a minimal 
effect on structure and function. Crystallization of 3FY-Brd4(1) is itself significant as 
less than 20 fluorinated protein crystal structures have been reported. 
 
Figure 2.3 ITC Binding isotherm of (+)-JQ1 with unlabeled Brd4(1) and 5FW Brd4. 
Isothermal titration calorimetric analysis of binding of (+)-JQ1 to unlabeled (filled circle) 
and 5FW labeled (open circle) Brd4(1) at 25 C. 	
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Figure 2.4 Circular dishcorism of Brd4, 3FY-Brd4, and 5FW-Brd4. 
Far-UV spectra of unlabelled, 3FY and 5FW labelled Brd4(1). Each spectrum was 
measured at 25 oC and protein concentration for each spectrum was 20 µM in 50 mM 
Tris buffer pH 7.4 containing 100 mM NaCl. 
 
Figure 2.5 Circular dichroism thermal melts of Brd4, 3FY-Brd4, and 5FW-Brd4. 
Thermal denaturation curve of unlabeled (filled circle), 3FY labeled (open circle) and 
5FW labeled (open triangle). The change in ellipticity at 222 nm was measured with 
increasing temperature from 20 oC to 80 oC. 20 µM protein was used in 50 mM Tris 
buffer pH 7.4 and 100 mM NaCl. 
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Table 2.2 CD data of unlabeled and fluorine-labeled Brd4(1) 
Protein Tm  (oC) MRE at 222 nm 
Unlabeled Brd4 (1) 52.40 ± 0.1 -14893 
3FY labeled Brd4 (1) 49.57 ± 0.3 -14413 
5FW labeled Brd4 (1) 49.90 ± 0.2 -15677 
 
19F NMR spectra of both proteins display well-dispersed resonances indicative of 
folded proteins.   From the 19F NMR spectrum of 5FW-Brd4(1), resonances for W75, 
W81, and W120 were clearly resolved (Figure 2.9). The seven 3FY resonances in 3FY-
Brd4(1) span over 12 ppm suggesting a diverse environment of the aromatic side chains 
(Figure 2.9).  Two of the resonances at -136.6 ppm are partially overlapping. To our 
knowledge, this is the largest chemical shift range reported for a fluorinated protein but 
remains to be tested if this range is similar in other bromodomains, which have similar 
arrangements of aromatic amino acids. 
Resonance assignments were made via a combination of site-directed mutagenesis 
and ligand binding experiments (explained below). For site-directed mutagenesis, a single 
tryptophan or tyrosine to phenylalanine mutant was expressed and the disappearance of a 
single resonance was used to assign the side-chain in the parent 19F NMR spectrum. 
Complete resonance assignments enabled us to test the sensitivity of our fluorine NMR 
method for characterizing binding footprints and quantifying affinity of weak binding 
molecules for fragment-based screens (Figure 2.6, Figure 2.7). 
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Figure 2.6 Assignment of 3FY tyrosine chemical shifts on 1D 19F NMR spectra. 
1D 19F NMR spectra of 3FY labeled wild-type and tyrosine to phenylalanine point 
mutated Brd4(1). Asterisks represent the position of missing peaks of corresponding 
mutated tyrosine. The Y118F expressed poorly, and had low stability. In the Y118F 
spectrum a partial resonance (which integrates to 0.49) grows in obscuring the absence of 
the resonance at this position. We have identified this resonance as either a degradation 
product or resonance from aggregation of the protein (Figure 2.8).  The two rotamers for 
Y98, as seen in the Y139F spectrum, aided in the assignment of the shifted Y139 
resonance in the acetaminophen binding experiment. 
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Figure 2.7 Assignment of tryptophan chemical shifts on 1D 19F NMR spectra. 
1D 19F NMR spectra of 5FW-labeled wild type and tryptophan to phenylalanine point 
mutated Brd4(1).  Asterisks represent the position of missing peaks corresponding of the 
mutated tryptophan.		
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Figure 2.8 Time dependent degradation of a phenylalanine 3FY-Brd4 mutant. 
19F NMR spectra collected over time of a 3FY-Brd4 mutant. A new resonance gradually 
increases in intensity at -138 ppm. The narrowness of the resonance is consistent with 
degradation of the protein, but may also result from aggregation.		
 
Crystallographic evidence supports the role of W81 for determining the 
specificity of (+)-JQ1 for binding BET bromodomains in a region termed the WPF 
shelf.12,13 W81 was first tested as a diagnostic residue for binding studies. Slow exchange 
binding was readily detected upon titrating (+)-JQ1, in which case the intensity of the 
W81 resonance at -126.3 ppm disappeared as a new downfield resonance at -124.0 ppm 
grew in (Figure 2.9). The observed slow exchange of bound and free protein is consistent 
with submicromolar binding.  Closer inspection of the spectrum revealed a small upfield 
shift of the W75 resonance located underneath W81 on the Z-helix of Brd4(1), but 
outside the binding site (Figure 2.9). 
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Figure 2.9 PrOF NMR titration of (+)-JQ1 with Brd4(1). 
A) Bottom to top: 5FW-Brd4(1) (25 μM); with 1 eq. (+)-JQ1; with 5FW-BPTF (25 μM); 
with 5FW-BPTF (25 μM)  and 1 eq. (+)-JQ1, with unlabeled BrdT(1) (50 μM)  and 1 eq. 
(+)-JQ1.  B) 3FY-Brd4(1) (47 μM) titrated with 2 eq. (+)-JQ1. 
 
 
Titrating (+)-JQ1 with 3FY-Brd4(1) provided further binding information. Y97, 
Y98, and Y139 are located within the binding site for (+)-JQ1. All three resonances 
shifted (slow exchange) and broadened upon titration. The most upfield resonance was 
assigned to Y97, which forms a bridging hydrogen bond to (+)-JQ1 via a structurally 
conserved water molecule (Figure 2.9). Y137, on the outside of the binding site, moved 
downfield but remained sharp. The BC loop near Y137 is highly dynamic.13 Our 
observations are consistent with a protein conformational change with considerable 
flexibility at this site. 
Fragment screening is a promising method for early stage ligand discovery and is 
well-suited for NMR analyses due to the ability to characterize protein ligand interactions 
at the high concentrations needed to detect small molecule binding.105 Acetaminophen 
represented an ideal test case as it was shown to bind BET bromodomains via x-ray 
crystallography, but its affinity for its target was reported as too weak for characterizing 
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by fluorescence anisotropy or TR-FRET.33  The small size of this molecule (MW = 160 
g/mol) is representative of many compounds in fragment libraries. Using 3FY-Brd4(1), 
we detect binding as low as (47 µM) with chemical shift changes > 0.6 ppm when fully 
bound (Figure 2.10, Figure 2.11, Figure 2.12, Table 2.3, Table 2.4). Based on the crystal 
structure with Brd2 and site directed mutant analysis, we assigned this shifted resonance 
to Y139. Y97, which is expected to make a water-mediated hydrogen bond, also 
broadens. Titration of acetaminophen yielded a Kd of 290 ± 40 µM. This results in a high 
ligand efficiency (0.44 kcal/mol/non-hydrogen atom) for acetaminophen as a 
bromodomain inhibitor scaffold. Titration with 5FW-Brd4(1) yielded a similar Kd based 
on the chemical shift perturbation of W81 (230 ± 30 µM). The two Kds are within error 
arguing against a specific fluorine perturbing binding. Due to the speed of data collection 
(chemical shift information can be acquired in < 5 min), low protein concentration (40-50 
µM), and conserved aromatic contacts, we anticipate this method will be well-suited for 
bromodomain fragment screening. This is especially useful where there is a lack of 
suitable ligands for competition-based experiments or affinities are weak  (Kd > 100 
µM).30  
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Figure 2.10 19F NMR spectral analysis of 5FW-Brd4 with acetaminophen. 
A) Representative 19F NMR spectra from titration with acetaminophen. Ribbon diagram 
of acetaminophen bound to Brd2(1) (PDB Code: 4A9J) was aligned to Brd4(1) (PDB 
Code: 3MXF), Brd2(1) was removed to indicate probable binding mode of 
acetaminophen to Brd4(1). The α-carbon of tryptophan are indicated as spheres. B) 
Absolute value of chemical shift perturbation for the 5FW-Brd4 tryptophan resonances at 
628 μM acetaminophen. C) A binding isotherm of W81 perturbation for the 
acetaminophen titration. 
 
 
  44 
	
B	 	 	 	 	 	 										C	
	
Kd = 290 ± 40 μM 
A	
 
Figure 2.11 19F NMR spectral analysis of 3FY-Brd4 with acetaminophen. 
A) Representative 19F NMR spectra from titration with acetaminophen. Ribbon diagram 
of acetaminophen bound to Brd2(1) (PDB Code: 4A9J) was aligned to Brd4(1) (PDB 
Code: 3MXF), Brd2(1) was removed to indicate probable binding mode of 
acetaminophen to Brd4(1). The α-carbon of tyrosine are indicated as spheres. B) 
Absolute value of chemical shift perturbation for the 3FY-Brd4 tyrosine resonances at 
1470 µM acetaminophen. C) A binding isotherm of Y139 perturbation for the 
acetaminophen titration. 			
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Table 2.3 5FW-Brd4 19F NMR chemical shift perturbations at different 
acetaminophen concentrations: 
Acetaminophen 
Concentration Chemical Shift W75 W120 W81 
0 µM Chemical shift (ppm) -124.90 -125.420 -126.259 
80 µM Δδ (ppm) 0.02 0.01 0.04 
158 µM Δδ (ppm) 0.02 0.01 0.07 
316 µM Δδ (ppm) 0.02 0.00 0.11 
628 µM Δδ (ppm) 0.03 -0.01 0.14 		
Table 2.4 3FY-Brd4 19F NMR chemical shift perturbations at different 
acetaminophen concentrations: 
Ligand 
Conc. 
Chemical 
Shift Y119 Y137 
Y98/13
9 
Y98/13
9 Y65 Y118 Y97 
0 µM 
Chemical 
shift 
(ppm) -128.02 -134.01 -136.60 -136.60 -137.43 -138.05 -140.09 
48 µM Δδ (ppm) 0.04 0.02 0.11 -0.08 -0.01 -0.02 -0.06 
95 µM Δδ (ppm) 0.04 0.04 0.20 -0.05 0.01 -0.02 -0.28 
188 µM Δδ (ppm) 0.09 0.03 0.26 -0.06 -0.01 -0.09 -0.13 
375 µM Δδ (ppm) 0.02 0.04 0.37 -0.02 -0.02 -0.05 -0.15 
746 µM Δδ (ppm) 0.12 0.07 0.51 0.04 0.03 -0.01 -0.22 
1470 µM Δδ (ppm) 0.05 0.06 0.61 0.05 0.01 -0.01 -0.18 
 
 
BET bromodomains are inhibited by several classes of kinase inhibitors affording 
molecules with dual modes of actions and a new source of ligand diversity for screening 
against bromodomains.30 We chose three inhibitors covering a wide range of IC50 values: 
BI2536 (Figure 2.15, Figure 2.16, Table 2.7, Table 2.8), (0.025 µM) TG101348 (Figure 
2.17, Figure 2.18, Table 2.9, Table 2.10), (0.29 µM) and Dinaciclib (Figure 2.13, Figure 
2.14, Table 2.5, Table 2.6) (19 µM) to compare their binding footprints to x-ray structures 
with Brd4 (Figure 2.12). 
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Figure 2.12 Binding footprint and affinity determination with Brd4(1) and various 
ligands. 
A-C) Residues whose fluorinated resonance were, highly perturbed tend to cluster near 
the binding site. Acetaminophen was overlaid on Brd4(1) based on the crystal structure 
with Brd2(1) (PDB IDs 3MXF, 4O70, 4A9J) D) Binding isotherms for acetaminophen 
titration with 3FY-and 5FW-Brd4(1). 
 
During Dinaciclib titration, the resonance for W81 broadened significantly. 
Perturbation of the fluorine resonance for W75, gave rise to a small chemical shift 
perturbation in fast exchange. We used this perturbation to estimate a Kd of 60 µM ± 20. 
BI2536 and TG101348 have nanomolar binding affinity. In both cases W81 was highly 
perturbed. With BI2536, a new resonance in slow exchange grows in upfield and is 
consistent with ring current effects based on analysis of the co-crystal structure and the 
reported nanomolar affinity.  Similar to (+)-JQ1 binding, the resonance for W75 showed 
a small perturbation. W75 shows the most pronounced effect for TG101348 binding. 
Inspection of crystal structure overlays reveals very minor perturbations to the residues 
and neighboring side-chains highlighting the sensitivity of 19F NMR for identifying small 
conformational effects. 3FY-Brd4(1) was used to further characterize the kinase inhibitor 
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binding modes for Dinaciclib (Figure 2.12) BI2536, and TG101348. The results were 
consistent with x-ray data and induced conformational effects along the Z-helix. 
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Figure 2.13 19F NMR spectral analysis of 5FW-Brd4 with dinaciclib. 
A) Representative 19F NMR spectra from titration with dinaciclib. Ribbon diagram of 
dinaciclib bound to Brd4(1) (PDB Code: 4O70). The α-carbon of tryptophan are 
indicated as spheres. B) Absolute value of chemical shift perturbation for the 5FW-
Brd4(1) tryptophan resonances at 294 µM dinaciclib. C) A binding isotherm of W75 
perturbation for the dinaciclib titration.		
  49 
	
 
Figure 2.14 19F NMR spectral analysis of 3FY-Brd4 with dinaciclib. 
A) Representative 19F NMR spectra from titration with dinaciclib. Ribbon diagram of 
dinaciclib bound to Brd4(1) (PDB Code: 4O70). The α-carbon of tyrosine are indicated 
as spheres. B) Absolute value of chemical shift perturbation for the 3FY-Brd4(1) tyrosine 
resonances at 186 µM dinaciclib. C) A binding isotherm of Y137 perturbation for the 
dinaciclib titration.  These values are slightly different than obtained from the 5FW-
Brd4(1) titration, suggesting potential effects from fluorine incorporation and/or the error 
in the affinity estimate.				
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Table 2.5 5FW-Brd4 19F NMR chemical shift perturbations at different dinaciclib 
concentrations: 
Dinaciclib 
Concentration Chemical Shift W75 W120 W81 
0 µM 
Chemical shift 
(ppm) -124.875 -125.400 -126.178 
19 µM Δδ (ppm) -0.015 0.005 0.233 
38 µM Δδ (ppm) -0.031 0.009 * 
75 µM Δδ (ppm) -0.069 -0.016 0.546 
149 µM Δδ (ppm) -0.089 -0.032 * 
294 µM Δδ (ppm) -0.105 -0.031 0.748 		
Table 2.6 3FY-Brd4 19F NMR chemical shift perturbations at different 
dinaciclib concentrations: 
Ligand 
Conc. 
Chemical 
Shift Y119 Y137 Y98/139 Y98/139 Y65 Y118 Y97 
0 µM 
Chemical 
shift (ppm) -127.88 -133.99 -136.59 -136.59 -137.41 -138.03 -140.07 
24 µM Δδ (ppm) -0.10 0.18 -0.04 -0.04 -0.00 -0.06 -0.03 
47 µM Δδ (ppm) -0.08 0.28 -0.02 -0.02 0.04 -0.01 -0.18 
94 µM Δδ (ppm) -0.03 0.32 -0.03 -0.03 0.05 -0.01 -0.19 
186 µM Δδ (ppm) -0.01 0.37 -0.04 -0.04 0.08 -0.03 -0.21 	
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Figure 2.15 19F NMR spectral analysis of 5FW-Brd4 with BI2536. 
A) Representative 19F NMR spectra from titration with BI2536. Ribbon diagram of 
BI2536 bound to Brd4(1) (PDB Code: 4O74). The α-carbon of tryptophan are indicated 
as spheres. B) Absolute value of chemical shift perturbation for the 5FW-Brd4(1) 
tryptophan resonances at 149 µM BI2536. 		
Table 2.7 5FW-Brd4 19F NMR chemical shift perturbations at different 
BI2536 concentrations: 
BI2536 
Concentration Chemical Shift W75 W120 W81 
0 µM Chemical shift (ppm) -124.884 -125.417 -126.207 
149 µM Δδ (ppm) 0.024 0.015 -0.421 
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Figure 2.16 19F NMR spectral analysis of 3FY-Brd4 with BI2536. 
A) Representative 19F NMR spectra from titration with BI2536. Ribbon diagram of 
BI2536 bound to Brd4(1) (PDB Code: 4O74). The α-carbon of tyrosine are indicated as 
spheres. B) Absolute value of chemical shift perturbation for the 3FY-Brd4(1) tyrosine 
resonances at 47 µM BI2536. The star indicates broadening into baseline. 			
Table 2.8 3FY-Brd4 19F NMR chemical shift perturbations at different BI2536 
concentrations: 
BI2536 
Concentration 
Chemical 
Shift Y119 Y137 Y98/139 Y98/139 Y65 Y118 Y97 
0 µM 
Chemical shift 
(ppm) 
-
127.9 -134 -136.6 -136.6 -137.4 -138 -140.084 
47 µM Δδ (ppm) 
-
0.032 0.398 0.1853 0.1853 0.1233 0.0788 * 
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Figure 2.17 19F NMR spectral analysis of 5FW-Brd4 with TG101348. 
A) Representative 19F NMR spectra from titration with TG101348. Ribbon diagram of 
TG101348 bound to Brd4(1) (PDB Code: 4PS5). The α-carbon of tryptophan are 
indicated as spheres. B) Absolute value of chemical shift perturbation for the 5FW-
Brd4(1) tryptophan resonances at 75 µM TG101348. Because the new resonances cannot 
be unambiguously assigned, two graphs have been generated representing the two 
possible tryptophan assignments of the new resonances. 	
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Table 2.9 5FW-Brd4 19F NMR chemical shift perturbations at different TG101348 
concentrations with the first possible resonance assignment: 
TG101348 
Concentration Chemical Shift W75 W120 W81 
0 µM Chemical shift (ppm) -124.887 -125.415 -126.210 
75 µM Δδ (ppm) -0.259 0.031 1.742 
		
Table 2.10 5FW-Brd4 19F NMR chemical shift perturbations at different TG101348 
concentrations with the second possible resonance assignment: 
TG101348 
Concentration Chemical Shift W75 W120 W81 
0 µM Chemical shift (ppm) -124.887 -125.415 -126.210 
75 µM Δδ (ppm) 0.420 0.031 1.064 
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Figure 2.18 19F NMR spectral analysis of 3FY-Brd4 with TG101348. 
A) Representative 19F NMR spectra from titration with TG101348. Ribbon diagram of 
TG101348 bound to Brd4(1) (PDB Code: 4PS5). The α-carbon of tyrosine are indicated 
as spheres. B) Absolute value of chemical shift perturbation for the 3FY-Brd4(1) tyrosine 
resonances at 186 µM TG101348. 
 	
Table 2.11 3FY-Brd4 19F NMR chemical shift perturbations at different TG101348 
concentrations: 
Ligand 
Conc. 
Chemical 
Shift Y119 Y137 Y98/139 Y98/139 Y65 Y118 Y97 
0 µM 
Chemical 
shift (ppm) 
-
127.950 
-
133.980 
-
136.577 -136.577 
-
137.416 
-
138.055 
-
140.07
3 
186 µM Δδ (ppm) 0.020 0.538 0.679 0.679 0.087 0.074 -0.126 
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Figure 2.19 19F NMR spectral analysis of 5FW-Brd4 with DMSO. 
A) Representative 19F NMR spectra from titration with DMSO. Ribbon diagram of 
DMSO bound to Brd4(1) (PDB Code: 4IOR). The α-carbon tryptophan are indicated as 
spheres. B) Absolute value of chemical shift perturbation for the 5FW-Brd4(1) 
tryptophan resonances at 3.8% DMSO. 	
Table 2.12 5FW-Brd4 19F NMR chemical shift perturbations at different DMSO 
concentrations: 
DMSO 
Amount Chemical Shift W75 W120 W81 
0% Chemical shift (ppm) -124.8749 -125.3996 -126.1784 
3.8% Δδ (ppm) 0.0588 -0.0709 -0.1473 
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Figure 2.20 19F NMR spectral analysis of 3FY-Brd4 with DMSO. 
A) Representative 19F NMR spectra from titration with DMSO. Ribbon diagram of 
DMSO bound to Brd4(1) (PDB Code: 4IOR). The α-carbon of tyrosine are indicated as 
spheres. B) Absolute value of chemical shift perturbation for the 3FY-Brd4(1) tyrosine 
resonances at 2% DMSO. 		
Table 2.13 3FY-Brd4 19F NMR chemical shift perturbations at different 
DMSO concentrations: 
DMSO 
Amount 
Chemical 
Shift Y119 Y137 Y98/139 Y98/139 Y65 Y118 Y97 
0% 
Chemical 
shift 
(ppm) -128.04 -134.15 -136.64 -136.64 -137.45 -138.10 -140.17 
0.25% Δδ (ppm) 0.03 0.01 0.06 0.06 0.02 0.03 0.15 
2% Δδ (ppm) 0.02 0.02 0.16 0.16 0.08 0.03 0.23 
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Figure 2.21 19F NMR spectral analysis of 3FY-Brd4 with ethylene glycol. 
A) Representative 19F NMR spectra from titration with ethylene glycol. B) Absolute 
value of chemical shift perturbation for the 3FY-Brd4(1) tyrosine resonances at 2% 
ethylene glycol.				
Table 2.14 3FY-Brd4 19F NMR chemical shift perturbations at different ethylene 
glycol concentrations: 
Ethylene 
Glycol 
Amount 
Chemical 
Shift Y119 Y137 Y98/139 Y98/139 Y65 Y118 Y97 
0% 
Chemical 
shift (ppm) -128.044 -134.186 -136.643 -136.643 -137.469 -138.120 -140.172 
1% Δδ (ppm) 0.025 0.015 0.004 0.004 0.015 0.034 -0.018 
2% Δδ (ppm) -0.002 0.014 -0.005 -0.005 0.013 0.016 -0.024 
4% Δδ (ppm) 0.017 0.008 -0.020 -0.020 0.056 0.007 0.002 
A 
B 
  59 
 
 
Based on the Brd4(1) results, we tested the generality of using PrOF NMR with a 
second BET bromodomain, BrdT, of interest as a male contraception target,107 and a non-
BET bromodomain, BPTF, for which no small molecule screens nor small molecule x-
ray complexes have been reported.  Both proteins contain a WPF shelf; therefore, we 
labeled these proteins with 5FW. BI2536 and (+)-JQ1 bind to BrdT. We detect a 
perturbation of the fluorinated protein resonances in slow exchange, consistent with their 
reported nanomolar affinity. (+)-JQ1 is selective for BETs, and thus in the presence of 
5FW-BPTF, we do not detect binding (Figure 2.25, Table 2.16). Surprisingly, PrOF 
NMR reveals BI2536 binds to 5FW-BPTF (Figure 2.22, Figure 2.23, Table 2.15), which 
went undetected in existing selectivity screens using BROMOscanSM and thermal 
shifts,29,30 highlighting the sensitivity of 19F NMR. Deconstruction of the BI2536 ligand 
may lead to a useful starting point for BPTF chemical probe development to study its role 
in cancer.38  
Finally, screening in the presence of other BET proteins can increase the 
stringency and binding information for finding selective BET inhibitors. Binding induced 
shifts from pan-BET inhibitor (+)-JQ1 are reversed in the presence of excess unlabeled 
BrdT(1) (Figure 2.9, Figure 2.24), The 19F NMR spectrum with BI2536 is similarly 
perturbed.  The non-BET, BPTF bromodomain has one tryptophan in the WPF shelf. As 
a new experiment, due to the significant chemical shift dispersion and simplified 19F 
NMR spectra, we decided to simultaneously test two fluorinated proteins.  Consistent 
with single protein binding studies, addition of (+)-JQ1 to 5FW-Brd4(1) and 5FW-BPTF 
shows selectivity for Brd4(1) (Figure 2.9), whereas BI2536 exhibits binding to both 
bromodomains.  
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Figure 2.22 19F NMR spectral analysis of 5FW-BPTF with BI2536. 
Above are representative 19F NMR spectra from titration with BI2536.  						
Table 2.15 5FW-BPTF 19F NMR chemical shift perturbations at different BI2536 
concentrations: 
BI2536 
Concentration Chemical Shift W2824 
0 μM Chemical shift (ppm) -125.031 
7 μM Δδ (ppm) -0.072 
14 μM Δδ (ppm) -0.092 
109 μM Δδ (ppm) * 
217 μM Δδ (ppm) -1.621 				
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Figure 2.23 19F NMR spectral analysis of 5FW-Brd4 and 5FW-BPTF with BI2536. 
The 5FW-Brd4 W81 resonance is perturbed, and the 5FW-BPTF W2824 resonance 
broadens and shifts upfield. This is indicative of intermediate exchange of BI2536 with 
5FW-BPTF in the presence of 5FW-Brd4.															
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Figure 2.24 19F NMR spectral analysis of 5FW-Brd4 with BI2536 in the presence of 
other bromodomains. 
Above, wtBrdT is shown to partially compete off BI2536 from Brd4 as there are two 
populations of 5FW-Brd4 present in the NMR spectrum. Protein wtBPTF is shown to not 
compete off BI2536 from Brd4, as there is only one population present in the NMR 
spectrum indicative of the fully bound state obtained from using only 5FW-Brd4 and 
BI2536.																
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Figure 2.25 19F NMR spectral analysis of 5FW-BPTF with (+)-JQ1. 
Above are 19F NMR spectra from titration with (+)-JQ1.  Small chemical shift 
perturbations in fast exchange at high micromolar concentrations of (+)-JQ1 could not be 
separated from solvent effects with just ethylene glycol, supporting selectivity of (+)-JQ1 
for BET bromodomains.						
Table 2.16 5FW-BPTF 19F NMR chemical shift perturbations at different (+)-JQ1 
concentrations: 
(+)-JQ1 
Concentration Chemical Shift W2824 
0 µM 
Chemical shift 
(ppm) -125.036 
95 µM Δδ (ppm) -0.026 
376 µM Δδ (ppm) -0.099 
3.6% Ethylene 
Glycol Δδ (ppm) -0.088 
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2.3 Conclusion 
Using a validated therapeutic epigenetic protein, we evaluated fluorinated 
bromodomains as sensitive tools for detecting ligand binding modes via 19F NMR. By 
labeling two different aromatic amino acids, we characterized variations in binding 
modes of (+)-JQ1 and new ligands repurposed from the kinase field. We further showed 
that our method can detect protein binding with weak fragments, DMSO (Figure 2.19, 
Figure 2.20, Table 2.12, Table 2.13) and acetaminophen. This is encouraging due to the 
success of developing fragments into lead molecules in drug discovery campaigns. Based 
on the high conservation of aromatic amino acids across 61 bromodomains, we anticipate 
our method should be generalizable for bromodomains, many lacking specific tool 
compounds to study their biology such as BPTF. We further demonstrate the non-
perturbing nature of fluorine for Brd4(1), by solid and solution state methods. Future 
studies will use PrOF NMR in a full fragment screen. This side-chain labeling technique 
has been employed for studying small to medium-sized proteins (10 to 60 kDa),106,108 as 
well as G-protein coupled receptors.109 Here we apply it to bromodomains both in 
isolation and in mixtures. Due to the speed of PrOF NMR, ease of interpretation, and 
availability of 19F-tuned NMR probes in academic and industrial settings, this approach 
should be of broad appeal for early stage ligand discovery. 
 
2.4 Methods 
Brd4(1)(42-168), BrdT(1)(29-134 ), and BPTF (2793-2911) Protein Expression:  
The pNIC28-BSA4 plasmid containing the Brd4(1)and BPTF genes were kind 
gifts from the laboratory of Stefan Knapp. For protein expression, either the E. coli 
Rosetta (DE3) strain (Novagen) was first transformed with the respective expression 
plasmid or the BL21(DE3) strain was cotransformed along with the pRARE (Novagen) 
plasmid and plated onto agar plates containing kanamycin (100 mg/L) and 
chloramphenicol (35 mg/L). Following overnight incubation at 37 oC, a single colony 
was selected from the agar plate and inoculated in 50 mL of LB media containing 
kanamycin (100 mg/L) and chloramphenicol (35 mg/L). The primary culture was grown 
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overnight at 25 oC while shaking at 250 rpm. For secondary culture growth, 1 L of LB 
media containing kanamycin (100 mg/L) was inoculated with the primary culture and 
cultured at 37 oC while shaking at 250 rpm. When the O.D. of culture at 600 nm reached 
0.6, the shaker temperature was reduced to 20 oC.  After 30 minutes, the expression was 
induced with 1 mM IPTG overnight for 12-16 h. Cells were harvested by centrifugation.  
 
Expression of 3FY and 5FW labeled Brd4(1), 5FW-BrdT(1), and 5FW-BPTF: 
3FY and 5FW labeled Brd4(1) were expressed based on established methods96,99 
using E. coli DL39(DE3) + pRARE and E. coli Bl21(DE3) + pRARE strains 
respectively.  To express the labeled protein, the secondary culture in LB media was 
grown until an O.D. at 600 nm of 0.6 was reached followed by harvesting and washing 
the cells with PBS. Washed cells were resuspended in defined media of Muchmore et 
al.110 containing either 3FY (70 mg/L) in place of tyrosine, or 5-fluoroindole (60 mg/L) in 
place of tryptophan. The resuspended E. coli were incubated at 37 oC while shaking for 1 
h followed by the cooling to 20 oC and media temperature equilibration for 30 min. 
Protein expression was induced with 1 mM IPTG overnight (14-16 h) at 20 oC. The cells 
were harvested and stored at -20 oC.  5FW-BrdT(1) and 5FW-BPTF were expressed by 
the same protocol. Cell pellets were thawed at room temperature followed by the addition 
of lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl and 10% v/v glycerol) containing 
protease inhibitor PMSF (5 mM) and purified according to methods described in the 
appendix using Ni-Affinity chromatography. Yields following purification are 60 mg/L 
Brd4(1), 60 mg/L, 5FW-Brd4(1) (78-90% 5FW incorporation) and 10 mg/L 3FY-Brd4(1) 
(>95% 3FY incorporation)  26 mg/L 5FW-BPTF (94%, incorporation) and 22 mg/L 
BrdT, 11 mg/L 5FW-BrdT(1) (91%, incorporation). Purity of proteins was assessed by 
SDS-PAGE. Fluorinated amino acid incorporation efficiency in proteins was measured 
by mass spectrometry as described in the appendix. Concentration was determined via 
absorbance at 280 nm according to published values.99  
1D 19F NMR Parameters: 
19F NMR spectra were acquired at 470 MHz on a Bruker 500 spectrometer with a 
5 mm Prodigy TCI Cryoprobe without proton decoupling. Samples containing 40-50 µM 
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bromodomains labeled in 50 mM TRIS, 100 mM NaCl, 1 mM CHAPS, 2 mM DTT, 5% 
D2O, pH 7.4 for binding assays unless otherwise stated. Spectra were referenced to 
trifluoroacetate (−76.55 ppm). Measurement parameters included a relaxation delay time 
of 0.7 s for 5FW-Brd4(1) and a 90o flip angle, and a relaxation delay of 0.2 s for 3FY-
Brd4(1) containing a 30o flip angle. An acquisition time of 0.05 s was used for all 
experiments. A sweepwidth of 10 ppm was used for 5FW-Brd4(1) spectra, and 18 ppm 
for 3FY-Brd4(1). A 20 Hz line-broadening was applied after 500-3000 transients unless 
otherwise stated. 
Ligand Binding Studies: 
Small molecules were titrated into the protein solution from concentrated stock 
solutions of ethylene glycol (10 mM for all small molecules except acetaminophen, 
which was 50 mM). Final ethylene glycol concentrations were kept below 4% ethylene 
glycol. For small molecule titrations 500 scans were acquired with 5FW-Brd4(1) and 
3000 with 3FY-Brd4(1) to ensure good S/N resolution for improved fitting of the data. 
However, good chemical shift estimates can be readily acquired at 200−400 scans in 
under 5 min for initial screening as described in the appendix. Stock solutions of kinase 
inhibitors were prepared from preweighed 5 mg samples which were used to estimate 
final concentrations. Kd values were obtained using a one-site-binding equation 
accounting for ligand depletion. Reported errors are from the non-linear regression fit of 
the data. 
 
Structure determination: 
Protein crystallization was performed with the mosquito LCP (TTP Labtech) 
crystallization robot at 18 °C using the sitting drop vapor diffusion method.  Crystals of 
3FY-Brd4(1) were grown in the presence of 1 mM (+)-JQ1 and 10 % (v/v) DMSO from 
0.2 M NH4C2H3O2, 0.1 M HEPES (pH 7.5) and 25 % (w/v) PEG 3350, harvested in 
cryoprotectant (reservoir containing 25 % (v/v) ethylene glycol and 0.5 mM ligand) and 
flash frozen in a stream of nitrogen gas.  X-ray diffraction data were collected at -180 °C 
using station 22-ID, SER-CAT, Advanced Photon Source, Argonne National 
Laboratories.   
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Protein Expression and Molecular Biology Materials: 
For E. coli growth, LB agar, LB media, defined media components including 
unlabeled amino acids, uracil, thiamine-HCl, nicotinic acid, biotin and buffer components 
were purchased from RPI corp. 3-Fluorotyrosine, thymine, cytosine, guanosine were 
purchased from Alfa Aesar. Magnesium chloride, manganese sulfate, succinic acid, 
calcium chloride and 5-fluoroindole were purchased from Sigma-Aldrich. Miniprep 
plasmid purification kit was purchased from Clontech.  		
 
Unlabeled Brd4(1), BrdT(1), and BPTF Protein Expression:  	
The pNIC28-BSA4 plasmid containing the Brd4(1) and BPTF genes were kind 
gifts from the laboratory of Stefan Knapp. For protein expression, either the E. coli 
Rosetta (DE3) strain (Novagen) was first transformed with the respective expression 
plasmid or the BL21(DE3) strain was cotransformed along with the pRARE (Novagen) 
plasmid and plated onto agar plates containing kanamycin (100 mg/L) and 
chloramphenicol (35 mg/L). Following overnight incubation at 37 oC, a single colony 
was selected from the agar plate and inoculated in 50 mL of LB media containing 
kanamycin (100 mg/L) and chloramphenicol (35 mg/L). The primary culture was grown 
overnight at 25 oC while shaking at 250 rpm. For secondary culture growth, 1 L of LB 
media containing kanamycin (100 mg/L) was inoculated with the primary culture and 
cultured at 37 oC while shaking at 250 rpm. When the O.D. of culture at 600 nm reached 
0.6, the shaker temperature was reduced to 20 oC.  After 30 minutes, the expression was 
induced with 1 mM IPTG overnight for 12-16 h. Cells were harvested by centrifugation 
and stored at -20 oC. 
	
Bromodomain Purification: 
     To purify fluorinated and unlabeled Brd4(1), the cell pellet was thawed at 
room temperature followed by the addition of lysis buffer (50 mM Tris pH 7.4, 150 mM 
NaCl and 10% v/v glycerol) containing protease inhibitor PMSF (5 mM). Cells were 
lysed by sonication and the cell lysate was centrifuged at 6500 g for 30 minutes followed 
by supernatant filtration over Whatman filter paper. Filtrate containing the histidine-
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tagged Brd4(1) was loaded on to a nickel-NTA affinity column and eluted with an 
imidazole gradient on an AKTA FPLC system monitoring the O.D. at 280 nm. Imidazole 
was removed from the buffer using a HiPrep column (GE) for buffer exchange into either 
50 mM potassium phosphate, pH 7.4, and 100 mM NaCl or 50 mM Tris pH 7.4, 100 mM 
NaCl. Purified and buffer exchanged protein was treated with TEV protease for either 2 
hours at room temperature or alternatively at 4 oC overnight on a rotating carrousel. The 
cleaved His-tag, TEV protease and uncleaved Brd4 were removed using nickel-NTA 
affinity resin.  	
Site-directed mutagenesis: 
To assign the fluorinated resonances in the 19F NMR spectrum, we mutated single 
tyrosine and tryptophan residues to phenylalanine using a standard PCR amplification 
method. One common reverse primer and forward primers containing point mutation for 
(Y65F, Y98F, Y118F, Y137F, Y139F, W75F and W120F) and a primer pairs for (Y97F, 
Y119F and W81F) were used for PCR amplification. Primer sequences are shown in 
Table 2.17. Parent plasmid template was digested by Dpn1 nuclease followed by 
transformation into E. coli BL21(DE3). Three colonies for each mutant were picked and 
grown in LB media containing kanamycin followed by miniprep plasmid purification 
(kits from Clontech). Point mutations on plasmids were confirmed by Sanger sequencing. 
Auxotrophic E. coli DL39(DE3) + pRARE and E. coli BL21(DE3) + pRARE cells were 
transformed with tyrosine and tryptophan mutation containing plasmids respectively and 
subjected to protein expression and purification. After several attempts Y97, Y119 and 
W81 mutants did not express well, and were not purified.  These assignments were either 
inferred (last resonance unassigned for W120) or validated by binding a known ligand 
(Y119 vs. Y97). 						
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Table 2.17 Primer sequences for point mutation of tyrosine and tryptophan to 
phenylalanine: 
S. No. Residue Name Primer Sequence 
1. Y65F Forward CCAACTGCAATTCCTGCTCAGAG 
2. Y98F Forward CCTCCCTGATTACTTCAAGATCAT 
3. Y118F Forward GGAAAACAACTTCTACTGGAATGC 
4. Y137F Forward ACAAATTGTTTCATCTACAACAAGCC 
5. Y139F Forward TGTTACATCTTCAACAAGCCTGG 
6. W75F Forward CAAGACACTATTTAAACACCAGTT 
7. W120F Forward CAACTATTACTTTAATGCTCAGGAAT 
8. Common Reverse CAGCAGCCAACTCAGCTTCCT 
9. Y97F Reverse GATCTTATAGAAATCAGGGAGG 
10. Y119F Reverse CCTGAGCATTCCAGAAATAGTTG 
11. W81F Reverse CTGCTGGAAAGGAAATGCAAACT 		
Protein Mass Spectral Analysis: 
Product molecular weight was confirmed by electrospray ionization mass 
spectrometry (ESI-MS) using a Thermo Scientific Orbitrap Velos LC-MS, Table 2.18. To 
determine the percent incorporation for fluorinated proteins the integration values of the 
different deconvoluted mass peaks are entered into the following equation to determine 
the relative incorporation e..g, FWBrd4: 	 	*	100		
0FWBrd4 is 5FWBrd4 with no fluorine substitutions, 1FWBrd4 is 5FWBrd4 with 
one fluorine substitution, 2FWBrd4 has two fluorines substituted and FWBrd4 has 3 
fluorines substituted. 									
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Table 2.18 Deconvoluted mass spectral data of wild-type Brd4(1) as well as 
fluorinated variants and mutants.  Only data for fully labeled or unlabeled proteins 
are shown. 
Protein Calculated  Observed 
wtBrd4 15083.33 15083.2 
5FW-Brd4 15137.3 15136.8 
3FY-Brd4 15209.26 15206.6 
Y98F Brd4 15175.27 15173 
Y118F Brd4 15175.27 15174.2 
Y137F Brd4 15175.27 15172.8 
Y139F Brd4 15175.27 15174.3 
W75F Brd4 15080.27 15079.4 
W120F Brd4 15080.27 15080.1 
wtBPTF 14437.40 14434.4 
5FW-BPTF 14455.40 14454.3 
wtBrdT 14148.44 14153.3 
5FW-BrdT 14184.42 14188.5 
	
	
Circular Dichroism: 
To check the secondary structural content, far-UV CD spectra (200-260 nm) of 
unlabeled and labeled proteins were collected using a peltier equipped temperature 
controlled Jasco J-815 spectropolarimeter at 25 oC. For all measurements, 20 m M (50 
mM Tris buffer pH 7.4 containing 100 mM NaCl) of protein and a 1 mm cuvette path-
length were used. Spectral data were collected at a scan rate of 50 nm/min with averaging 
of 5 spectra.  Processed data were baseline corrected against spectra taken with buffer 
alone. 
	
Thermal Melting: 
Thermal stabilities of labeled and unlabeled proteins were measured by the 
change in ellipticity at 222 nm with the increase in temperature from 20 oC to 80 oC at 
the scan rate of 60 degrees/h. The Mid-point of transition was calculated by a sigmoidal 
fit to determine the Tm. 
 
Isothermal titration calorimetry of unlabeled, 3FY and 5FW labeled Brd4(1): 
Auto ITC200 (GE) and Nano-ITC were used to perform isothermal titration 
calorimetry experiments. A 3FY-Brd4(1) solution was loaded in the Auto ITC200 
calorimeter and titrated with (+)-JQ1 diluted in the same buffer as protein (50 mM 
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potassium phosphate pH 7.4, 100 mM NaCl). Note: to facilite solubility, JQ1 solutions 
were sonicated immediately prior to use. We used 47 µM of 3FY-Brd4(1). A 50 mM (+)-
JQ1 stock solution was prepared in DMSO and diluted in the same buffer as protein at 
concentration of 500 µM and used for the titration. Titrations were carried out by using 2 
µL per injection volume of 500 µM (+)-JQ1. Heat liberated by each injection was 
integrated (DH) and plotted against molar ratio of ligand and protein. Obtained data was 
fitted by using predefined one and two binding site modes. The fitting of data was not 
sufficient with one binding site whereas a two binding site model produced an 
appropriate fit, indicating a potential low affinity binding (Kd = 1.6 mM) site which could 
be from DMSO. The reported Kd is an average value from of two separate titrations. 
 
For binding of (+)-JQ1 (50 µM) to unlabeled Brd4(1) at 25 oC, the experiments 
were performed using Nano-ITC (TA Instruments). In this experiment, 550 µM unlabeled 
in 50 mM Tris pH 7.4, 100 mM NaCl and 4 mM DTT and 500 µM 5FW labeled proteins 
in 50 mM HEPES pH 7.5, 150 mM NaCl and 4 mM DTT were used as a ligand and 
loaded to the microsyringe (50 µL). The first injection of 0.5 µL was followed by 20 and 
24 identical injections of 2 and 2.5 µL respectively with a releasing period of 8 seconds 
per injection with 200-300 second spacing time between injections. Control heat of 
dilution was measured by independent protein titration into buffer and was subtracted 
from the protein-ligand binding experimental data. Data was analyzed by NanoAnalyze 
software to calculate enthalpy of binding (ΔH) and dissociation constants (Kd). In all 
cases an independent binding model was used for data fitting. 
	
	
Table 2.19 ITC experimental conditions and obtained values: 
Exp. Protein Condition Kd nM n 
value 
1 Brd4 50 mM Tris pH 7.4, 100mM NaCl, 4 mM  DTT 76.0 1.02 
2 Brd4 50 mM Tris pH 7.4, 100mM NaCl 75.1 ± 4.5 1.51 
3 5FW-Brd4 50mM HEPES pH 7.5 150mM NaCl+ 4 mM DTT 77.6 ± 2.0 0.95 
4 3FY-Brd4 50 mM Tris pH 7.4, 100mM NaCl 88.7 ± 4.7 0.96 	
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Table 2.20 Data collection and refinement statistics for the crystal structure 
determination of 3FY-Brd4(1) 	   Space	group	and	unit	cell	dimensions	 P212121;	a	=	36.8,	b	=	44.9,	c	=	78.6;	α	=	β	=	γ	=	90°	
     Resolution	(Å)	 1.45	-	20.0	(1.45-1.47)	        Unique	reflections	 22,274	(1,016)	 	        Rsyma	(%)	 7.6	(33.0)	 	 	        Completeness	(%)	 93.5	(86.8)	 	        I/σI	 	 21.6	(2.9)	 	 	        Rcrystb	(%)	 14.0	 	 	        Rfreec	(%)	 18.5	 	 	        Average	B	alld	(Å²)	 12.54	 	 	        Average	B	proteind	(Å²)	 11	 	 	        Average	B	ligandd	(Å²)	 8.36	 	 	        Average	B	solventd	(Å²)	 22.76	 	 	        Wilson	B	(Å)	 9.78	 	 	        rmsde	bonds	(Å)	 0.009	 	 	        rmsd	angles	(deg)	 1.46	 	 	        Coordinate	Error	(Å)	 0.13	 	 	        Ramachadran	 favored	(%)	 97.74	 	 	        Ramachadran	 allowed	(%)	 2.26	 	 	        	 	 	 	 	        Values	 in paranthesis	 are	 for	 the	 highest	 resolution	shell.	
       a	Rsym	=	100	xΣhΣi|Ihi-Ih|/ΣhiI	where	h	are	unique	reﬂection	indices.		      c	Rfree	is	Rcryst	calculated	for	1112	randomly	chosen	unique	reﬂections.		d	Excluding	hydrogen	atoms	 	 	  e	rmsd	=	root-mean-square	deviation	from	ideal	values.		  	  
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Chapter	3. Protein-observed	19F-NMR	for	fragment	screening,	affinity	
quantification	and	druggability	assessment	
 
Reproduced with permission from “Protein-observed 19F-NMR for fragment screening, 
affinity quantification and druggability assessment,” C. T. Gee, K. E. Arntson, A. K. 
Urick, N. K. Mishra, L. M. L. Hawk, A. J. Wisniewski, W. C. K. Pomerantz, Nature 
Protocols 2016, 1414-1427. Copyright 2016 Nature Publishing Group. 
 
Reproduced in part with permission from “Paramagnetic relaxation enhancement for 
protein-observed 19F NMR as an enabling approach for efficient fragment screening,” L. 
M. L. Hawk, C. T. Gee, A. K. Urick, H. Hu, W. C. K. Pomerantz, RSC Advances 2016, 
95715-95721. Copyright 2016 Royal Society of Chemistry. 
 
Note: The following was a strongly collaborative work with Clifford Gee, and will also 
be reproduced in his dissertation. 
 
Motivation: The purpose of this protocol was to disseminate the ability to express 
fluorinated proteins, and describe the basics of analyzing binding interactions using a 
titration experiment. This is to facilitate wide-spread use of the screening technology. 
 
 
NMR spectroscopy, using either labeled proteins or labeled small molecules, is 
emerging as a preferred method for screening low-complexity molecules (typically <300 
Da with a minimal number of functional groups), termed 'fragments' in early-stage ligand 
discovery campaigns.111,112 Fragments typically bind to their protein target with low 
affinity (mid-micromolar to millimolar dissociation constants). These low-affinity 
interactions are readily detected using NMR methods.113,114 Fragment molecules can be 
compared with higher-molecular-weight counterparts found in traditional high-
throughput screening libraries, via evaluation of their ligand efficiency (LE), which 
compares binding affinity or activity relative to the number of atoms in the 
molecules.115,116 Highly ligand-efficient compounds can be developed in an atom-
economical manner into more potent compounds by fragment linking or growing 
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approaches.67,117 Enthusiasm for this approach remains high with the approval of 
vemurafenib in 2011, discovered through an initial fragment screening campaign, and 
several more lead molecules that emerged from fragment screens are in late-stage clinical 
trials.55,118 
Fluorine NMR is an attractive approach for fragment screening because the spin-
1/2 nucleus 19F is stable, has a natural abundance of 100% and is nearly absent in 
biological systems. Many fluorinated amino acids and building blocks are commercially 
available, including aromatic amino acids 3-fluorotyrosine (3FY), 4-fluorophenylalanine 
(4FF) and 5-fluoroindole, described herein. In many cases, minimal structural and 
functional perturbation has been observed.106,119,120 19F chemical shifts are also sensitive 
to changes in the molecular environment, and therefore 19F is an ideal background-free 
NMR-active nucleus for studying challenging problems of molecular recognition by 
biopolymers.85,106 In the case of fluorine-labeled proteins, the environmental sensitivity of 
fluorine nuclei typically results in well-resolved 1D 19F NMR spectra of proteins whose 
fluorine-labeled side chains are observed at low to mid-micromolar concentrations (e.g., 
25–100 µM).106 
Fragment screening using low-molecular-weight, low-complexity molecules has 
attracted considerable attention because of the reduction of chemical space compared 
with that of higher-molecular-weight, functional-group-rich small molecules used in 
high-throughput screening. As a result, fragment libraries are typically smaller than high-
throughput screening libraries.111,112,118,121 An analysis by Scanlon and co-workers122 of 
20 different fragment libraries developed in the context of academic or industrial research 
yielded an average library size of 4,543 fragment library members and a median size of 
1,280. The use of smaller library sizes is further supported by the hit rates from these 
fragment screens, in which the researchers detected a binding event averaging 8.2%, as 
reported by 11 different screening centers. The high hit rates suggest that adequate 
chemical space is being covered. Fragments identified as hits have been used to develop 
efficient ligands with favorable physicochemical properties.123 
One of the challenges when screening fragment molecules for binding to a 
specific protein target is the detection and quantification of low-affinity interactions. 
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Achieving this important research goal often forces researchers to use high ligand 
concentrations. NMR is a technique that is well-suited for working at these high 
concentrations. With NMR, mixtures of fragment molecules can also be tested 
simultaneously. In experiments using proteins labeled with NMR-active nuclei, the NMR 
spectrum of a mixture that results in a large change in chemical shift of the NMR-active 
nucleus is deconvoluted by obtaining NMR spectra of the protein with individual 
molecules to find the small molecule that actively binds the protein (thus causing the 
observed change in chemical shift). One advantage of this fragment mixture approach is 
that it enables researchers to test a large number of compounds in a shorter period of time 
than would be needed to test individual compounds one at a time. A second advantage 
when using a labeled protein (i.e., protein-observed NMR methods) is the added 
structural information that the protein resonances provide. These specific resonance 
perturbations can be used to guide molecular designs that are aimed at increasing 
fragment affinity. 
Ligand-observed NMR methods, such as saturation transfer difference or 
transverse relaxation Carr–Purcell–Meiboom–Gill-based experiments,124,125 provide 
complementary information that can be used in parallel with protein-observed methods. 
Ligand-observed and PrOF NMR-based methods are tolerant of a variety of experimental 
conditions. For example, contrary to many 1H NMR-based experiments, NMR spectra of 
fluorine-labeled small molecules or fluorine-labeled proteins are not affected by the 
presence of detergents and buffers that are traditionally used.112 Advantages associated 
with the implementation of ligand-observed experiments with respect to protein-observed 
experiments are the lower protein concentration (0.1–10 µM) needed in many cases—
although increasing protein concentration can lead to a better signal126—and the lack of 
an upper limit in protein size. In addition, with respect to protein-observed experiments, 
the active ligand can be readily identified from the fragment mixture without 
deconvolution. However, in saturation transfer difference NMR, false-positive hit rates 
can be as high as 50%,122 although the occurrence of such false positives can be partly 
mitigated by repeating the experiment in the presence of a competitor ligand (if one is 
known). 
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We have proposed a PrOF NMR screening method in which we rapidly monitor 
changes in the chemical shifts of fluorine resonances in 19F-labeled protein side chains 
induced by the presence of small molecules (Figure 3.1). This approach is analogous to 
that adopted in determining structure–activity relationships by NMR using labeled 
amides in 1H–15N heteronuclear single-quantum coherence spectroscopy experiments7. 
The increasing availability of improved instrumentation using 19F-tuned cryoprobes (e.g., 
the QCI-F cryoprobe from Bruker), speed of PrOF NMR experiments and ease of spectral 
interpretation have increased the accessibility of these experiments in academic and 
industrial settings. We recently applied PrOF NMR for fragment screening with the 
transcription-factor-binding domain KIX.99,127 In this study, we analyzed 85 mixtures 
(comprising a total of 508 small molecules) in 10 h using a total of 20 mg of protein. This 
method has been used by others, including follow-up screens against the SPRY-domain-
containing SOCS box protein 2128 and AMA1129, and it was shown to be more than twice 
as fast as 1H–15N heteronuclear single-quantum coherence spectroscopy NMR for small 
proteins.127,130 We have also used the bromodomain BrdT, which is described below.131 
G-protein-coupled receptor agonists and antagonists can also be identified by this 
method.89 2D PrOF NMR methods have validated binding modes of fluorinated ligands 
via 19F–19F homonuclear nuclear Overhauser effect experiments with BcL-xL.132 As the 
incorporation of fluorine in drug molecules increases, nuclear Overhauser effect 
experiments provide an additional structural biology tool for the characterization of 
ligand-binding modes. Our lab recently demonstrated a simultaneous analysis (i.e., 
multiplexed) of small-molecule binding using two 15-kDa bromodomains, Brd4 and 
BPTF.131 In this study, 229 small molecules were screened using this approach.32 
Because a protein and the potential off-target are screened together, this multiplexed 
experiment is similar to the RAMPED-UP 2D NMR experiments with differently labeled 
proteins.133 These approaches are advantageous for studies in which protein selectivity is 
important. 
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Figure 3.1 General workflow for using PrOF NMR for fragment screening and 
ligand characterization 
 
In 1974, Sykes et al.87 first reported the 19F NMR analysis of an 86-kDa protein, 
alkaline phosphatase, using 3FY to label the protein. Sequence-selective labeling of 
recombinant proteins with fluorinated amino acids is now a well-documented 
methodology that facilitates the general use of the present screening method based on 
PrOF NMR.95,96 In this protocol, using sequence-selective labeling with fluorinated 
aromatic amino acids, we describe the application of PrOF NMR to the screening of 
small-molecule libraries for potential protein ligands and the quantification of the 
micromolar to millimolar dissociation constants from chemical shift perturbation 
analysis. We demonstrate our ligand-binding screening method with two proteins, the 
transcription-factor-binding domain of the CREB-binding protein, KIX, and the 
bromodomain Brd4 (Figure 3.2). Application of PrOF NMR with a third protein, the first 
bromodomain of BrdT, will be subsequently described to highlight several additional 
important aspects of the PrOF NMR protocol. The sequence-selective incorporation of 
the three fluorinated aromatic amino acids, 3FY, 4FF and 5-fluorotryptophan (5FW), into 
recombinant proteins in Escherichia coli using either the auxotrophic bacterial cell lines 
(e.g., DL39(DE3)) or standard bacterial strains (e.g., BL21(DE3)) will first be detailed, as 
previously described.95,96,99 This section of the PROCEDURE will then be followed by 
our ligand-discovery procedures. 
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Figure 3.2 PrOF NMR examples. 
(a) Crystal structure of Brd4 (PDB 3MXF) with its three tryptophan residues shown in 
red. (b) Crystal structure of KIX (PDB 1KDX). (c) PrOF NMR spectra for each of these 
variants, in which the residues highlighted in a and b were replaced by 5FW (Brd4), 3FY 
(KIX) or 4FF (KIX). In these spectra, the wide chemical shift dispersion of the signals 
due to the fluorine-labeled, aromatic amino acid analogs are highlighted. The structures 
of the mentioned fluorinated amino acids are shown next to their corresponding spectra. 
 
3.1 Experimental design 
Fluorinated protein expression and characterization. All expressed proteins in the 
PROCEDURE are characterized for purity and fluorine incorporation via SDS–PAGE 
and protein mass spectrometry via electrospray ionization. Protein yields vary on the 
basis of the protein system, fluorinated amino acid and the cell line used. We have 
achieved yields as high as 70 mg/l for 3FY-labeled KIX and 65 mg/l for 4FF-labeled KIX 
using auxotrophic DL39(DE3) cells, and obtained up to 62 mg/l 5FW-labeled KIX23 
(C.T.G., unpublished data) using non-auxotrophic BL21(DE3) cells with 5-fluoroindole 
added to the cell culture medium. All expressions led to a high labeling efficiency. We 
observed even higher yields with our fluorinated bromodomains (84 mg/l for 5FW BPTF 
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and 88 mg/l for 5FW Brd4).32 The SDS–PAGE gel in Figure 3.3 shows four KIX protein 
samples that are unlabeled, 3FY-labeled, 4FF-labeled or 5FW-labeled. 
 
Figure 3.3 Characterization of fluorinated proteins expressed according to present 
protocol. 
(a) SDS–PAGE gel stained with Coomassie blue showing wild-type and three fluorinated 
variants of KIX. (b) Deconvoluted electrospray ionization mass spectrometry (ESI-MS) 
spectrum (left) and 19F NMR spectrum (right) of 3FY-labeled KIX with 98% fluorine 
incorporation. The dominant population present is the fully fluorinated variant. (c) 
Deconvoluted ESI-MS spectrum (left) and 19FNMR spectrum (right) of 3FY-labeled KIX 
with 64% fluorine incorporation.127 
 
Mass spectrometry is used to assess fluorine incorporation into the protein. For 
the mass spectrogram of 3FY-labeled KIX, the dominant mass of 12,021.8 Da 
corresponds to the incorporation of a fully labeled protein (five 3FY residues). The minor 
mass of 12,004.6 Da corresponds to four of the five tyrosine residues being replaced with 
3FY. These major and minor populations lead to a 98% labeled protein (Figure 3.3). Low 
levels of incorporation can result in a heterogeneous protein sample, which can 
complicate the analysis of 19F NMR spectra. A 19F NMR spectrum of 3FY-labeled 
protein that is only 64% labeled is reported for comparison (Figure 3.3). The resulting 
spectrum is a statistical mixture of multiply labeled proteins, and it can result in 
additional (e.g., Y650) or broadened resonances. In some instances, if needed, the 
concentration of fluorinated amino acids can be increased in the culture medium with 
respect to those recommended in the PROCEDURE, to increase the extent of protein 
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labeling. Low levels of labeling can also be attributed to residual unlabeled amino acid 
from the initial expression conditions, an inconvenience that can be reduced with careful 
washings of bacterial pellets and preincubations with fluorinated amino acids. 
Fluorine is not an element that is naturally found in proteins. Therefore, before the 
implementation of the screening protocol, the structural and functional perturbation 
caused by the introduction of the fluorine-based label into the protein must be carried out. 
We have characterized our proteins by a variety of methods, using X-ray crystallography, 
circular dichroism and thermal stability measurements to assess structure.99,131 When a 
ligand was known beforehand, we have also used isothermal titration calorimetry or 
fluorescence anisotropy ligand-binding experiments to compare the affinity of the known 
ligand with those of the fluorinated and nonfluorinated proteins. A direct binding 
experiment with a fluorescently labeled bromodomain ligand, BI-BODIPY, with 5FW-
labeled Brd4 and unlabeled Brd4 yielding dissociation constants of 110 and 55 nM, 
respectively. In our experience, we have considered a two- to threefold change in binding 
affinity between fluorine-labeled and unlabeled protein to be acceptable for continuing on 
with the labeled protein in a ligand screen. We recommend trying alternative labeling 
approaches or using different amino acids (e.g., 6-fluoro versus 5-fluorotryptophan) if 
larger perturbations are observed. 
PrOF NMR. PrOF NMR spectra of small- to medium-sized fluorinated proteins 
typically reveal well-resolved resonances for each labeled aromatic amino acid, but not in 
all cases. The different aromatic residues are seen in close but distinct chemical shift 
regions (Figure 3.2). A well-dispersed NMR spectrum is an additional confirmation of a 
well-folded protein. Protein resonances tend to be broad. Fluorine resonances from small-
molecule impurities or peptides resulting from proteolytic degradation appear as sharp 
signals in 19F NMR spectra, and their presence can help assess the stability and purity of 
the protein. A resonance due to a small-molecule impurity can be seen in Figure 3.2 at 
−120 p.p.m. In some cases, protein precipitation or aggregation leads to loss of signal for 
all of the protein resonances, which can be useful for the identification of false positives 
in a ligand screen. 
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Resonances can be assigned by recording the spectrum of a fluorinated protein for which 
one residue has been mutated to an amino acid that can no longer be fluorine-labeled in 
the expression conditions because the corresponding fluorinated analog is not present in 
the culture medium (e.g., Trp to Phe). As an example, three relevant spectra are reported 
in Figure 3.4. In this case, the bromodomain Brd4 is labeled with three 5FW residues, 
which results in three well-resolved resonances. The disappearance of the resonances at 
−124.9 and −126.2 p.p.m. upon directed mutation of specific tryptophan residues leads to 
the assignment of these resonances to fluorine-labeled W75 and fluorine-labeled W81 
(Figure 3.4, middle and top spectra). However, because of the sensitivity of fluorine to 
subtle changes in environment, additional chemical shift changes can occur, which, in 
some cases, preclude assignment. In this case, the addition of a known ligand can help 
identify side-chain resonances in the ligand-binding site. For example, the first 
bromodomain of BrdT has two tryptophan resonances, and W50 is known to be located 
in the 'WPF shelf' at the histone-binding site. Addition of the known BrdT ligand 
dinaciclib (IC50 = 61 µM) was used to help assign the resonance due to the fluorine-
labeled W50. The broadening and the 0.25-p.p.m. chemical shift perturbation of the 
upfield resonance is consistent with X-ray crystallography data on the co-crystal 
structures, which show a conformational change of W50 upon binding28 (Figure 3.5). 
Chemical shift perturbation upon the addition of a known ligand can also serve as a 
useful confirmation of the functional integrity of a fluorine-labeled protein.99,131 
Fragment screening can be carried out once a well-folded, highly labeled protein has been 
obtained, although the protein NMR spectrum does not necessarily need to be assigned 
first. 
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Figure 3.4 Using site-directed mutagenesis to assign PrOF NMR resonances. 
Asterisks denote the resonance that has disappeared after mutation of the relevant 
(fluorine-labeled) tryptophan into a phenylalanine, which allows assignment of that 
resonance to the specific mutated amino acid residue.131 
 
 
Figure 3.5 Results from experiments involving small-molecule ligands for BrdT. 
(a) Crystal structure of BrdT (PDB 4FLP) showing the two tryptophans. Please note that 
W50 is located in the protein's WPF shelf. (b) PrOF NMR spectra of 5FW-BrdT by itself 
(bottom spectrum) and in the presence of two different small molecules, fragment A, 
middle spectrum (see also the structure of the compound above the spectrum, to the right-
hand side), and dinaciclib, top spectrum (see also the structure of the compound above 
the spectrum, to the right-hand side). (c) Binding isotherms for fragment A generated by 
plotting the change in chemical shift for both 5FW resonances as a function of ligand 
concentration, which yield comparable Kd values. *Resonance assignments that were 
inferred from small-molecule binding. 
 
Dissociation constant and LE determination. The affinity of fragment hits from 
the screen can be readily assessed for protein ligands with up to millimolar dissociation 
constants via ligand titration and subsequent nonlinear regression of the binding isotherm 
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produced by monitoring changes in chemical shift. This chemical shift perturbation 
experiment is valid when the molecules are in fast exchange, as indicated by the presence 
of a single resonance signal whose chemical shift is the weighted average of the bound 
and unbound states. The speed of the experiment, the low concentration of proteins 
needed for it and the possible automation of the procedure enable the rapid testing of 
multiple small molecules. 
In the present approach, separate samples are set up with varying concentrations 
of the small molecule. The dissociation constant (Kd) is obtained by fitting the obtained 
data to a nonlinear regression curve using the following equation, accounting for receptor 
depletion.130 Analysis of the affinity of the small molecule and location of perturbed 
resonances can then be used to assess valuable structure–activity relationships between 
molecules and differential binding to various surfaces on a protein. 
 
In equation 1, S is the observed change in chemical shift, D is the maximum 
change in chemical shift, Kd is the dissociation constant of the ligand, L is the ligand 
concentration and P is the protein concentration. The maximal shift, D, can be obtained 
through nonlinear regression, or experimentally, when further addition of a small 
molecule no longer perturbs the resonance. In addition, as a means of prioritizing ligands 
for future development, these affinity data can be used to calculate the LE using the 
following equation, which enables this efficiency to be calculated on the basis of the 
binding affinity of the ligand and the contribution of each nonhydrogen atom to the free 
energy of the interaction. 
 
Although this scenario is not commonly encountered in fragment screens, ligands 
with high affinity may have a sufficiently long residence time on the protein that the 
bound and unbound states are partially resolved (intermediate exchange) or fully resolved 
(slow exchange) during the 19F NMR experiment. In these instances, titration will not 
result in a binding isotherm. Intermediate exchange kinetics results when interchanging 
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species at equal populations (e.g., bound and unbound states) lead to coalescence into a 
single resonance.134,135 
 
In the coalescence equation, the frequency difference in Hertz between the two 
resonances (Δν)—bound versus unbound state—establishes a relationship that enables 
researchers to estimate the residence time of the ligand on the protein based on the rate of 
dissociation (k−1). In the case in which the rate of exchange approaches the coalescence 
point (τ ≈ Δν) during a protein–ligand titration, the resonances will coalesce so that the 
signal will initially broaden, but it will become sharp again, in a dose-dependent manner, 
as the chemical shift is perturbed by the titration process. With slow exchange kinetics 
(likely to be associated with a low dissociation constant), both resonances can be well 
resolved, and, during a protein–ligand titration, one resonance will gradually disappear 
while another will grow from the baseline in a dose-dependent manner. 
Experimental considerations and assay limitations. The additional rotational 
freedom in protein side chains versus the amide backbone can lead to smaller linewidths 
relative to amide resonances. One consideration that should be made before using 19F-
labeled proteins for NMR is the sensitivity of the fluorine nucleus to substantial chemical 
shift anisotropy (CSA) relaxation effects. CSA relaxation leads to resonance broadening, 
which is enhanced by protein dynamics, including long rotational correlation times of 
amino acids found in large proteins.136 CSA relaxation is proportional to the square of the 
magnetic field strength. From a practical standpoint, we carry out NMR experiments at 
471–564 MHz using fluorinated aromatic amino acids. 5FW experiences a lower degree 
of CSA relative to other fluorinated tryptophan analogs, and in some cases it has been 
used with proteins as large as 65 kDa.137 As an alternative to 5FW, fluorine-labeled 
cysteine or methionine derivatives with substantially reduced CSA effects are 
recommended for proteins larger than 40 kDa, as has been demonstrated in experiments 
with G-protein-coupled receptors and amyloid-β aggregates.89,138–140 Site-selective 
fluorine labeling with trifluoromethylphenylalanine has also been used for large 
proteins.141,142 For small- to medium-sized proteins, PrOF NMR is applicable using a 
variety of fluorine-labeled amino acids, including singly fluorinated (tyrosine, 
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phenylalanine and tryptophan, Figure 3.2) and more heavily fluorinated amino acids such 
as di- and trifluoromethylmethionine,143,144 and tri- and hexafluoroleucine.145–147 We 
propose using singly fluorinated aromatic amino acids, as this approach reduces spectral 
complexity with respect to using amino acids with multiple nonequivalent fluorines. 
Furthermore, it allows high levels of enrichment in labeled amino acids at protein–protein 
interaction interfaces100 while minimizing the perturbing effect of fluorine substitution. 
Nevertheless, we reiterate that protein structural and functional perturbation caused by 
fluorine substitution should always be assessed by conducting preliminary 
complementary structural and functional biophysical experiments. 
3.2 Materials 
Reagents: Unless noted, reagents of comparable quality from alternative suppliers 
can be substituted. 
Protein Expression Components 
• Fragment mixtures. <CRITICAL> These are prepared according to guidelines 
outlined in Box 1. Sources of fragment libraries include Maybridge and 
Chembridge 
• Plasmid encoding your protein of choice that also encodes for the resistance to an 
antibiotic of choice  
CRITICAL: For nickel affinity purification, ensure that the plasmid includes a His 
tag described in step 9 and in the appendix.  
 
• Plasmid vectors pRARE (Novagen), pRSETB-HIS6KIX (Invitrogen), pNIC28-
BSA4 (Addgene, used in Supplementary Method) 
• Competent DL39(DE3)* (DL39, CGSC) or BL21(DE3) (Novagen) Escherichia 
coli cell lines 
Note: We thank I. Ropson for providing the DL39(DE3) cell line. 
 
Critical: Choice of cell lines must be made carefully. Auxotrophic cell lines (e.g., 
DL39(DE3)) are necessary for labeling with 3-fluorotyrosine or 4-fluorophenylalanine. 
For tryptophan labeling, 5-fluoroindole with non-auxotrophic cell lines (e.g., 
BL21(DE3)) is recommended for higher protein yields.  
 
• QiAprep Spin Miniprep Kit (250) (Qiagen, Cat. No. 27106) 
• Lennox L. Broth (LB) (RPI, powdered or granulated, L24066)Lennox L  Agar 
(RPI, powdered or granulated, L24030) 
• Super Optimal Broth with Catabolite Repression (SOC) (SOB with added 
glucose) (RPI, S25000)  
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• Antibiotics:  Ampicillin (RPI, A40040), Kanamycin (RPI, K22000), 
Chloramphenicol (RPI, C61000) 
• Natural amino acids (Table 3.1) (RPI)  
• Isopropyl β–d-1-thiogalactopyranoside (IPTG)(RPI, I56000)  
• Imidazole (RPI, I52000) 
• Sodium Phosphate Monobasic, monohydrate (RPI, S23120) 
• Sodium Phosphate Dibasic, heptahydrate (Sigma, S9390)  
• Sodium chloride(Fisher, S2713). 
• HEPES (Fisher, BP310) 
• Tris (Acros, 167620010) 
• 3-fluoro-DL-tyrosine (Alfa Aesar, L01479) 
• 4-fluoro-DL-phenylalanine (Sigma Aldrich, F5251) 
• 5-fluoro-indole (Sigma Aldrich, F9108) 
• Ultrapure water 18.2 ΜΩ x cm 
Protein Purification Components 
• Lysozyme (Gold Biotech, L040) 
• β-mercaptoethanol (Sigma Aldrich, M6250) 
• Phenylmethanesulfonylfluoride (PMSF), (RPI, P20270)  
NMR Components 
• Dimethylsulfoxide (Fisher, D128) 
• Ethylene Glycol (Sigma Aldrich, 102466) 
• Trifluoroacetic acid (TFA, Sigma Aldrich, T6508) 
• Deuterium oxide (Cambridge Isotope Labs, DLM-6) 
Prepared Buffer Solutions (Filtered and stored at room temperature) 
• Lysis Buffer: 50 mM Phosphate, 300 mM NaCl, pH = 7.4 
• Wash Buffer: 50 mM Phosphate, 100 mM NaCl, 30 mM Imidazole, pH = 7.2 
• Elution Buffer: 50 mM Phosphate, 100 mM NaCl, 400 mM Imidazole, pH = 7.2 
• NMR Buffer for Brd4: 50 mM Tris, 100 mM NaCl, pH = 7.4 
• NMR Buffer for KIX: 50 mM HEPES, 100 mM NaCl, pH = 7.2 
Protein Characeterization/SDS-PAGE Components:  
• Formic Acid (Sigma, 56302) 
• Acetonitrile (J.T. Baker, 9853) 
• 40% Acrylamide/Bis solution (Bio-Rad, 1610148)  
• Ammonium persulfate (Sigma Aldrich, 248614)  
• Bis-Tris (RPI, B75000) 
• Tetramethylethylenediamine, (TEMED) (RPI, T18000) 
• Coomassie Brilliant Blue R-250 (Bio-Rad, 161-0400) 
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Equipment 
• Refrigerated Incubator Shaker  
• UV/Vis spectrophotometer  (e.g., Varian Cary 50 Bio UV/Vis spectrophotometer) 
• High speed centrifuge  
• Sonicator (Fisher FB505) with 1/8” microtip (FB 4418) 
• FPLC (GE Äktapurifier) 
• HiPrep 26/10 Desalting Column (GE Healthcare 17-5087-01) 
• 50 mL Superloop (GE Healthcare 18-1113-82) 
• Ni-NTA Agarose Beads (Life Technologies R901-01) 
• NMR spectrometer (Recommended 19F S/N ≥ 550:1) 
Critical: NMR probe must be able to tune to the 19F nucleus (e.g. Bruker BBO probe), 
For optimal PrOF NMR experiments, a cryoprobe (e.g. Bruker TCI-Prodigy) should be 
used for increased S/N.)  
 
• 19F tuned NMR probe, e.g. (TCI-Prodigy cryoprobe, Bruker)   
• Electrospray Ionization Mass Spectrometer 
Critical: Mass spectrometer must be capable of resolving proteins to 2-3 amu for 
accurate protein characterization as fluorinated proteins will differ by 18 amu per 
incorporated fluorine. 
 
• SDS PAGE gel apparatus and power supply (for use in protein characterization 
• NMR tubes 
• Microcentrifuge tube 
• 15-ml Falcon Tubes 
• 50-ml Falcon Tubes 
• Protein concentrators (Millipore Centricon UFC900324, UFC800324) 
Software 
• NMR processing software (e.g. TopSpin, MNova, etc…) 
• Non-linear regression software (e.g. OriginPro, GraphPad, etc…) 
 
 
Reagent Setup 
LB Media/Agar: Autoclave media prior to using.  
 
 
Preparation of the defined media 
To simplify the preparation if it is going to be done multiple times, a sterile-filtered stock 
solution consisting of the reagents listed in Step 3 (CaCl2 through biotin) may be 
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prepared and stored at 4°C for several months; an appropriate volume of stock solution 
would then be added to the defined media instead of adding the components individually. 
 
1. Combine the amino acids, salts, and nucleotide bases listed below in a total 
volume of 1 L of deionized water, omitting the amino acid that will be labeled, 
and autoclave the solution. Natural amino acids were all purchased from RPI. 
Pause Point: If the defined media is not going to be used right away, do not 
continue media preparation beyond this step. Media with just the amino acids and 
salts with no carbon source (glucose) or vitamins can be stored covered at room 
temperature for several months.  
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Table 3.1 
Component Supplier (Cat. #) Amount for 1L expression  
Alanine  RPI (A20060) 500 mg 
Arginine  (A50010) 400 mg 
Asparagine  (A50030) 400 mg 
Aspartic Acid  (A50060) 400 mg 
Cystine HCl  (C81020) 50 mg 
Glutamine  (G36040) 400 mg 
Glutamic Acid  (G36020) 650 mg 
Glycine  (G36050) 550 mg 
Histidine  (H75040) 100 mg 
Isoleucine  (I54020) 230 mg 
Leucine  (L22000) 230 mg 
Lysine HCl  (L37040) 420 mg 
Methionine  (M22060) 250 mg 
Phenylalanine  (P20260) 130 mg 
Proline  (P50200) 100 mg 
Serine  (S22020) 2.1 g 
Threonine  (T21060) 230 mg 
   
Tyrosine  (T68500) 170 mg 
Valine (V42020) 230 mg 
Sodium acetate  Macron (7372) 1.5 g 
Succinic acid  Sigma Aldrich (S3674) 1.5 g 
Ammonium chloride  Fisher (A661) 500 mg 
Sodium hydroxide  Alfa Aesar (A16037) 850 mg 
Potassium phosphate 
(dibasic)  
RPI (P41300) 10.5 g 
Adenine RPI (A11500) 500 mg 
Guanosine Alfa Aesar (A11328) 650 mg 
Thymine TCI (T0234) 200 mg 
Uracil RPI (U32000) 500 mg 
Cytosine Alfa Aesar (A14731) 200 mg 
 
2. Once the solution is sterilized, add the components sequentially, adding MgSO4 
last   
Component Supplier (Cat. #) Amount for 1-L 
expression 
40% (wt/vol) glucose 
solution 
RPI (G32030)  50 ml 
0.01M FeCl3 Sigma Aldrich (157740) 1 ml 
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Table 3.2 Vitamin solution composition 
Vitamin Solution   
Component  Amount for 1-l expression 
Tryptophan  RPI (T60080) 50 mg 
CaCl2 dihydrate  Sigma Aldrich (C3306) 2 mg 
ZnSO4 heptahydrate Sigma Aldrich (Z4750) 2 mg 
MnSO4 monohydrate Sigma Aldrich (M7634) 2 mg 
Thiamine RPI (T21020) 50 mg 
Niacin Sigma Aldrich (72340) 50 mg 
Biotin RPI (B40040) 1 mg 
1M MgSO4 Sigma Aldrich (M7506) 4 ml 
 
3. Adjust the pH to 7.2 using HCl or NaOH. Media can be stored at room 
temperature for a few weeks, though it is recommended that the glucose and 
vitamin solutions not be added until immediately prior to use (Table 3.2). 
4. Add the necessary fluorinated amino acid(s) or amino acid precursor for 
appropriate fluorine labeling.  
 
Table 3.3 Fluorinated amino acids or precursor for defined media. 
Fluorine 
Label 
Fluorinated Substitution  Amount for 1-L 
expression 
Final concentration in 
media 
3FY 3-fluoro-DL-tyrosine  80 mg 400 µM 
4FF 4-fluoro-DL-phenylalanine 
a 29 mg 
160 µM 
5FW 5-fluoroindole  60 mg 444 µM 
 
aAddition of 5 µM of phenylalanine to the defined media when using 4-
fluoro-DL-phenylalanine has led to increased protein yield but minimal effects on 
fluorinated amino acid incorporation. 
 
Equipment Setup 
 
Sonicator Program. Sonication time = 4 minutes at 30% amplitude (this entails eight x 
30 second pulses with 60 second rest times between pulses.) Total elapsed time: 12 
minutes 
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Ni Affinity Gradient Elution Method. Set up the FPLC method that will be used in Step 
9. In our laboratory we use a GE Äktapurifier with a column packed with Ni-NTA 
Agarose for affinity purification. The four steps are as follows: Wash the nickel column 
with 15 column volumes of wash buffer. Perform a gradient elution across 20 column 
volumes ramping from 0 to 100% elution buffer. Wash with 5 column volumes of 100% 
elution buffer. Return to 0% elution buffer by applying the reverse gradient in 5 column 
volumes. UV absorbance is monitored at 280 nm. Total time (at 1 mL/min flow rate): 4 
hours 
 
Buffer Exchange Method. Set up the FPLC method that will be used in step 10. In our 
laboratory, we use a GE Äktapurifier with a GE HiPrep 26/10 Desalting column (17-
5087-01). Equilibrate the column with 0.5-1 column volume of buffer prior to loading the 
sample. Elute the column with 1 column volume of buffer and monitor the UV 
absorbance at 280 nm. Total time (at 2 mL/min flow rate): 40 minutes.  
 
3.3 Procedure 
 
Bacterial Transformation (Timing: 1 day) 
1. Prepare bacterial colonies transformed with the plasmid for the protein of interest using 
standard transformation and inoculation methods. A detailed sample protocol is provided 
in Supplementary Method.  
 
Critical As noted in the materials section, choice of cell lines must be made carefully. 
Auxotrophic cell lines (e.g., DL39(DE3)) are necessary for labeling with 3-fluorotyrosine 
or 4-fluorophenylalanine. For tryptophan labeling, 5-fluoroindole with non-auxotrophic 
cell lines (e.g., BL21(DE3)) is recommended for higher protein yields. 
 
Pause Point Culture plates with transformed bacteria may be stored at 4 °C for up to a 
month.  
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Fluorinated protein expression Timing: 2 days 
 
Critical: Maintain sterile conditions while working with media. Standard protein 
expression methods can be used; these steps are those that are used routinely in our 
laboratory and provide information about when in the process, the fluorinated amino 
acids should be added. 
 
2. Inoculate primary and secondary cultures using standard E. coli expression methods. 
Detailed steps of a sample protocol are provided in the appendix.  
 
3. Using a spectrophotometer, determine the optical dispersion at 600 nm (OD600). 
Remove the culture from the shaker when the OD600 is between 0.6 and 0.8. Please note 
that this value may vary based on the cuvette distance to the detector in the 
spectrophotometer. 
 
4. Centrifuge the culture for 20 min at 6000 g at 4 °C.  
 
5. Decant the LB media and resuspend the pellet in an equivalent amount of the defined 
media containing the desired fluorinated amino acid or amino acid precursor [see Reagent 
setup] and appropriate antibiotic.  
 
6. Shake the solution prepared in the previous step at 37 °C and 250 RPM for 90 min as a 
recovery time for the bacteria then decrease the temperature to 20 °C to cool down the 
media. Continue to shake for an additional 30 min to allow the solution to equilibrate. 
Please note that the most suitable temperature and recovery time will vary for each 
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protein. Our lab has generally found the above conditions to work well, though there are 
cases when a shorter recovery time has produced better results.  
 
7. Induce protein expression by adding IPTG to the solution to a final 1-mM 
concentration. Continue to shake at 20 °C and 250 RPM for 16–20 h. Please note that the 
most suitable IPTG concentration and induction time will vary for each protein.  
 
8. Centrifuge the cell culture at 6000 g at 4 °C for 20 min. For ease of purification, we 
recommend centrifuging cultures in 500-ml aliquots or smaller. Decant the supernatant 
medium and store the cell pellet at –20 °C or –80 °C.  
 
Pause Point The cell pellet may be stored at –20 °C or –80 °C for months. 
 
9. Purify and characterize overexpressed protein. Sample purification methods are 
described in the appendix and mass spectrometry characterization is described in Box 1. 
SDS PAGE characterization can be performed at this step to evaluate the presence of the 
desired protein. However, due to the low resolution nature of SDS PAGE 
characterization, it will not be able to quantify fluorine incorporation or distinguish 
between fluorinated variants. (Figure 3.3) 
 
10. Buffer exchange the protein into the desired buffer. In our lab we use a HiPrep 
desalting column, but other methods work as well (Nap-5 columns, PD-10 columns, and 
dialysis are all viable options). For PrOF NMR, it is best to avoid buffers with high 
concentrations of high mobility salts due to their impact on NMR signal sensitivity. 
When possible, the lower mobility salts (e.g. Tris, HEPES, etc…) are preferred.  
 
Pause Point: The purified protein can be stored at 4 °C or flash-frozen and stored at –
20 °C for several months. For long-term storage, we recommend flash-freezing and 
storing at –20 °C. Exact storage conditions may vary from one protein to another. 
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Box 1 – Fluorine Incorporation Characterization Timing 0.5-1 h 
1. Concentrate protein to at least a low µM concentration. In our lab we utilize centrifugal 
protein concentrators with either a 3k or 5k MW cutoff. The exact membrane cutoff needed 
will depend on the size of the protein of interest 
2. On an ESI mass spectrometer equipped with a liquid chromatography system, use 
0.1% formic acid in water (v/v) and acetonitrile as solvents and a C18 column for 
separation. Run a gradient elution ramping from 8% acetonitrile to 80% acetonitrile.  
3. Select the protein peak on the chromatogram and deconvolute the corresponding 
mass spectrum.  
4. Integrate the peaks corresponding to the protein of interest and its fluorinated 
variants.  
5. Use the following formula to calculate the percent of fluorine incorporation.  
 
Where n corresponds to the number of incorporated fluorinated residues.  
 
 
Protein-Observed Fluorine (PrOF) NMR Timing 5 min–1 h 
11. Concentrate the protein solution to 40–50 µM as done in Box 1  
 
12. To a microcentrifuge tube, add 2 µl of 0.1% (v/v) TFA, 25 µl of D2O, and 473 µl of 
protein solution just prepared. Mix well and transfer solution to a 5-mm NMR tube.  
 
13. Acquire two fluorine NMR spectra. Focus the first experiment on the TFA reference 
peak, which can be obtained within several scans, and focus the second experiment on the 
protein. We find that a spectral width (sw) of 10–20 ppm is sufficient with an offset 
(O1P/tof) of –76.5 ppm for the TFA, –136 ppm for 3FY-labeled proteins, –125 ppm for 
5FW-labeled proteins, or –117 ppm for 4FF-labeled proteins. Experiment time and 
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number of scans required will be dependent on availability of a cryoprobe versus a room-
temperature probe as well as protein On a 500 MHz NMR with a Prodigy inverse 
cryoprobe (19F S:N 2100:1) 400 scans are sufficient for proteins KIX and bromodomain 
Brd4, which would lead to a 4–5-min experiment. 
 
14. Process the data setting the TFA reference peak to –76.5 ppm and applying the same 
correction factor to the second experiment. Resonance assignments can be performed as 
described in Box 2.  
 
 (Optional) Assigning PrOF Resonances Timing ~3 weeks 
Note: PrOF NMR screening and binding experiments can still be performed without 
resonances assigned. The assignments can provide additional structural information but 
are not necessary to evaluate small molecule binding. 
 
1. Perform site-directed mutagenesis to mutate each amino acid of interest to an 
alternate amino acid chosen such that it will have very little effect on the protein 
structure (e.g., Y->F) 
2. Obtain PrOF NMR spectra of each mutant (see Steps 11-14 of the Procedure). The 
resonance that has disappeared corresponds to the mutated amino acid residue.  
  
Fragment Mixture Preparation Timing Variable  
1. Obtain or prepare concentrated ligand stock solutions (200 mM) in a given solvent 
(e.g., DMSO or ethylene glycol) for the fragments of interest. Please note that solvent 
choice will depend on ligand solubility and solvent effects on the protein of interest. 
 
Critical Step The maximum volume of solvent that will be tolerated without 
significantly perturbing the chemical shifts or the shapes of the 19F NMR resonances 
must be determined in order to accurately assess ligand binding. We recommend that the 
final solution is composed of 1–5% organic solvent.  
 
2. Determine the desired number of fragments for each screening mixture. Commonly 
screening mixtures include 5–10 fragment compounds.  Fragment mixtures of five of six 
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compounds will reduce the number of compounds needed in the deconvolution step, if a 
high hit rate is anticipated. 
 
3. Decide the concentration at which each fragment will be screened. Fragment mixture 
concentrations will depend on the expected Kd’s for ligands in the mixture. Due to the 
low affinity nature of fragment compounds, mid-µM to low-mM Kds for individual 
fragments are common. For example, using six fragments per mixture starting from 
200 mM DMSO stock solutions yields mixtures containing ligands at 33.3 mM and a 
final ligand concentration of 833 µM at 2.5% (v/v) DMSO in the NMR sample. 
Screening ligands at lower concentrations will yield smaller changes in chemical shift, 
potentially resulting in more false negatives. If the ligandability and/or druggability of the 
protein is unknown, a pilot screen with ligands at various concentrations can be 
performed.  
 
4. Compile the fragment mixtures, taking into account the number of acidic, basic, and 
neutral compounds present to avoid significant pH dependent effects.  
 
Fragment screening via PrOF NMR Timing Variable 
 
15. Prepare a blank sample (See step 10) with the addition of the selected amount of the 
organic solvent for the fragment mixtures (no ligand or ligand mixtures), maintaining a 
total sample volume of 500 µL. (e.g. 2 µL 0.1% (v/v) TFA, 25 µL D2O, 468 µL protein 
solution, and 5 µL DMSO) 
Critical Step This blank sample must be identical to the screening samples in regards to 
the protein concentration and amount of solvents used. The only difference should be that 
the blank contains organic solvent (with no ligands) while the screening samples will 
contain the same amount of organic solvent (with the ligand mixtures).   
 
16. Prepare the fragment mixture NMR samples in a similar manner to Step 15 with the 
ligand mixture in place of just the organic solvent.  
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17. Acquire and process PrOF NMR spectra for each mixture (see Steps 13 and 14) 
 
18. Record the chemical shift of each fluorine resonance and calculate the change in 
chemical shift for each resonance relative to the ‘blank’ spectrum.  
 
19. Using the results obtained in the library screen, identify promising mixtures by 
statistically analyzing the changes in chemical shifts for each resonance from each 
mixture, and select the mixtures that yield a change in chemical shift between one and 
two standard deviations above the average change in chemical shifts from all experiments 
obtained from the library screen. 
 
Deconvolution of fragment mixtures Timing Variable 
 
20. Identify the compounds comprising the mixtures that yielded significant changes in 
chemical shift.  
 
21. Prepare NMR samples with each of these compounds separately maintaining 
equivalent ligand concentrations.  
 
22. Collect the PrOF NMR spectra for each new sample (see Step 13) 
 
23. Process and analyze the data as before calculating the changes in chemical shift to 
identify the ligand or ligands that bind to the protein target. (see Steps 14 and 19)  
 
Kd determination of fragment compounds Timing Variable 
 
24. Select a range of ligand concentrations for the binding isotherm being sure to include 
points below and above the anticipated Kd.  
 
25. Prepare NMR samples with varying concentrations of ligands, making sure to add 
solvent until the final volume of ligand solution is equal to the total amount of solvent 
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that was added to the blank prepared in step 15. (1 µL ligand/4 µL DMSO, 2 µL ligand/3 
µL DMSO, etc…) 
 
26. Mix the solutions well and transfer them to NMR tubes.  
 
27. Collect PrOF NMR spectra for each sample and analyze data (see Steps 13, 14 and 
18).  
 
28. Plot the change in chemical shift (Δδ) as a function of ligand concentration.  
 
29. Fit the data using non-linear regression software (e.g. Originpro or Graph Pad Prism) 
the following equation to solve for Kd.  
 
                                                                               
Timing  
Steps 1, Bacterial Transformation: 1 d 
Steps 2-10, Fluorinated Protein Expression and Purification: 2 d (plus characterization 
time; see Box 1) 
Steps 11-14, Protein Observed Fluorine (PrOF) NMR: 5 min-1 h (plus resonance 
assignments; see Box 2) 
Steps 15-19, Fragment Screening via PrOF NMR: Variable (plus fragment mixture 
preparation time; see Box 3) 
Steps 20-23, Deconvolution of Fragment Mixtures: Variable  
Steps 24-27, Kd determination of Fragment Compounds: Variable 
 
Troubleshooting 
Troubleshooting advice can be found in Chapter 7 
 
During fragment screening, resonance assignments facilitate the characterization 
of the binding site of small molecules and of the environmental changes experienced by 
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the labeled protein side chain. Fragment-mixture hits can result in a large change in 
chemical shift (e.g., 0.1–1 p.p.m.) due to the responsiveness of fluorine to changes in its 
chemical environment. The 19F NMR spectra shown in Figure 3.6 show that a peak at 
−134.5 p.p.m. observed in the spectrum of the fluorinated protein 3FY-KIX undergoes a 
change in chemical shift of 0.32 p.p.m. in the spectrum of the same protein in the 
presence of a mixture of different potential ligands. 
 
Figure 3.6 Deconvolution of fragment mixture. 
The bottom spectrum corresponds to the fluorinated protein with no ligands added. 
Asterisks denote resonances that have been significantly perturbed. In this particular 
mixture, compound 3 is responsible for the chemical shift perturbation seen in the 
mixture. The top spectrum represents a global reduction in signal due to nonspecific 
effects. 
 
Protein aggregators and denaturants, whose presence is common in many screens, 
can be detected by global analysis of all of the resonances present in the protein. Global 
coalescence, broadening or a decrease in intensity are all indications of nonspecific 
effects induced by the small molecule on the protein, which may lead to false positives in 
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ligand-observed experiments (e.g., top spectrum in Figure 3.6). Active molecules within a 
mixture are then identified by testing the molecules from the fragment mixture hit one at 
a time. Figure 3.6 shows an example of such a 'deconvolution', which helps to identify 
compound 3 as the active compound, i.e., the compound that caused the change in 
chemical environment sensed by the fluorine labels in the protein. 
Chemical shifts are easily measured and highly reproducible. In particular, 3FY-
KIX, across 23 replicate experiments, had a standard deviation in chemical shift over five 
resonances from 0.011 to 0.037 p.p.m. The latter measurement was from the broadest 
resonance, the one assigned to fluorine-labeled Y649. Although only one resonance was 
observed for fluorine-labeled Y649, the potential for rotamers of the ortho-substituted 
phenol, from restricted motion in this environment, leads to a broadened resonance. In the 
case of 5FW-labeled Brd4, for which the resonances are sharper, the standard deviation 
range for the fluorine resonances was narrower, from 0.009 to 0.026 p.p.m. In addition, 
although aromatic amino acids are commonly found at protein binding sites,100 labeled 
amino acids that are far away from the binding site serve as important internal control 
resonances for nonspecific binding and other factors that may globally affect the 
chemical shift. In the 229-compound screen with 5FW-labeled Brd4, the average change 
in chemical shift (Δδ) of fluorine-labeled W120, which is located outside the ligand 
binding site, was 0.001 ± 0.014 p.p.m. However, in the case of W81, which is located at 
the ligand binding site, the average Δδ of W81's fluorine-labeled analog was 0.033 ± 
0.026 p.p.m. 
Compound affinity is determined for each fragment-hit molecule. Figure 3.7 
shows three binding isotherms. The first binding isotherm was used to identify molecule 
9B11, which is a ligand that binds to the protein KIX in the presumed MLL-binding site 
near Y631 (Kd = 1.6 mM, LE = 0.27). The six experiments can be completed in 30 min. 
In the following two binding isotherms, the protein Brd4 was separately labeled with 
5FW and 3FY. Titration with the Brd4 ligand acetaminophen yielded a similar Kd value 
for the two proteins (LE = 0.44). Titration of two alternatively labeled proteins is a useful 
control for assessing any perturbing effects of fluorine on ligand–protein binding. In 
addition, the magnitude of chemical shift change was substantially larger for the protein 
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labeled with 3FY than for that labeled with 5FW (0.61 p.p.m. versus 0.14 p.p.m.). These 
data are consistent with acetaminophen binding farther away from W81 than the affected 
tyrosine side chains. In some cases, more than one resonance in the NMR spectrum is 
affected by ligand binding. In these instances, binding isotherms can be obtained based 
on perturbation of each resonance, thus providing multiple dissociation constant 
determinations from the same experiment. An example of two affected resonance 
perturbations for the 5FW-labeled bromodomain, BrdT, in the presence of a new 
fragment is shown in Figure 3.5, yielding comparable dissociation constants of 250 and 
210 µM. The larger magnitude of the change in chemical shift is consistent with ligand 
binding near the presumed WPF resonance W50. 
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Figure 3.7 Binding isotherms from PrOF NMR titrations. 
(a) Stacked spectra for the titration of 3FY KIX with molecule 9B11 (see structure at the 
top of the panel). A dashed line is added for reference. The asterisk denotes a partial 
degradation resonance. (b) Binding isotherm generated by monitoring the change in 
chemical shift of fluorine-labeled Y631 as a function of small-molecule concentration. (c) 
Stacked spectra for the titration of 3FY Brd4 with acetaminophen (see structure at the top 
of the panel). A dashed line is added for reference. (d) Binding isotherm generated by 
monitoring the change in chemical shift of fluorine-labeled Y139 as a function of small-
molecule concentration. (e) Stacked spectra for the titration of 5FW Brd4 with 
acetaminophen (see structure at the top of the panel). A dashed line is added for 
reference. (f) Binding isotherm generated by monitoring the change in chemical shift of 
fluorine-labeled W81 as a function of small-molecule concentration. 
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Hajduk et al.148 have demonstrated the efficacy of NMR-based screening methods 
for assessing the druggability of a protein target. Proteins with screening hit rates that are 
lower than 0.1% using fragment libraries are characterized as having low druggability. 
Upon completion of the fragment screen, PrOF NMR can also provide druggability 
information based on the screening hit rate, both for different proteins and for different 
binding sites within a single protein. As an example, of the 508 compounds screened 
against KIX, the MLL site was preferential for ligand binding (0.8% hit rate) over the 
CREB site (0% hit rate),127 consistent with previously reported work149. 
To further increase the speed of PrOF NMR experiments, paramagnetic relaxation 
agents can be used to enhance the relaxation of atomic nuclei. In NMR experiments, the 
recycle delay, during which the spectrometer is idle while the magnetization relaxes after 
a radio frequency pulse, comprises up to 80% or more of the total experiment time 
(Figure 3.8).150 Shorter recycle delays allow more scans per unit time, leading to more 
efficient instrument use. One strategy employed to shorten recycle delays is the addition 
of a paramagnetic metal to decrease the longitudinal relaxation time (T1) of 1H, 13C, and 
15N nuclei in labelled proteins while minimizing unfavorable line-broadening from 
decreasing transverse relaxation time (T2).150–155 
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Figure 3.8 Mechanism of paramagnetic relaxation enhancement molecules. 
(A) Brd4 with sites of fluorine-labelled tryptophans highlighted in blue. (B) Standard 1D 
19F NMR pulse sequence with 90° pulse. (C) Structures of EDTA and DTPA chelates 
used in these experiments. 
   We explored the application of paramagnetic relaxation enhancement (PRE) to 
PrOF NMR, utilizing a solvent-accessible side-chain labelling scheme. This labelling 
scheme is well-suited to studying protein–protein interaction interfaces, which contain a 
high proportion of aromatic amino acids100 that can readily be biosynthetically replaced 
with their fluorinated counterparts. The appended fluorine atoms on the side chains can 
be more solvent exposed than backbone amides, and thus more accessible to 
paramagnetic additives in the bulk solvent. We demonstrate that PRE can reduce 
experiment times significantly by shortening the recycle delay with minimal line 
broadening from T2 effects, ultimately leading to a marked enhancement in sensitivity. In 
the context of low-complexity molecules commonly used in fragment-based ligand 
discovery screening, we further show improvements by using this method for rapidly 
obtaining dissociation constants for weak-binding fragments. In addition to fragment 
screening, this method may also be useful for proteins available in limited abundance 
such as GPCRs,89,156 as the signal to noise increases by the square root of the number of 
scans. Importantly, this approach is also compatible with proteins containing metal 
binding hexahistidine affinity tags and with various fluorinated amino acids. 
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In the absence of Ni-DTPA, experiments were carried out with a recycle delay of 
1 second (1.2 times the measured T1 value of W81, the residue most affected by ligand 
binding in the binding pocket), with a total experiment time of five minutes (280 scans) at 
modest protein concentrations of 50 µM. With 20 mM Ni-DTPA present, the recycle 
delay was shortened to 0.24 seconds for a consistent value of 1.2 times the measured T1 
of W81. In this case, the experiment time was reduced to two minutes (350 scans) at the 
same protein concentration with similar signal-to-noise for the W81 resonance (11.8 with 
Ni-DTPA vs. 10.9 without), a 60% reduction in experiment time (Figure 3.9). The signal-
to-noise ratio may be further improved if Q-damping effects could be mitigated. The T1 
value of W120 (0.15 s) is more reduced than that of W81 (0.20 s) by the addition of 20 
mM Ni-DTPA. Consequently, the relative intensity of W120 increases with the addition 
of 20 mM Ni-DTPA because the net magnetization has more fully relaxed back to the 
ground state before application of the next pulse. In contrast, W75 has a longer T1 value 
(0.27 s) than W81 and thus its resonance is truncated by the short recycle delay of this 
experiment. Because W75 is farther from the binding pocket, the experiment was 
optimized for maximizing signal-to-noise per unit time of W81. Because binding sites 
must be accessible to their binding partners, amino acid side chains located at protein–
protein interaction interfaces should also be accessible to paramagnetic additives and thus 
subject to substantial PRE effects, allowing for shortened recycle delays and experiment 
times. Protein stability does not undergo large perturbations upon titration of Ni-DTPA, 
as measured by differential scanning fluorimetry, a thermal shift assay. Changes in 
melting temperature were ≤1.2 °C by this method (Figure 3.10). 
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Figure 3.9 Comparison of 19F NMR spectra of 50 μM 5FW-Brd4 in the presence 
and absence of paramagnetic additive. 
The addition of 20 mM Ni-DTPA allows a 60% reduction in experiment time while 
preserving the signal-to-noise ratio of W81, perturbations of which report on ligand 
binding. The signal-to-noise ratio of W81 without Ni-DTPA was 11.8, and with Ni-
DTPA was 10.9. 
 
 
Figure 3.10 Differential scanning fluorimetry performed on Brd4 at increasing Ni-
DTPA concentrations. 
Only small changes are seen in the melting temperature. (A) Melting curves at three 
different Ni-DTPA concentrations showing changes in fluorescence upon increasing 
temperature. (B) Melting temperature of Brd4 plotted against Ni-DTPA concentration. 
The melting temperature was 46.4 °C in the absence of Ni-DTPA, 47.3 °C in the 
presence of 10 mM Ni-DTPA, 47.6 °C with 20 mM Ni-DTPA, and 47.4 °C with 40 mM 
Ni-DTPA. 
 
 
In conclusion, PrOF NMR offers the medicinal chemist a useful screening 
platform for small-molecule fragments in early-stage ligand discovery campaigns as 
either a primary or secondary screen informing future ligand optimization efforts. Since 
the seminal studies by Sykes et al.87 on alkaline phosphatase, 19F probe developments and 
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improvements in fluorinated amino acid incorporation have led to ligand identification 
and affinity quantification with small- to medium-sized proteins in a time-efficient 
manner.119 However, in all cases, fluorine perturbation to protein function should be 
assessed. Although current limitations to PrOF NMR exist—including mixture 
deconvolution steps and CSA relaxation effects on fluorine nuclei located on protein side 
chains with limited mobility or in large proteins—these challenges are beginning to be 
addressed by complementary ligand-observed NMR methods, as well as new fluorinated 
amino acid labeling strategies106. 
 
Table 3.4 Troubleshooting 
 
Step	 Problem	 Possible	Reason	 Solution	
9	 Low	 protein	 yield	
relative	 to	 protein	
expression	 yields	
using	 natural	 amino	
Acids	
Cell	 line	 may	 not	 be	robust	 for	 protein	expression			Poor	 compatibility	 with	tRNA	synthetase		Toxic	levels	of	fluorinated	amino	acids	
	
Change	 cell	 lines.	Auxotrophic	 cell	 lines	tend	 to	 provide	 lower	yields	 than	 non-auxotrophic	cell	lines	Use	 glyphosate	 to	induce	 auxotrophy	 in	 a	standard	 cell	 line	 [e.g.	BL21(DE3)]53,54	Cotransform	 with	 a	plasmid	 to	 increase	tRNA	 synthetase	levels47	Utilize	 cell-free	methods55		Reduce	 the	concentration	 of	fluorinated	amino	acids	
Box	1	 Poor	 label	incorporation	 (<	90%)	 Non-optimized	 recovery	time		Not	 enough	 fluorinated	amino	acid	or	amino	acid	precursor	
Experiment	with	longer	recovery	 times	following	 the	 media	swap		Increase	 the	 amount	 of	the	 fluorinated	 amino	
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acid	
13	
	
Extremely	broad	NMR	resonances	 Magnetic	 field	strength	 is	too	 high	 or	 side	 chain	dynamics	 are	 too	 slow,	which	 can	 cause	significant	 broadening	 of	resonances	 due	 to	chemical	shift	anisotropy			Protein	is	too	large	
We	 find	 ideal	 field	strengths	 to	 be	 500	MHz	 –	 600	 MHz.	 The	signal	 sensitivity	 and	resolution	 benefits	 of	higher	 field	 strength	magnets	 can	 be	cancelled	 out	 by	 CSA	and	 shortened	 T2	relaxation.			Use	 alternate	 labeling	strategies	 that	 utilize	fluorinated	amino	acids	with	 more	 rapidly	rotating	fluorine	groups	(e.g.,	trifluoromethyl)43,46				Unknown	 fluorine	resonances	 in	 the	NMR	spectrum	 A	 fluorinated	 impurity	 is	present	 Fluorinated	 impurities	in	 your	 sample	may	 be	removed	 by	 a	 buffer	exchange	Alter	 spectral	 window.	Polymer	 background	 is	most	 pronounced	beyond	-140		
  109 
14	 Fluorine	 referencing	problems	 Fluorine	 reference	 is	sensitive	 to	 solution	conditions	 or	 the	presence	 of	 small	molecule	ligands	
Alternative	 fluorine	references	 (e.g.	trifluoroethanol)	can	be	used	 	Alternative	NMR	pulses	(e.g.	 ERETIC)	 can	 be	utilized.56,57		
Box	2,	Step	2	 Site	 directed	mutagenesis	failure	 The	 specific	 amino	 acid	may	be	necessary	 for	 the	protein	 to	 adopt	 its	proper	 secondary	structure	 or	 affects	more	than	one	resonance	
Site-selective	 labeling	of	 4FF	 and	 3FY	 can	 be	used	 to	 label	 individual	residue	 positions	rather	 than	 globally	changing	 all	 of	 a	 given	amino	acid58,59	Kitevski-LeBlanc	 et	 al.	describe	 a	multidimensional	 NMR	method	 to	 assign	resonances60	Paramagnetic	 metals	(e.g.,	 Gd3+)	 can	 be	 used	to	 broaden	 surface	exposed	residues	
19	 Protein	 signal	overwhelmed	 by	additional	 fluorine	resonances	
A	 fluorine-containing	molecule	is	present	in	the	mixture	 Deconvolute	 the	mixture	 to	 ascertain	 if	other	 ligands	 are	binding	Test	 fluorinated	molecules	 separately	and	 at	 lower	concentrations		Use	 a	 different	fluorinated	 amino	 acid	labeled	protein	
23	 No	 deconvoluted	compounds	 exhibit	the	 same	 change	 in	chemical	 shift	 as	 the	mixture	
Small	 molecules	 may	have	 additive	 effects	 on	the	protein	signals	
Select	 the	 compound	that	 contributes	 the	most	 towards	 the	change	Prioritize	 other	mixtures	 with	 more	distinct	effects	from	the	
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compounds	
29	 Data	do	not	fit	well	for	Kd	 determination	(Poor	R2	value)	
Saturation	 point	 not	 yet	reached,	 making	 it	difficult	 to	 accurately	determine	 a	 Kd	 using	 the	equation	Nonspecific	 or	 multi-site	binding	
Increase	 the	concentration	 of	 the	ligand	 to	 approach	saturation	Deprioritize	 this	compound	Change	 non-linear	regression	 analysis	 to	include	 multiple	binding	sites	
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Chapter	4. Dual	screening	of	BPTF	and	Brd4	uncovers	new	probe	
molecules	
 
Reproduced with permission from “Dual Screening of BPTF and Brd4 Using Protein-
Observed Fluorine NMR Uncovers New Bromodomain Probe Molecules,” A. K. Urick, 
L. M. L. Hawk, M. K. Cassel, N. K. Mishra, S. Liu, N. Adhikari, W. Zhang, C. O. dos 
Santos, J. L. Hall, W. C. K. Pomerantz, ACS Chemical Biology 2015, 2246-2256. 
Copyright 2015 American Chemical Society. 
 
Motivation: Bromodomain-containing protein dysregulation is linked to cancer, diabetes, 
and inflammation. Selective inhibition of bromodomain function is a proposed 
therapeutic strategy. The bromodomain of BPTF was implicated in various cancers, so 
we developed a probe to enable these studies. The chemical shift dispersion of 19F NMR 
is sufficient to allow simultaneous analysis of two bromodomains labeled with 
fluorinated tryptophan. This allows the screen and counter-screen simultaneously with a 
single NMR experiment. Isoform selectivity is known to be challenging between 
bromodomains, so in order to elucidate the role of the bromodomain of BPTF in disease 
we knew that selectivity would be challenging but required. Using Brd4 as the counter 
screen, this was the first communication of a small molecule inhibitor selective for BPTF 
over Brd4. This aryl-urea containing inhibitor was termed AU1, and is a scaffold for 
further chemical probe development. 
 
4.1 Introduction  
Lysine acetylation is an important post-translational modification that is 
significant in the epigenetic regulation of both health and disease. Histone proteins that 
are acetylated are bound by bromodomain-containing proteins facilitating assembly of 
transcription complexes. Small molecules that enable characterizing the role of these 
epigenetic proteins will improve our understanding of signaling pathways and may 
ultimately lead to new therapeutics.157 Clinical trials are underway evaluating inhibition 
of several members of the bromodomain and extra terminal family (BET) bromodomains 
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(i.e, Brd2, 3, 4 and T) in cancer, diabetes, and inflammation, supporting bromodomain 
modulation as a potential therapeutic approach.158 The bromodomain PHD finger 
transcription factor, BPTF, is thought to play a significant role in melanoma,39 
leukemia,38 colorectal,159 bladder cancer,109 and is required for c-MYC transcriptional 
activity42. Both the PHD finger and bromodomain are important for chromatin binding.44 
No selective inhibitors for the BPTF bromodomain had been reported to test its role in 
regulating transcription or cancer, which motivated this research. 
The lack of suitable ligands for competition-based experiments provides a 
challenge for developing reliable screens for bromodomain ligand development, 
specifically for BPTF.52 Direct binding experiments using NMR have become a valued 
method for screening, due to the ability to quantify small molecule protein interactions 
over a wide range of affinities, particularly weak ligands, and have been used for 
bromodomain ligand discovery.68,104,160 Protein-based methods using labelled amides 
(e.g., 1H-15N HSQC) provide additional structural information for developing small 
molecules; however, the experiment can be material intensive and time consuming.70 The 
fluorine nucleus is highly sensitive to changes in chemical environment.  Using this 
environmental sensitivity, we and others reported on a protein-observed fluorine NMR 
method (PrOF NMR) for characterizing ligand binding at protein-protein interaction sites 
using fluorine-labelled side chains which showed a time enhancement of at least 2-fold 
over HSQC on 12 and 15 kDa proteins.99,127,130,161,162 19F is 83% as sensitive as 1H and 
100% isotopically abundant (thus inexpensive), facilitating detection of 19F at low 
concentrations (µM) for small and medium-sized proteins. We previously applied PrOF 
NMR for fragment-based screening of over 500 small molecules, and previously 
characterized the bromodomains Brd4, BrdT, and BPTF.99,127,131  
In this report, we demonstrate how the bromodomain for BPTF and the first 
bromodomain of Brd4 can be screened simultaneously due to the significant chemical 
shift dispersion and simplified 19F NMR spectra. This approach is similar to RAMPED-
UP NMR developed by Zartler et al. who demonstrated the screening potential of three 
differentially labelled proteins via 2D-HSQC NMR experiments.133 These multiplexed 
protein experiments offer selectivity information up front and can lead to the discovery of 
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new ligands for two to three biological targets in one screen. Selective targeting of 
bromodomains remains a significant challenge due to binding site similarity.131 We aimed 
to test if screening in the presence of other BET bromodomains could increase assay 
throughput, stringency, and binding information for finding selective inhibitors. Several 
structural classes of kinase inhibitors show preferential binding to BET bromodomains, 
including the PLK-1 kinase inhibitor BI2536.29,30 We reported its additional binding to a 
non-BET bromodomain BPTF using PrOF NMR.131 We have now screened 229 related 
compounds and disclose our findings for both Brd4 and BPTF selective compounds, 
including the first reported for BPTF.  We validated our ligands using non-fluorinated 
proteins in protein stability, fluorescence anisotropy, and isothermal titration calorimetry 
(ITC) experiments (Figure 1). These led to submicromolar inhibitors for Brd4 and a 
selective BPTF ligand (Kd = 2.8 µM) that we term AU1, which is active in cell culture. 
Finally, we compare our screening hits to a prior screen using x-ray crystallography.29 
We anticipate new Brd4 and BPTF ligands will be valuable probes for studying the role 
of these bromodomains in various cancers. 
 
Figure 4.1 The dual screening workflow. 
A selection of compounds from the Public Kinase Inhibitor Set from GSK were screened 
against 5FW-BPTF and 5FW-Brd4. Hits for BPTF were then rank-ordered by titration of 
ligand, and then one final compound was analyzed by isothermal titration calorimetry 
(ITC). Hits for Brd4 were rank ordered by differential scanning fluorimetry (DSF), and 
then Ki information determined by fluorescence anisotropy (FA). 
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4.2 Results and Discussion 
4.2.1 Design of a dual Protein-Observed 19F NMR screening assay with bromodomains 
Brd4 and BPTF 
 
At least four aromatic amino acids for fluorine labeling are found in the histone 
binding site for more than half of all bromodomains.131 We chose to incorporate 
fluorinated tryptophan residues into both proteins (three for Brd4: W120, W81, and W75; 
one for BPTF: W2824).  Tryptophan 81 of the first bromodomain of Brd4 is located in 
the “WPF shelf”, and is important for recognition of small molecule inhibitors including 
(+)-JQ113 and BI253629. Tryptophan 2824 is the homologous residue in BPTF (Figure 
2A). We can isolate our fluorinated proteins in high yield (84-88 mg/L with high fluorine 
labeling, >95%). We found fluorination to be only modestly perturbing to bromodomain 
structure and function.131 For Brd4, the binding affinity of (+)-JQ1 is 78 and 75 nM for 
the 5-fluorotryptophan (5FW)-labeled and unlabeled proteins respectively. Thermal 
stability is only affected by a two degree change of the thermal melting temperature (Tm) 
from 52 to 50 °C for 5FW-labeled Brd4. In the case of BPTF, we measure a negligible 
change in Tm for the single 5FW incorporation relative to the unlabeled protein (Tm = 53 
°C in both cases) using variable temperature circular dichroism (Figure 4.3, Figure 4.4). 
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Figure 4.2 PrOF NMR dual screening examples. 
A.) The tryptophan at the WPF shelf is in close proximity to the binding site in both Brd4 
and BPTF. B.) A sample of NMR spectra from the screen with the second spectrum 
illustrating a selective Brd4 binder (only the W81 resonance is perturbed), and the third 
spectrum illustrating a selective BPTF binder (only the W2824 resonance is perturbed). 
C.) A titration of BPTF binder AU1 into a solution of 50 µM 5FW-BPTF. Consistent 
with intermediate exchange kinetics, the BPTF resonance broadens into baseline and then 
begins to sharpen at saturating ligand concentrations that reach the solubility limit of 
AU1. 
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Figure 4.3 Circular dichroism of wtBPTF and 5FW-BPTF. 
Secondary structure circular dichroism experiments indicate that fluorinating the 
tryptophan of BPTF only modestly perturbs the secondary structure.	
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Figure 4.4 Circular dichroism thermal melts of wtBPTF and 5FW-BPTF. 
Thermal melting experiments at 222 nm result in negligible differences in melting 
temperatures (Tm = 53 °C in both cases).	
 
Fluorine NMR spectra can be obtained for both proteins at 50 µM in 5 minutes 
(which includes a short reference experiment) leading to four resolved fluorinated 
tryptophan resonances corresponding to fluorine signals from both proteins (Figure 4.2). 
The commonly used solvent dimethylsulfoxide (DMSO) for screening libraries can also 
inhibit bromodomains.163 For NMR, addition of this solvent does not dramatically alter 
the chemical shift dispersion nor the binding ability of the dual Brd4/BPTF ligand 
BI2536 at 1% (v/v). Therefore all screening experiments were carried out at 1% DMSO 
in the presence of 50 µM Brd4 and BPTF. 
The simultaneous screen of Brd4 and BPTF offers an efficient method to discover 
small molecule binders for both bromodomains at the same time. Due to the similarity of 
the acetylated-lysine binding pocket, it is common for molecules to bind with multiple 
bromodomains; therefore, selectivity information is necessary when designing 
bromodomain inhibitors. The published kinase inhibitor set (PKIS I and II) contains 
small molecules designed for kinase inhibitor campaigns and is made widely available by 
GlaxoSmithKline.164 A portion of this library has already been screened by x-ray 
crystallography against Brd4 and allows a basis for comparison of our results.29 As an 
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initial test case, we studied two reported kinase inhibitors (TG-101348 and SB-202190) 
reported to be selective for Brd4 over BPTF.29,30 Our NMR experiment reproduced this 
selectivity (Figure 4.5). We then screened 229 compounds individually at 100 µM. 
Chemical shift perturbations for all compounds were analyzed and the compounds were 
annotated as dual binders, selective BPTF or Brd4 binders, or non-binders (Table 4.4). 
-122 -124 -126 -128 -130 [ppm]
50 μM 5FW-BPTF, 1% DMSO
50 μM 5FW-BPTF, 100 μM TG101209 1% DMSO
50 μM 5FW-BPTF, 100 μM SB-202190, 1% DMSO
 
Figure 4.5 PrOF NMR experiments to assess screening conditions with known 
binders.	
 
The PrOF NMR binding information from the simultaneous screen was readily 
interpreted for most binders that induced significant resonance broadening and chemical 
shift changes (Figure 4.6).  In some cases, the resonance was completely broadened into 
baseline (Figure 4.2). NMR resonances exhibiting this broadening behavior from binding 
are dependent on both the residence time in the bound state and the chemical shift 
difference between the free and bound state.134 In our experience, this is consistent with 
molecules with approximate Kd values from 0.1 to 100 µM. Small molecules can be 
further titrated into the protein solution until the resonance grows out of baseline, and 
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relative binding information can be estimated by the magnitude of change in chemical 
shift (Figure 4.2). We and others have also described PrOF NMR experiments yielding 
both slow and fast exchange binding kinetics, demonstrating the ability to detect 
molecules with dissociation constants in the low nanomolar up to millimolar 
range.99,127,131,161,162 Finally, binding site position can be estimated by which resonance is 
perturbed. In most cases, the W81 resonance of Brd4 located in the WPF shelf is the most 
dramatically perturbed by a binding interaction in the histone recognition pocket, while 
W120 on the other side of the protein remains unperturbed. The stability of W120 offers 
confidence that the protein is still well-folded and in solution. On BPTF, W2824, the only 
tryptophan present, is also located on the WPF shelf. 
 
Figure 4.6 A selection of NMR spectra from the dual bromodomain screen. 
There are spectra indicative of nonselective binders as well as ligands that selectively 
target Brd4 or BPTF. The protein target is indicated on the right of each spectrum.	
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4.2.2 PrOF NMR Screening Results for Brd4 Ligands 
 
From our initial screen we further elucidated the 1,4,5- and 2,4,5-substituted-
imidazole class that was previously disclosed as a ligand class for Brd4, and uncovered 
two new binding classes for both BPTF and Brd4, 1,2,5-oxadiazoles and arylureas 
containing 2,4-disubstituted pyrimidines. From the 1,2,5-oxadiazoles, 2/29 bound to 
BPTF (1 selective over Brd4).  For the arylureas, 6/24 bound to BPTF (2 selective over 
Brd4, Figure 4.2, Figure 4.7). A hit is described as the resonance broadening into 
baseline, and selective hits are defined as perturbing the resonance of the other protein by 
less than one standard deviation based on the average from all NMR experiments in the 
screen for both chemical shift perturbation and change in resonance width at half height. 
Both of these classes also contain compounds that resulted in moderate hits, where 
resonances were broadened but not significantly into baseline. 
 
Figure 4.7 Trisubstituted imidazole ligands. 
Structures of trisubstituted imidazole-containing compounds that are selective for Brd4 
over BPTF. Thermal stabilization and inhibitory potency is reported from differential 
scanning fluorimetry and fluorescence anisotropy experiments respectively. *SB-284847-
BT reported by Ember et al.19 is shown for comparison. 
 
The ligandability from the PKIS set for the first bromodomain of Brd4 was found 
to be slightly higher than BPTF (six selective strong binders versus three selective strong 
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binders), consistent with the druggability analysis of Vidler et al.19 However, due to the 
similarity of many compounds this may also represent a limited amount of explored 
chemical space. Trisubstituted imidazole-containing compounds have been previously 
found to bind to Brd4, and we found additional compounds of this class that bind to this 
protein. Of the seven active trisubstituted imidazole-containing compounds (six of which 
were selective for Brd4), the most dramatic effects observed were for alkyl substitution 
on the phenylether at the 2-position on the pyrimidine. Ember et al. had previously 
reported a 2,3-dimethyl substitution pattern,29 whereas in this study a 3,5-dimethyl, 2,5-
dimethyl, and 4-ethyl were discovered (molecules 1, 2, and 4, Figure 4.7).  As NMR 
could only provide an estimate of the affinity, we turned our attention to complementary 
binding assays, using non-fluorinated bromodomains. 
 
Figure 4.8 Selectivity of different actives from the screen. 
Left.) Selected compounds of varying specificity for BPTF over Brd4, and non-binder 
GSK1379724A.  Right.) ITC binding isotherm for AU1 (46 μM) titrated with 
bromodomain of BPTF (635 µM) 
4.2.3 Thermal Stability Evaluation with Brd4 Ligands using Differential Scanning 
Fluorimetry 
Differential scanning fluorimetry (DSF) has proven to be an effective screening 
tool for Brd4, demonstrating a linear correlation of ligand dissociation constants with 
thermal stability.13,29 To rank order our newly discovered Brd4 ligands using a non-
fluorinated protein, we generated a correlation curve based on published affinity values 
using six known Brd4 binders and thermal melting temperatures measured by DSF under 
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our experimental conditions (Figure 4.9, Figure 4.10). We used this curve to estimate the 
affinity of newly discovered small molecules from our screen, as has previously been 
demonstrated by Ember et al.29 Of the 31 discovered Brd4 ligands, 21 showed a 
stabilization > 1 °C. Eight non-binding compounds for Brd4 were also tested, five of 
which did not result in stabilization larger than 1 °C; none of the non-binders stabilized 
greater than 2.5 °C (Table 4.1). The high confirmation rate supported the sensitivity of 
PrOF NMR for ligand detection, reducing concerns over potential false positive effects 
from fluorine incorporation. The trisubstituted imidazole SB-284851-BT possessed one 
of the largest changes in thermal stability (DTm = 7.4 °C, Table 4.2, Figure 4.7, Figure 
4.10). Due to the only modest linear correlation in our calibration curve, the affinity of 
this compound and analogs were subsequently quantified in competitive inhibition 
assays. 
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Figure 4.9 Thermal shift data from Brd4 with various ligands identified from the 
NMR screen. 
Compounds that were not detected as hits in the NMR screen are labeled as negative 
controls (NC).		
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Figure 4.10 Callibration curve for DSF with Brd4. 
A DSF calibration curve of previously published Brd4 binders is shown, correlating 
change in thermal melting with reported binding affinity. Compounds from this screen 
are illustrated with their respective lines, plotted according to change in melting 
temperature for estimation of dissociation constants from the linear regression shown in 
hashed lines. 
4.2.4 Competitive Inhibition using Fluorescence Anisotropy for Brd4 Ligand Affinity 
Determination. 
To quantify the ligand affinity for Brd4, we designed a competitive inhibition 
assay using fluorescence anisotropy (FA) and a fluorescently labeled derivative of 
BI2536, which was chemically synthesized and reported previously as a fluorescent PLK-
1 kinase probe.165 Chung et al. previously published a similar assay using fluorescently 
labeled analog I-BET762 as a Brd4 ligand.33 A competition experiment eliminates the 
need to fluorescently label all newly discovered small molecules which could alter 
binding and is higher throughput than ITC. We measured a Kd of 50 ± 11 nM for a 
BODIPY-conjugated BI2536 probe in direct binding experiments (Figure 4.11), similar 
to reported values of 48 nM.30 Importantly, the probe could be self-competed with 
unlabeled BI2536 (IC50 = 130 nM for Brd4). We also measured a Kd of 67 ± 21 μM 
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binding to BPTF, consistent with the moderate affinity detected in our NMR binding 
study and within 2-fold of our ITC measurements (Kd = 37 µM) (Figure 4.11). We used 
this probe to determine dissociation constants from a competitive inhibition experiment 
(i.e., Ki) for our new Brd4 ligands. 
BPTF concentration (µM)
An
is
ot
ro
py
-4 -3 -2 -1 0 1 2
80
100
120
140
log competitor concentration (µM)
An
is
ot
ro
py
-2 0 2
60
80
100 SB-590885-AAD
GSK260205A
Dinaciclib
GSK837331
GSK949675A
A
B
 
Figure 4.11 Fluoresence anistropoy with BTPF and BODIPY-BI2536. 
Direct binding fluorescence anisotropy experiments between BODIPY-BI2536 and 
varying concentrations of BPTF were used to determine the Kd = 67 µM +/- 21.			
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Figure 4.12 Determination of Ki of Brd4 binders by fluorescence anisotropy 
competition assay. 
Fluorescence anisotropy signal is shown for several Brd4 binders, including dinaciclib 
(diamonds, Ki=41 µM), GSK260205A (squares, Ki=6.7 µM), and SB-590885-AAD 
(circles, Ki= 0.39 µM), GSK837331 (unfilled squares, 18% inhibition at 100 µM), and 
GSK949675A (unfilled triangles, 60% inhibition at 100 µM).	
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Figure 4.13 Fluorescence anisotropy direct binding and competition experiments 
with Brd4. 
A) Direct binding between BODIPY-BI2536 and varying concentrations of Brd4 yields a 
Ki of 50 ± 11 nM B) Normalized fluorescence anisotropy signal is shown for Brd4 
binders of various potencies, including SB242719 (crosses), SB242851-BT (circles), 
SB242852-BT (triangles), and unlabeled BI2536 (diamonds).  Competition experiments 
were performed against bound BODIPY-BI2536. 
 
We previously determined a Kd of 70 ± 20 μM of a small molecule Dinaciclib 
binding to fluorinated Brd4,131 a known moderate affinity inhibitor.29 Using our FA 
assay, when Dinaciclib was dissolved in ethylene glycol, a bromodomain compatible 
solvent, we obtained a partial inhibition curve with an estimated IC50 of 220 µM (Figure 
4.12, Table 4.1). From this study, we conclude that inhibitors with weaker affinity than 
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Dinaciclib will be difficult to characterize in this current FA format, and therefore we 
report only on a limited set. 	
Table 4.1 Comparative assay data from the Dual Bromodomain Screen 
Compound 
Regno 
aPrOF 
NMR 
ΔTm 
(°C) 
bIC50 
(µM) 
bKi 
(µM
) 
Structure 
SB-284851-
BT +++ 
7.4 ± 
0.2 
2.2 ± 
0.4 
0.31 
± 
0.04 
 
GSK2219329
A +++ 
6.3 ± 
0.5   
 
GSK1379765
A +++ 
6.1 ± 
0.3   
 
SB-590885-
AAE +++ 
5.1 ± 
0.4 
2.5±1.
4 
0.40 
± 
0.23 
 
SB-264866 +++ 4.8 ± 0.1 >100  
 
GSK260205A +++ 4.2 ± 0.8 
39 ± 
65 
7 ± 
12 
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SB-250715 +++ 4.1 ± 0.8 >100  
 
GW837331X +++ 3.8 ± 0.5 
18% 
inhibit
ed at 
100 
 
 
SB-251527 +++ 3.4 ± 0.6   
 
GSK2220400
A +++ 
3.1 ± 
1.2   
 
GSK1379767
A +++ 
3.1 ± 
3.9   
 
GW439255X +++ 3.0 ± 1.0   
 
SB-710363 ++ 2.7 ± 0.9   
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GW829055X - 2.5 ± 0.7   
 
SB-400868-A - 2.3 ± 0.8   
 
GW622475X +++ 2.2 ± 0.8   
 
SB-242719 +++ 2.1 ± 0.5 
70 ± 
17 
13 ± 
3 
 
SB-217360 ++ 2.0 ± 0.8   
 
GW702865X +++ 2.0 ± 0.7   
 
GW684941X +++ 1.9 ± 0.5   
 
GW831090X + 1.8 ± 0.5   
 
  130 
GW525701A + 1.8 ± 0.6   
 
GSK1321565
A ++ 
1.5 ± 
0.6   
 
SB-254169 +++ 1.5 ± 0.5   
 
SB-358518 +++ 1.4 ± 0.1   
 
SB-253228 +++ 1.3 ± 0.1   
 
SB-211743 + 1.3 ± 1.1   
 
GSK1379763
A +++ 
1.3 ± 
0.3   
 
  131 
SKF-86055 +++ 1.2 ± 0.3   
 
GSK1379800
A - 
1.1 ± 
0.5   
 
GW607117X + 1.0 ± 0.4   
 
GSK248233B - 0.9 ± 1.5   
 
GW873004X ++ 0.8 ± 0.4   
 
GW775608X - 0.7 ± 0.7   
 
SB-708998 ++ 0.6 ± 0.7   
 
SB-708999 ++ 0.6 ± 0.7   
 
GW493036X ++ 0.6 ± 0.7   
 
  132 
SB-732941 ++ 0.6 ±  0.7   
 
GSK1379753
A +++ 
0.5 ± 
0.5   
 
GW450241X - 0.5 ± 0.5   
 
GSK1023156
A +++ 
0.4 ± 
1.1   
 
GSK300014A ++ 0.4 ±  0.5   
 
GSK1173862
A ++ 
0.4 ± 
0.5   
 
GSK1030058
A - 
0.2 ± 
1.0   
 
GW679662X +++ 0.2 ± 1.0   
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GSK317354A +++ 0.0 ± 0.7   
 
GW335962X + -0.2 ± 0.8   
 
SKF-106164-
A2 +++ 
-0.3 
± 1.2   
 
SB-633825 + -0.4 ± 0.9 >100  
 
GSK620503A +++ -0.7 ± 1.1    
 
GSK312948A ++ -0.8 ± 0.8   
 
GW876790X ++ -0.9 ± 0.9   
 
GSK180736A + -1.5 ± 0.8   
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SB-738004 +++ -1.9 ± 1.1 >100  
 
GW824645A ++ -1.9 ± 0.7   
 
SB-390526 ++ -1.9 ± 1.0 >100  
 
SB-707548-A ++ -2.1 ± 0.5 >100  
 
GW407323A +++ -2.2 ± 1.0 >100  
 
GSK949675A ++ -2.4 ± 0.7 
60% 
inhibiti
on at 
100 
 
 
GSK711701A ++ -2.7 ± 0.3 >100  
 
SB-747651-A - -4.6 ± 1.4   
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SB-284852-
BT   
4.7 ± 
1.4 
0.58 
± 
0.23 
 
BI2536   0.16 ± 0.05 
Not 
deter
mine
d 
N
NN
N
O
N
HO
O
N
H
N
 
a +++, a resonance from the protein in question has been completely broadened 
into baseline 
++, a resonance from the protein in question has been perturbed by 2 standard 
deviations in either chemical shift or linewidth +, a resonance from the protein in 
question has been perturbed by 1 standard deviation in either chemical shift or 
linewidth 
-, resonances are minimally to non perturbed 
b values were obtained for via FA for Brd4 only 
 	
 
The labs of Schönbrunn29 and Knapp30 found that 1,4,5- and 2,4,5-trisubstituted 
imidazoles bound to Brd4. Trisubstituted imidazoles were also found to bind to 
BAZ2A/B.166 We have now discovered analogs in our PrOF NMR experiment with 
submicromolar affinity, the most potent of these scaffolds for Brd4 to date. For 1,4,5-
trisubstituted imidazoles in the FA competitive inhibition experiment, we determined a Ki 
of 310 nM for SB-284851-BT (Figure 4.13,Table 4.2), our most promising candidate 
from DSF and PrOF NMR experiments, a modestly higher affinity than estimated from 
the calibration curve. The arylalkyl substitution pattern bonded to the pyrimidine is 
important for binding. Based on the results with SB-284851-BT having a 3,5-dimethyl 
substitution pattern, we tested SB-284852-BT (previously not screened by PrOF NMR) 
with a 2,5-dimethyl group substituted on the aromatic ring. SB-284852-BT has a slightly 
higher Ki of 580 nM (Figure 4.13,Table 4.2). A regioisomer with a 2,3-dimethyl 
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substituted aromatic ring (SB-284847-BT) was co-crystallized by Ember et al. with Brd4 
but inhibited with a much weaker potency (IC50 = 20 μM).29 A 4-ethyl group on SB-
242719 also results in 40-fold weaker affinity with a Ki of 13 µM in our assay and a DTm 
= 2.1 °C by DSF (Figure 4.13,Table 4.2). 
Table 4.2 Comparative assay data from the Dual Bromodomain Screen 
Structure BPTF 19F 
NMRa 
Brd4 
19F  
NMR
a 
Brd4 
ΔTm 
(°C) 
Ki, (FP, 
Brd4)  
 
Kd (ITC, 
BPTF) 
 
 
GSK1379725A (AU1) 
+++ - N/A N/A Kd = 2.8 
µM 
 
GSK1379746A 
+++ - N/A N/A N/A 
 
GSK1379767A* 
+++ +++ 3.1 ± 
3.9 
b N/A 
 
GSK260205A 
+++ +++ 4.2 ± 
0.8 
Ki = 7 ± 
12 µM 
N/A 
 
GSK561866B 
++ - N/A N/A N/A 
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SB-242719 
+ +++ 2.1 ± 
0.5 
Ki = 13 ± 
3 µM 
N/A 
 
SB-284851-BT 
- +++ 7.4 ± 
0.2 
Ki = 0.31 
± 0.04 
µM 
N/A 
 
SB-284852-BT 
N/A N/A N/A Ki = 0.58 
± 0.23 
µM 
N/A 
 
SB-590885-AAE 
- +++ 5.1 ± 
0.4 
Ki = 0.40 
± 0.23 
µM 
N/A 
a +++, a resonance from the protein in question has been completely broadened into 
baseline 
++, a resonance from the protein in question has been perturbed by 2 standard 
deviations in either chemical shift or linewidth +, a resonance from the protein in 
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question has been perturbed by 1 standard deviation in either chemical shift or linewidth 
-, resonances are minimally to non-perturbed 
b Compound was not soluble in assay buffer 
 
 
Our newly discovered Brd4 inhibitors SB-284851-BT and a 2,4,5-
trisubsitutedimidazole SB-590885-AAE (Ki = 400 nM, Table 4.2) were previously 
characterized as selective B-Raf kinase (Kd = 0.3 nM)167 and p38α kinase (IC50 = 41 
nM)168 inhibitors. Although a variety of trisubstituted imidazoles have been reported to 
bind to Brd4, to date these two compounds are the most potent analogs, and may 
represent a starting point for ligand design or use in cell culture experiment to test the 
polypharmacology and potential synergy for p38a or B-Raf and Brd4 inhibition in 
various cancer models.   
 
4.2.5 PrOF NMR Screening Results and Structure Activity Relationships for BPTF 
Ligands 
 
In addition to new Brd4 ligands, several selective compounds were also found to 
bind to BPTF.  These results are encouraging due to an absence of reported ligands for 
the bromodomain of BPTF.  The arylurea containing compounds were the tightest 
binders that we found for BPTF exhibiting greater than two standard deviation changes in 
chemical shift and resonance broadening into baseline. Two arylurea containing 
compounds completely selective for BPTF over Brd4 were obtained, GSK1379746A and 
GSK1379725A.  GSK1379725A was selected for follow-up studies, and so we now refer 
to it as AU1 (Figure 4.2, Figure 4.8, Figure 4.14). Negligible chemical shift changes were 
observed for Brd4 in the presence of AU1 at up to 160 µM (Figure 4.15). In addition, a 
1,2,5-oxadiazole (GSK561866B) was highly selective for BPTF (Figure 4.8). Non-
selective arylurea containing compounds from the screen that have a trimethoxy-
substituted aryl ring and bound in the intermediate exchange regime by PrOF NMR, are 
anticipated to bind with the trimethoxyphenyl ring in the acetyl-lysine binding pocket 
based on the binding mode of the trimethoxyphenyl ring of GW61228X bound to Brd4 
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reported by Ember et al.29. Arylurea-containing compounds that lacked the trimethoxy-
substituted aryl ring in some cases bound more weakly to Brd4.  
 
Figure 4.14 BPTF binders at lower concentrations. 
The strongest selective binders were added into 5FW-BPTF at ¼ the concentration of the 
screen to rank-order the compounds. The rapid broadening of AU1 suggests a lower 
dissociation constant than the slight broadening of SB-744941. 
  140 
	
 
Figure 4.15 Fluorine NMR spectra analyzing 5FW-Brd4 with AU1. 
A graph accompanying graph showing absolute chemical shift perturbation of each 
resonance. The low chemical shift perturbations as well as no significant broadening 
indicate minimal interaction of AU1 with 5FW-Brd4. 
	
 
Of the six high affinity BPTF binding compounds of the arylurea class, binding 
appears to be correlated to a benzene ring with a meta-substituted carbonyl present. 
Computational binding studies using the Phase169–171 module of Schrödinger indicate the 
placement of both the aromatic ring and hydrogen bond acceptor strongly correlate with 
binding (Table 4.3, Figure 4.16, Figure 4.17). Docking studies indicate probable p-p 
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interactions with the nearby phenylalanine 2887 and hydrogen bonds to the asparagine 
2881 side chain in the binding site.172,173 Compound GSK1379724A is similar to AU1 
(Figure 4.8), but contains a cyclic acetal in place of a carbonyl group on the phenyl ring. 
This compound is unable to bind to either BPTF or Brd4, and represents a useful negative 
control compound for future studies. Related molecules without a carbonyl group showed 
poor BPTF binding. Additional arylurea-containing compounds will be developed to 
determine a more extensive structure activity relationship prior to obtaining higher 
resolution structural information. 
 
Figure 4.16 A per-residue interaction map of AU1 with BPTF developed from 
QM/MM docking studies in Glide. 
Please note that the residue numbers do not correspond to standard numbering for BPTF. 
The phenylalanine engaging in the pi-pi interaction is F2887 and the asparagine hydrogen 
bonding to the oxygen of AU1 is N2881. While (S)-AU1 is shown here, the SAR of the 
different stereoisomers has yet to be elucidated.			
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Figure 4.17 A pharmacophore model of the aryl-urea compounds generated using 
Phase. 
Of particular interest are R12 and A5, both of which seem to correlate heavily with 
binding. 
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Table 4.3 A list of arylurea compounds used for the phase analysis, and their 
required activity by the generated pharmacophore model. 
Name  Pharm Set 
 
GSK1379706A 
 inactive 
GSK1379710A  inactive 
GSK1379712A  inactive 
GSK1379714A  inactive 
GSK1379717A  inactive 
GSK1379720A  inactive 
GSK1379721A  inactive 
GSK1379722A  inactive 
GSK1379723A  inactive 
GSK1379724A  inactive 
GSK1379725A  inactive 
GSK1379727A  inactive 
GSK1379731A  inactive 
GSK1379741A  inactive 
GSK1379742A  inactive 
GSK1379745A  inactive 
GSK1379746A  inactive 
GSK1379748A  inactive 
GSK1379753A  active 
GSK1379762A  inactive 
GSK1379763A  active 
GSK1379765A  active 
GSK1379766A  active 
GSK1379767A  active 	
 
4.2.6 Dissociation Constant Determination for a Selective BPTF Ligand AU1  
Due to the absence of ligands for the BPTF bromodomain, a correlation between 
DSF thermal stability values and Kd have yet to be reported.  In fact, for BI2536 we 
measured a slight decrease in the Tm for BPTF of -1.2 oC consistent with other reports30, 
although we have determined a Kd of 37 μM and 67 μM via ITC and FA respectively 
(Figure 4.11). The origins of the slight destabilization are yet unclear. From the NMR 
titration of AU1, the bound and unbound resonance were separated by 171 Hz (Figure 
4.2), providing an upper bound for the chemical exchange rate.134 Assuming an 
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association rate of 1 x 108 M-1 s-1 as a high end for a range of protein-small molecule 
interactions, (e.g., chymotrypsin:proflavin k1 = 1.2 x 108 M-1 s-1),174 we estimate an upper 
Kd of 8 µM from this experiment. For a more accurate determination with a non-
fluorinated protein, we used ITC as a complementary direct binding assay using 
unlabeled BPTF. We obtained a Kd of 2.8 μM (Figure 4.8), consistent with our 
intermediate exchange resonance broadening by PrOF NMR. We are encouraged by this 
initial potency as a starting point for future cell-based studies, although new analogs are 
anticipated to be necessary, including the identification of the active stereoisomer and 
removal of the methyl ester hydrolysis susceptibility. A summary of our recorded data 
from the biochemical experiments described above is found in Table 4.1. 
Although AU1 has been demonstrated to be selective over Brd4, a full selectivity 
panel against other bromodomains will be needed.  A database search using ChEMBL 
only showed AU1 to be active in five whole cell assays with an EC50 of 500 nM carried 
out by Gamo et al.175  However, the targets are unknown, which we are following up. 
Additionally, no kinase activity has been reported for AU1 despite the growing screening 
use of the PKIS library.  These results are encouraging regarding off target effects for this 
BPTF ligand.   
 
4.2.7 AU1 transcriptional inhibition experiments in live cells.  
As an initial test for the effect of BPTF bromodomain inhibition on transcription, 
we first measured the cellular toxicity against healthy human cells. The prior study by 
Gamo et al. did not detect cellular toxicity in hepatocytes at 10 µM compound,175  which 
is more than 3-fold above the Kd of AU1.  We also observe no cellular toxicity against 
HEK 293T cells after 24 hours at 3 and 10 µM. Only after 48 hours of incubation at 10 
µM do cells have a reduced viability (76% viable) (Figure 4.18).  
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Figure 4.18 Toxicity assay of AU1 with mamallian cells. 
HEK 293T cells were plated in 96-well plates. 24h post plating, cells were treated with 
DMSO or AU1 (1 µM, 3 µM and 10 µM) for 24 (n=6, per treatment) and 48h (n=5, per 
treatment). Cell viability was assessed by using a CellTiter Blue Viability kit from 
Promega. 
	
 
Ruthenberg et al. demonstrated that both the PHD finger and bromodomain of 
BPTF were important for chromatin binding.44 Native chromatin precipitation 
experiments showed colocalization of BPTF at the MOBKL3 locus with histone H4, 
acetylated at lysine 16.44 To investigate the effect of AU1 treatment on BPTF-mediated 
gene regulation, we cloned a BPTF-regulatory region, localized upstream to the Mobkl3 
promoter region,44 into a firefly luciferase reporter plasmid (pGL3_Mobkl3p).  
Transfection of the pGL3_Mobkl3p into Eph4, a normal mouse mammary gland cell 
line176 displayed robust luciferase activity (Figure 4.19), ~7-fold greater than those 
observed with a control firefly luciferase reporter plasmid (pGL3_empty) lacking a BPTF 
regulatory region (Figure 4.19).  This data supports the association of factors to the 
Mobkl3 regulatory region, such as BPTF contributed to the increased luciferase activity. 
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Figure 4.19 AU1 treatment interferes with BPTF activity in cells. 
Eph4 normal mouse mammary gland cells were transfected with firefly pGL3_empty 
(background control), firefly pGL3_Mobkl3p and pRL Renilla control vectors and 
luciferase activity was measured. Firefly luciferase activity was normalized to Renilla 
luciferase activity. N = 4 biological replicates. * pGL3_empty pGL3_Mobkl3p,  
p=0.0002. ** pGL3_Mobkl3p untreated x pGL3_Mobkl3p plus AU-1, p=0.0006. 
 
To test if the pGL3_Mobkl3p luciferase levels were dependent on the 
bromodomain of BPTF, the Eph4 were again transfected with either the pGL3_Mobkl3p 
or the pGL3_empty vector and then treated with 5 µM AU1 for 12 hours. A significant 
loss of luciferase activity (~4-fold) was observed in cells transfected with 
pGL3_Mobkl3p vector, suggesting that the Mobkl3 regulatory region requires BPTF 
activity to support the regulation of luciferase activity (Figure 4.19).  Together our data 
suggests that binding of AU1 to the BPTF bromodomain interferes with its regulatory 
activity in cultured cells. This may represent a suitable system to study the net effects of 
the BPTF-bromodomain on gene regulation. 
 
4.2.8 Comparison of PrOF NMR to a prior X-ray Crystallography Screen     
A combination of PrOF NMR, DSF, and FA have led to several new small 
molecules for both Brd4 and BPTF. In 2014, two parallel screens using kinase inhibitor 
libraries against Brd4 were reported providing a useful data set for assessing the 
application of PrOF NMR in a discovery mode.29,30 From the x-ray crystallography 
screen29, 61 compounds overlapped with the molecules studied here. Of the 28 
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compounds where a high-resolution crystal structure was obtained (either apo or a co-
crystal), PrOF NMR uncovered seven hits while x-ray crystallography uncovered two, 
with one compound identified by both screening techniques. Although our PrOF NMR 
results reveal more binders than this screen with the PKIS set; both methods discovered 
ligands with similar structural classes.  In combination, PrOF NMR offers a 
complementary technique to x-ray crystallography, potentially guiding efforts for 
subsequent crystallization studies and improving on the structural biology efforts 
targeting bromodomain ligand discovery. 
In conclusion, this study presents the first simultaneous screen of two proteins by 
PrOF NMR, enhancing the throughput and stringency for finding selective ligands for 
structurally related proteins. This study is reminiscent of RAMPED-UP NMR by Zartler 
et al. highlighting the screening potential of three differentially labeled proteins via 2D-
HSQC NMR experiments.133 NMR screening has typically been employed in the area of 
fragment-based discovery. The hinge-binding kinase inhibitor classes have proven to be a 
privileged structural class for bromodomains allowing efficient exploration of chemical 
space and may be useful against other bromodomain family members outside the BET 
class. Several p38α B-Raf inhibitors with submicromolar affinity for Brd4 will allow for 
the testing of synergistic effects of dual protein inhibition in cancer and inflammation.  
Our newest ligand for BPTF, AU1, represents a useful starting point for testing the 
unexplored role of its bromodomain in various cancer models. Biological studies are 
currently underway. Our method has been applied to BPTF and BET bromodomain Brd4.  
Discovery of highly isoform selective ligands for bromodomains within the BET 
bromodomain family has yet to be successful.  In the future, PrOF NMR screening in the 
presence of multiple BET bromodomains may provide a method to achieve this goal.  
 
4.3 Future Directions 
4.3.1 The role of the bromodomain of BPTF and optimization of AU1 
Since initial publication of the preceding work, the structure of AU1 has been 
further optimized and preliminary data obtained to assess its effect in diseased cells. The 
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S enantiomer was confirmed to be the active enantiomer against BPTF, with an affinity 
confirmed by microscale thermophoresis (Figure 4.20). The R enantiomer showed no 
binding by PrOF NMR. The methylester as well as the urea were found to be important 
for BPTF binding, while the aniline portion of the molecule can be substituted with little 
effect on binding (Figure 4.21). The urea seems to be partially responsible for the poor 
solubility of this compound, as remove of the on the urea nitrogen results in a more 
soluble compound with a reduced binding affinity. In order to better enable successful 
SAR studies with AU1, we have attempted co-crystallization studies with (S)-AU1 and 
the bromodomain of BPTF. While we have successfully crystalized the apo-structure of 
BPTF several times, attempts to generate a co-crystal structure are still ongoing (Figure 
4.22). 
 
 
Figure 4.20 Microscale thermophoresis trace of (S)-AU1 with BPTF, resulting in a 
Kd of 807 nM +/- 440 nM. 
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Figure 4.21 Limited set of derivatives of AU1 that have been tested for binding 
against BPTF. 
 
 
Figure 4.22 X-ray crystal structure of BPTF with ethylene glycol in the binding site. 
Encouraged by how prone this protein is to crystallization, co-crystallization attempts 
with BPTF and various aryl-urea analogs are ongoing. 
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 Exposure of melanoma cells to (S)-AU1 in a synergistic experiment with 
vemurafenib resulted in almost complete reduction of cell proliferation. Further 
experiments will be assessed when a more potent version of (S)-AU1 can be developed. 
4.3.2 Development of HU-10 
 
The trisubstituted imidazole compound SB-284851-BT was further elaborated 
into HU-10 to increase binding affinity for Brd4 (Figure 4.23). It is being used to 
elucidate the polypharmacology of inhibiting the bromodomain Brd4 and kinases 
simultaneously. 
 
Figure 4.23 The structure of HU-10 
4.4 Methods 
Expression of 5FW-Brd4 (42−168), and 5FW-BPTF (2793−2911): 
3FY and 5FW labeled Brd4(1) were expressed based on established methods99 
using E. coli Bl21(DE3) + pRARE strains. To express the labeled protein, the secondary 
culture in LB media was grown until an O.D. at 600 nm of 0.6 was reached followed by 
harvesting. Cells were resuspended in defined media of Muchmore et al.110 containing 5-
fluoroindole (60 mg/L) in place of tryptophan96. The resuspended E. coli were incubated 
at 37 °C while shaking for 1.5 h followed by the cooling to 20 °C and media temperature 
equilibration for 30 min. Protein expression was induced with 1 mM IPTG overnight 
(14−16 h) at 20 °C. The cells were harvested and stored at −20 °C. 5FW-BPTF was 
expressed by the same protocol. Cell pellets were thawed at RT followed by the addition 
of lysis buffer (50 mM Phosphate pH 7.4, 300 mM NaCl) containing protease inhibitor 
PMSF (5 mM) as well as the Halt protease inhibitor and purified according to methods 
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described in the appendix using Ni-affinity chromatography. Yields following 
purification are 88 mg/L 5FW-Brd4 (>95% fluorine incorporation), 84 mg/L 5FW-BPTF 
(>95% fluorine incorporation). Purity of proteins was assessed by SDS-PAGE. 
Fluorinated amino acid incorporation efficiency in proteins was measured by mass 
spectrometry as described in the appendix. Concentration was determined via absorbance 
at 280 nm.177 
 
Protein Observed Fluorine NMR: 
1D 19F NMR Parameters. 19F NMR spectra were acquired at 470 MHz on a 
Bruker 500 spectrometer with a 5 mm Prodigy TCI Cryoprobe without proton 
decoupling. Samples containing 40−50 µM bromodomains were labeled in 50 mM TRIS, 
100 mM NaCl, and 5% D2O, pH 7.4 with 100 µM ligand for binding assays unless 
otherwise stated. Spectra were referenced to trifluoroacetate (−76.55 ppm). Measurement 
parameters included a relaxation delay time of 0.7 s for 5FW-Brd4(1) and a 90° flip 
angle. An acquisition time of 0.05 s was used for all experiments. A sweepwidth of 10 
ppm was used for 5FW-Brd4 spectra. All screening experiments used 400 transients. 
Small molecules were titrated into the protein solution from concentrated stock solutions 
of DMSO (10 mM for all small molecules except acetaminophen). Final DMSO 
concentrations were kept at or below 1% DMSO. 
 
Differential Scanning Fluorimetry (DSF): 
The inhibitory activities of compounds against Brd4 were assessed by DSF using a 
CFX384 Real-Time PCR Detection System (BioRad). Purified Brd4 (4 µM final 
concentration; 10 mM HEPES (pH 7.5), 100 mM NaCl, and 1 mM DTT) were assayed, 
in replicates of ten, in a 384-well plate. Inhibitors were added to a final concentration of 
100 µM and 1 % DMSO or ethylene glycol. SYPRO Orange Protein Gel Stain (1:5000; 
Sigma Aldrich) was used as the fluorescent probe. Protein stability was using 0.1 °C 
increments and 10 s incubations per increment from 25 to 75 oC. The inflection point of 
the transition curve/melting temperature (Tm) was calculated using the Boltzmann 
equation within the Protein Thermal Shift Software (v.1.1) (Applied Biosystems). (+)-
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JQ1 and dinaciclib were used as controls for strong and weak binders of Brd4, 
respectively. The ΔTm was calculated by using DMSO and ethylene glycol control wells 
as a reference.  
 
Fluorescence Anisotropy Direct Binding and Competition Experiments: 
Fluorescence anisotropy was measured from an absorption wavelength of 485 nm 
and an emission wavelength of 535 nm on a Tecan Infinite 500 plate reader using 384-
well plates (Corning 3676).  All experiments were carried out in 50 mM Tris, 100 mM 
NaCl, 5 mM CHAPS at pH 7.4. The fluorescently labeled tracer, BODIPY-BI2536, was 
synthesized according to published methods.165 For both direct binding and competition 
experiments, 25 µM stocks of a BODIPY-BI2536 stock solution in DMSO were diluted 
to a final concentration of 25 nM.  For direct binding experiments, Brd4 and BPTF were 
serially diluted from micromolar to subnanomolar concentrations.  For competition 
experiments, Brd4 was kept at a constant concentration of 156 nM, equivalent to 80% 
bound tracer as determined in direct binding experiments, and the concentration of 
competing ligand was serially diluted from micromolar to subnanomolar concentrations.  
Because of the capacity of DMSO to perturb bromodomain binding, competitors were 
diluted from 10 mM ethylene glycol stocks.  Data were collected within 30 minutes after 
plating to minimize Brd4 binding to the plate surface. Measurements taken after 30 
minutes led to a significant decrease in the apparent dissociation constant at longer time 
points.  All experiments were carried out in triplicate.  Acquired data were fit using 
GraphPad Prism.  Kd values were determined by fitting to the following equation, which 
accounts for ligand depletion. In this equation, b and c are the maximal and minimal 
anisotropy values, respectively, a is the concentration of fluorescently labeled tracer, x is 
the protein concentration, and y is the observed anisotropy value. 
y = c+ (b− c) (Kd + a+ x)− (Kd + a+ x)
2 − 4ax
2a   
IC50 values were determined using GraphPad Prism’s log(inhibitor) vs response function. 
Ki values were obtained using a variant of the Cheng-Prussof equation from Huang et 
al.102 
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Isothermal Titration Calorimetry: 
A Nano-ITC was used to perform isothermal titration calorimetry experiments. 
AU1 (46 µM) was diluted into the same buffer as BPTF (50 mM sodium phosphate pH 
7.0) from a 10 mM DMSO stock solution. The resulting solution was sonicated 
immediately prior to use. Titrations were carried out by using a first injection of 0.5 µM 
followed by 19 injections of 2.5 µL volume of 635 µM BPTF with a releasing period of 8 
seconds per injection with 300 second spacing time between injections. Heat liberated by 
each injection was integrated (ΔH) and plotted against molar ratio of ligand and protein. 
The obtained data was fit by using predefined two binding site model. The fitting of data 
was not sufficient with one binding site whereas a two binding site model produced an 
appropriate fit, indicating a potential low affinity binding (Kd = 1.0 mM) site. Data was 
analyzed by NanoAnalyze software to calculate enthalpy of binding (ΔH) and 
dissociation constants (Kd). A two binding site binding model was used for data fitting.  
ITC data was obtained in a similar fashion for BI2536, using a concentration of 0.5 mM 
of BI2536 and 7 mM BPTF. 
 
Viability Assays: 
Cell viability assay: Cell viability assay of HEK 293 cells were performed using 
resazurine dye based CellTiter-Blue® (Promega). HEK 293T cells were plated in 96 well 
plates and experiments conducted when cells were 80% confluent. Cells were treated 
with the 0, 1.0, 3.0 and 10.0 μM AU1 for 24 and 48 hours in 5% CO2 (n=5-6, per 
condition). 20 µL of CellTiter-Blue® was added to the each well and incubated for 2.5 h 
at 37oC. As resazurin dye is reduced by viable cells to resorufin. Resorufin is fluorescent 
at 580 excitation and 590 emission. The data is normalized with the control (DMSO 
treated), (mean +/- SE). 
 
Luciferase reporter array: 
The BPTF-regulatory region localized upstream to the Mobkl3 promoter region 
(~380bp) was amplified by PCR, cloned into pCR2.1-TOPO vector (Invitrogen) and 
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transferred to the firefly luciferase pGL3-Basic vector (Promega) using XhoI and HindIII 
restriction enzymes. pGL3_Mobkl3p and pGL3_empty vectors were propagated in 
TOP10 chemically competent bacteria (Invitrogen) and plasmid purification was 
performed with Qiagen kit (Qiagen). Purified plasmids were co-transfected into Eph4 
cells, a normal mouse mammary gland cell line (gift from Dr. Celeste M. Nelson) with 
pRL Renilla luciferase control vector (Promega) using PEI (Sigma). Transfection was 
carried out for 8 hours, followed by media change and treatment with AU1 (12 hours). 
Cells were then washed once with 1xPBS and lysed with Passive Lysis Buffer (Promega) 
for 20 minutes with constant agitation. Luciferase activity was measured with the Dual-
Glow luciferase reporter assay kit (Promega) on a Glomax 20/20 luminometer (Promega). 
Firefly luciferase levels were normalized to Renilla luciferase levels.  
 
Protein Expression and Molecular Biology Materials:  
For E. coli growth, LB agar, LB media, defined media components including 
unlabeled amino acids, uracil, thiamine-HCl, nicotinic acid, biotin and buffer components 
were purchased from RPI corp. Thymine, cytosine, guanosine were purchased from Alfa 
Aesar. Magnesium chloride, manganese sulfate, succinic acid, calcium chloride and 5-
fluoroindole were purchased from Sigma-Aldrich. Miniprep plasmid purification kit was 
purchased from Clontech.  
 
Unlabeled Brd4, and BPTF Protein Expression:  
The pNIC28-BSA4 plasmid containing the first bromodomain of Brd4 and BPTF 
genes were kind gifts from the laboratory of Stefan Knapp. For protein expression, either 
the E. coli Rosetta (DE3) strain (Novagen) was first transformed with the respective 
expression plasmid or the BL21(DE3) strain was cotransformed along with the pRARE 
(Novagen) plasmid and plated onto agar plates containing kanamycin (100 mg/L) and 
chloramphenicol (35 mg/L). Following overnight incubation at 37 °C, a single colony 
was selected from the agar plate and inoculated in 50 mL of LB media containing 
kanamycin (100 mg/L) and chloramphenicol (35 mg/L). The primary culture was grown 
overnight at 25 °C while shaking at 250 rpm. For secondary culture growth, 1 L of LB 
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media containing kanamycin (100 mg/L) was inoculated with the primary culture and 
cultured at 37 °C while shaking at 250 rpm. When the O.D. of culture at 600 nm reached 
0.6, the shaker temperature was reduced to 20 °C. After 30 minutes, the expression was 
induced with 1 mM IPTG overnight for 12-16 h. Cells were harvested by centrifugation 
and stored at -20 °C.  
 
Bromodomain Purification:  
To purify fluorinated and unlabeled Brd4, the cell pellet was thawed at room 
temperature followed by the addition of lysis buffer (50 mM Phosphate pH 7.4, 300 mM 
NaCl) containing protease inhibitor PMSF (5 mM) as well as the Halt protease inhibitor. 
Cells were lysed by sonication and the cell lysate was centrifuged at 7500 g for 30 
minutes followed by supernatant filtration over Whatman filter paper. Filtrate containing 
the histidine-tagged Brd4 was loaded on to a nickel-NTA affinity column and eluted with 
an imidazole gradient on an AKTA FPLC system monitoring the O.D. at 280 nm. 
Imidazole was removed from the buffer using a HiPrep column (GE) for buffer exchange 
into 50 mM Tris pH 7.4, 100 mM NaCl. Purified and buffer exchanged protein was 
treated with TEV protease for either 2 hours at room temperature or alternatively at 4 °C 
overnight on a rotating carrousel. The cleaved His-tag, TEV protease and uncleaved Brd4 
were removed using nickel-NTA affinity resin.  
Protein Mass Spectral Analysis  
Product molecular weight was confirmed by electrospray ionization mass 
spectrometry (ESI-MS) using a Thermo Scientific Orbitrap Velos LC-MS, reported 
previously. To determine the percent incorporation for fluorinated proteins the integration 
values of the different deconvoluted mass peaks are entered into the following equation 
to determine the relative incorporation e.g, FWBrd4:  	*	100		
0FWBrd4 is 5FWBrd4 with no fluorine substitutions, 1FWBrd4 is 5FWBrd4 with 
one fluorine substitution, 2FWBrd4 has two fluorines substituted and FWBrd4 has 3 
fluorines substituted.  
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Circular Dichroism:  
To check the secondary structural content, far-UV CD spectra (200-260 nm) of 
unlabeled and labeled proteins were collected using a peltier equipped temperature 
controlled Jasco J-815 spectropolarimeter at 25 °C. For all measurements, 20 µM (50 
mM Tris buffer pH 7.4 containing 100 mM NaCl) of protein and a 1 mm cuvette path-
length were used. Spectral data were collected at a scan rate of 50 nm/min with averaging 
of 10 spectra. Processed data were baseline corrected against spectra taken with buffer 
alone.  
 
Thermal Melting: 
Thermal stabilities of labeled and unlabeled proteins were measured by the 
change in ellipticity at 222 nm with the increase in temperature from 20 °C to 80 °C at 
the scan rate of 60 degrees/h.  
 
Kd estimation of AU1 by NMR: 
The upper limit of koff can be determined by the following equation: 
 
Where  is the energy difference between the two resonances in Hz and k1 = koff 
. The kon rate can be estimated as diffusion controlled (1.0 x 108 M-1/s). The following 
equation can then be used to estimate an upper limit to the Kd: 
 
The energy difference between the bound and unbound resonance of 5FW-BPTF 
when binding with AU1 is a difference of 171 Hz, which results in an upper limit Kd of 8 
µM 
 
 
 
  157 
Docking Studies of AU1 with Brd4 and BPTF: 
Brd4 (PDB ID: 3UVW) and BPTF (PDB ID: 3QZT) were prepared using the 
Protein Preparation Wizard workflow as follows: adding hydrogen, assigning partial 
charges using the OPLS-2005 force field, and assigning protonation states. AU1 was 
prepared using the Ligprep module, generating protonation states from pH range 6.2-8.2. 
The docking grid was generated by removing the bound peptides and analyzing the 
protein for binding sites using SiteMap with more restricted notion of hydrophobicity and 
fine grid. The known acetylated-lysine binding site was selected as the binding site to 
generate the grid. All tyrosines were allowed to rotate during the docking process. AU1 
was then docked using QM/MM ligand polarized docking with initial docking being 
Glide XP with ligand-van der waals scaling of 0.8. The partial charges of the ligand 
atoms were calculated using B3LYP with 6-31G*/LACVP* basis set with Ultra-fine SCF 
accuracy level. AU1 was then redocked using Glide XP and sorted by gscore. Gscores 
were favorable for AU1 binding to both BPTF and Brd4, so predictions based upon the 
Gscore are unlikely to be helpful. The docking study was primarily used to suggest 
binding poses for further analysis. One such pose showed the methyl ester of AU1 
hydrogen bonding with asparagine 2881 and a p-p interaction of the aryl ring with 
phenylalanine 2887. 	
Pharmacophore modeling studies: 	
Pharmacophore modeling was carried out using PHASE (version 3.9, 2014) 
module of the Schrödinger suite implemented in Maestro (Maestro 2014-2) molecular 
modeling package. PHASE identifies the spatial arrangement of functional groups that 
are common and essential for the biological activity of the compounds. The structures of 
compounds were prepared using LigPrep (version 3.0, 2014). Conformers were generated 
using ConfGen by applying OPLS-2005 force field. Four features/sites were considered 
in generating pharmacophore variants: hydrogen bond acceptor (A), hydrogen bond 
donor (D), hydrophobic group (H) and aromatic ring (R). The maximum number of sites 
was set to 7 and minimum to 3. Common pharmacophores were required in all 5 of the 
active compounds with a final box size of 1 Å and minimum intersite distance of 2 Å. 
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Resulting pharmacophore hypotheses were then scored using default weights of scoring 
parameters for both active (survival score) and inactive ones (survival-inactive scores). 
Many of the pharmacophore sites generated in the hypotheses were consistent across 
many of the developed models due to the similarity of the various aryl-urea compounds 
analyzed, but location of the aryl ring with a hydrogen-bond acceptor present at the 
carbonyl seemed to correlate heavily with binding. 	
Cell Viability Experiments in HEK 293T cells: 
A cell viability assay of HEK 293T cells was done by using a resazurine dye 
based CellTiter-Blue® from Promega assay. HEK 293T cells were plated in a 96 well 
plate and grew until 80% confluency. Desired confluent cells were treated with the 0, 1, 3 
and 10 µM AU1 for 24 and 48 hours in 5% CO2 (n=6 for 24 hours and n=5 for 48 hours 
treatment, per condition). After the desired time point of treatment 20 µL of CellTiter-
Blue® was added to the each well and incubated for 2.5 h at 37 oC. The fluorescence of 
the reduced dye, resofurin was measured at 580 excitation and 590 emission wavelengths 
by using an omega plate reader. The presented data is normalized with the control 
(DMSO treated), error bars are depicting the standard error of the mean. 	
Table 4.4 Summary of NMR screening data including change of Chemical Shift and 
line broadening upon ligand addition for Brd4 resonances and BPTF 
 W75 W2824 W120 W81 
Compound 
Regno 
Δδ ΔLW Δδ ΔLW Δδ ΔLW Δδ ΔLW 
GSK260205A 0.0928 -0.0194 N/A N/A -0.0033 0.0483 N/A N/A 
GSK1379767A -0.0104 -0.0273 N/A N/A -0.0007 -0.0076 N/A N/A 
SKF-106164-A2 -0.0177 0.0052 N/A N/A 0.0275 0.0406 N/A N/A 
GSK1379753A -0.0101 -0.0005 N/A N/A 0.0067 -0.0107 N/A N/A 
GSK1379710A -0.0005 -0.0078 N/A N/A -0.007 -0.0034 -0.0511 0.0255 
GSK1379731A -0.0062 -0.0025 N/A N/A -0.0002 0.0151 -0.058 0.0292 
SB-744941 -0.0004 0.0006 N/A N/A 0.0085 0.0337 0.0014 0.0037 
GSK1379746A -0.015 0.0061 N/A N/A -0.0028 -0.0026 -0.0244 0.0086 
GSK1379725A 0.0006 0.003 N/A N/A 0.0013 0.0064 -0.0092 0.0096 
GSK1379765A -0.0585 0.0187 -0.1275 0.0104 -0.0061 -0.0126 N/A N/A 
SB-738004 -0.0385 0.0399 0.0098 -0.0212 0.0199 0.0256 N/A N/A 
SKF-86055 -0.0043 0.0069 -0.1329 0.0635 0.0072 -0.0047 N/A N/A 
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GW876790X 0.0007 0.0325 -0.0468 0.0393 0.0019 0.0377 0.0049 0.0417 
GSK949675A 0.0024 -0.0046 -0.1232 0.0113 -0.0049 0.0111 0.0186 0.0313 
GSK711701A -0.0716 0.0211 0.1324 0.0146 0.0171 -0.0073 0.0656 -0.009 
SB-732881 -0.038 -0.0039 -0.1668 0.0252 -0.0081 0.0061 -0.0589 0.037 
GSK1007102A -0.015 -0.0055 -0.1787 0.014 0.0062 0.0151 0.1039 -
0.0016 
GSK619487A 0.0005 0.0073 -0.1237 0.0125 -0.0042 -0.0142 0.0189 -
0.0087 
GW301789X 0.0009 0.0148 -0.0361 0.0304 -0.0098 -0.0137 0.0049 -
0.0018 
GSK507274A 0.0033 -0.0148 -0.1481 0.0313 0 0.0132 0.0177 -
0.0008 
GSK902056A -0.0022 -0.0197 -0.162 0.0279 -0.0015 0.0071 0.011 0.0125 
GSK561866B 0.0047 0.002 -0.3035 0.0405 -0.0073 0.0312 0.0066 0.0008 
GW445017X -0.0105 0.0047 -0.0577 0.0395 0.0007 -0.0129 0.0095 0.0099 
SB-736290 -0.0072 -0.0049 -0.0313 -0.0224 -0.007 0.0047 0.0059 0.0067 
GSK943949A -0.0084 -0.0079 -0.1467 0.0217 -0.0033 0.0103 0.0569 0.0131 
GW679662X 0.0377 -0.0159 0.0481 0.0038 0.0223 -0.0099 N/A N/A 
SB-242719 -0.0727 0.0343 -0.0176 0.0175 0.0145 0.0148 N/A N/A 
GSK2219329A -0.0552 0.018 -0.057 0.0234 -0.0029 0.0009 N/A N/A 
SB-253228 -0.0378 0.0131 -0.0156 -0.0107 0.0074 -0.025 N/A N/A 
GSK1379763A -0.0438 0.0042 -0.0832 0.0036 -0.0075 -0.0173 N/A N/A 
GSK620503A -0.0456 0.0176 0.0653 0.0313 0.0069 -0.0023 N/A N/A 
GW684941X -0.0434 0.0006 -0.0908 0.0267 0.0017 0.0115 N/A N/A 
GSK1379766A -0.0169 0.0059 -0.0739 -0.0032 -0.0073 -0.0051 N/A N/A 
SB-251527 -0.0177 -0.0064 -0.0045 -0.0082 0.0054 0.0067 N/A N/A 
GSK312948A -0.0676 0.0269 0.0453 -0.0055 0.0029 -0.001 0.1733 0.0003 
GW873004X 0.0009 -0.0008 -0.0216 0.0167 0.0007 0.0244 0.0174 0.0324 
SB-708998 0.007 -0.0307 -0.0066 0.0154 0.0002 -0.0052 -0.0312 0.0047 
SB-708999 0.0544 -0.0093 0.0018 -0.0093 0.0051 -0.0056 0.1249 0.0052 
GSK2297542A -0.0338 0.0012 0.0524 -0.0012 0.0166 -0.0035 0.1581 0.0136 
GSK1379748A -0.0446 0.0093 -0.0904 0.0226 -0.0058 -0.0089 0.1348 0.0568 
GW782907X -0.0141 0.0151 0.0592 0.0127 0.0141 -0.0248 0.0212 -
0.0156 
SB-711805 -0.0435 -0.0162 -0.0926 0.0061 0.0019 0.0003 0.1369 0.004 
SB-390527 -0.0097 0.0125 -0.0301 0.0189 0.007 0.0103 0.0294 -
0.0101 
GW305178X -0.0018 -0.0029 -0.0795 0.0065 -0.0219 -0.008 0.1015 -
0.0064 
SB-751148 -0.0135 0.0102 -0.0631 0.0169 0.0063 -0.0255 0.1431 -0.007 
GW620972X 0.0057 -0.0046 -0.0268 0.0173 -0.0062 0.013 0.0024 -
0.0089 
SB-698596-AC -0.0199 -0.0023 -0.0769 0.0027 -0.0089 0.0134 0.0197 -
0.0086 
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GW784307A 0.0046 0.0037 -0.0227 0.0165 0.0009 -0.02 0.0128 -
0.0147 
GW786460X -0.0174 -0.0009 -0.0097 -0.0116 -0.0018 0.0009 0.026 -
0.0102 
SB-360741 -0.0153 -0.0033 -0.001 0.0201 0.0016 0.0099 0.0192 -
0.0085 
GW276655X -0.0086 -0.0013 -0.0116 -0.0118 0.0019 -0.0046 0.0205 -
0.0087 
GW694077X -0.0002 -0.002 -0.0738 0.0003 0.0063 0.0086 0.0926 -
0.0093 
SB-707548-A -0.1039 0.0316 -0.0095 -0.0093 0.0091 -0.0065 0.0826 0.0005 
GSK1379723A -0.0086 -0.0188 -0.0186 -0.0093 -0.0013 -0.0177 0.0351 0.0013 
GSK2297099A -0.0416 0.0053 0.0542 -0.0046 0.0105 -0.0073 0.0464 0.0054 
GW781483X 0.0154 0.0065 -0.0872 0.0154 -0.0028 0.0127 0.0743 -
0.0027 
GSK192082A 0.0013 0.0118 -0.0129 0.0154 0.0009 -0.023 0.0094 -
0.0049 
SB-747651-A 0.0018 0.0165 -0.0652 0.0003 -0.0016 0.0035 0.0128 0.0038 
GW796410X -0.0108 -0.0088 -0.006 -0.0084 0.0082 0.0272 -0.0056 0.0022 
GSK1379714A -0.0101 -0.0045 -0.0311 -0.0093 -0.0043 -0.0179 0.0147 -
0.0041 
GSK1379720A -0.0219 -0.0014 0.0329 0.0018 -0.0021 -0.0147 0.0139 0.0019 
GSK1535721A -0.0244 0.0055 -0.0952 0.0045 0.0106 -0.0029 0.0407 -
0.0079 
GW778894X -0.0187 0.0111 0.036 0.0051 0.0107 -0.0002 0.0352 0.0028 
GSK614526A 0.0031 0.0037 -0.1008 -0.006 -0.005 0.0221 0.0186 0.0024 
GW300660X -0.0141 -0.0016 -0.0757 0.0097 -0.0036 -0.0082 0.0457 0.0122 
GW811761X 0.0011 -0.0031 -0.0033 -0.0109 0.0008 -0.0067 0.0069 0.0084 
GW827105X -0.0035 -0.0031 0.0052 0.0209 0.0011 0.0069 0.032 0.0142 
GW810372X -0.0055 0 -0.0068 -0.0099 -0.0043 0.006 0.004 -0.007 
SKF-104365 -0.0018 -0.0073 -0.0145 0.0246 -0.0016 -0.0029 0.0009 0.008 
GSK1030058A 0.01 0.0073 -0.0239 -0.0087 0.0005 0.0007 -0.0114 -
0.0049 
GW440137A -0.0239 -0.0095 -0.0117 0.0161 -0.0041 -0.0073 0.0575 0.0034 
GW709213X -0.0059 0.0013 0.0019 -0.0111 0.0018 -0.0044 0.0761 0.0121 
GW693481X -0.0056 0.0032 -0.0165 0.016 0.0036 -0.007 0.0676 0.0056 
SB-400868-A -0.0047 0.0031 -0.0056 0.0201 0.0071 0.0017 -0.001 0.0085 
SB-772077-B -0.0168 0.0075 0.029 0.0024 0.0075 -0.0119 0.0376 0.0005 
SB-750140 -0.0011 -0.0088 -0.0072 -0.0139 -0.0014 0.0021 0.0313 0.0072 
SB-751399-B 0.003 -0.0023 0.0076 -0.0171 0.0015 -0.0071 0.0139 -
0.0025 
GW439255X N/A N/A -0.0137 0.0029 0.0007 0.0119 N/A N/A 
SB-264866 -0.0717 0.0281 -0.0124 -0.0002 0.0075 0.0251 N/A N/A 
SB-284851-BT -0.0779 -0.0229 -0.0195 0.0042 0.02 0.0107 N/A N/A 
GW837331X -0.0686 0.017 -0.0591 0.0056 0.0018 -0.0055 N/A N/A 
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SB-358518 -0.072 0.0104 -0.0176 0.0117 0.0026 -0.005 N/A N/A 
SB-590885-AAE -0.0401 0.0098 -0.0037 0.0122 -0.0146 0.0252 N/A N/A 
SB-250715 -0.041 0.0096 -0.0396 0.0037 0.0028 0.0249 N/A N/A 
GW622475X -0.0389 0.0037 -0.033 0.0065 0.0142 0.0086 N/A N/A 
GSK317354A -0.0444 0.0006 0 0.0079 -0.0067 -0.0106 N/A N/A 
GW407323A -0.0415 0.0234 0.0197 0.0003 0.0037 -0.0135 N/A N/A 
GSK2220400A 0.0311 0.0017 -0.0098 -0.002 0.0002 0.0017 N/A N/A 
GSK1023156A -0.0324 0.0115 0.011 -0.0066 0.0078 -0.0116 N/A N/A 
SB-254169 -0.0186 0.0068 -0.0225 0.0061 0.013 0.0034 N/A N/A 
SB-223133 -0.0024 0.0017 -0.0048 0.0058 -0.004 -0.0079 N/A N/A 
GW702865X -0.0093 0.0081 0.0062 -0.0053 -0.0003 -0.0075 N/A N/A 
GSK1321565A -0.0537 0.0024 -0.0186 -0.0061 0.0053 -0.0041 -0.2799 0.0237 
SB-217360 0.0177 -0.008 -0.0019 -0.0067 0.0245 -0.0046 0.3748 0.0054 
SB-732941 -0.0144 0.0144 -0.0159 0.0102 -0.0058 -0.008 0.1942 -
0.0076 
SB-710363 0.0262 0.0126 -0.0553 -0.0021 -0.0039 -0.0011 0.377 -
0.0001 
GW824645A 0.0005 -0.0005 0.0162 -0.0028 -0.0009 -0.0128 0.1708 0 
GW493036X -0.0299 -0.0014 0.0155 -0.0055 0.0096 -0.0047 0.2674 0.0277 
GSK1173862A 0.0034 0.006 0.0068 -0.0072 -0.0038 -0.0105 0.0661 0.0328 
GW57482A 0.0009 0.016 0.0069 -0.0025 0.0073 -0.0259 0.009 -
0.0104 
SB-226605 -0.0041 -0.017 0.0013 -0.0032 0.0115 -0.002 0.1069 0.0029 
GW335962X 0.0034 0.0157 -0.0552 -0.0035 -0.0077 0.0088 0.0105 -
0.0088 
GW831090X -0.0336 -0.012 -0.0239 -0.0064 0.0014 -0.0014 -0.0476 0.042 
GSK1653539A 0.0105 -0.013 -0.0051 -0.0013 -0.0035 -0.0013 0.0213 0.0215 
SB-814597 0.0093 0.0078 -0.0322 0.0032 -0.0196 -0.014 -0.0026 0.022 
GW583373A 0.0015 -0.0077 -0.0048 -0.0057 -0.0088 -0.0038 0.0145 0.017 
GSK1379727A -0.0196 -0.0052 -0.0417 0.0079 -0.0113 0.0021 -0.0481 0.0075 
GI261520A -0.0152 0.0113 -0.0044 -0.005 0.0055 0.0154 0.0281 -
0.0169 
GW771127A -0.01 0.004 -0.0192 -0.0061 0.0027 0.0145 0.012 -
0.0132 
GW632580X -0.0111 -0.007 -0.0109 0.0014 -0.004 0.013 -0.0164 -
0.0114 
GW525701A -0.0239 -0.004 0.0145 0.0036 0.0105 -0.0066 0.1124 0.0225 
GW697465A 0.0102 -0.002 0.0165 -0.004 0.0136 -0.0062 0.0104 -0.011 
SB-317658 0.0065 -0.006 0.0117 0.0006 0.0092 -0.0009 0.025 0.0165 
GW856804X -0.011 0.0073 -0.0412 0.0039 -0.0069 -0.0062 0.0151 0.0186 
SB-737198 -0.0017 0.0021 -0.0458 0.0136 0.0099 -0.0114 0.0575 -
0.0115 
GW711782X 0.0006 -0.0048 -0.009 -0.0017 0.0014 -0.0108 0.1141 0.0051 
GSK1379762A -0.0069 0.001 -0.0046 0.0133 0.0076 0.0058 -0.0076 0.0261 
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GW576609B -0.005 -0.0062 -0.0051 -0.0053 0.0078 0.0057 0.0183 -0.009 
GW607117X -0.0039 -0.0079 0.0034 0.0027 0.0023 -0.0053 -0.0158 0.0223 
GW651576X -0.0043 -0.0106 -0.0055 0.0015 0.0014 0.002 0.005 -
0.0157 
GW673715X -0.0097 0.0057 -0.0048 0.0056 0.0007 0.0021 0.0147 -
0.0125 
GSK466314A 0.0024 0.0067 -0.0165 0.0006 -0.0028 -0.0059 0.0306 -
0.0166 
GW572399X -0.0087 -0.0003 -0.0144 -0.0057 0.0022 -0.0023 0.0377 -
0.0163 
GW829877X -0.0043 -0.0047 -0.0033 -0.0006 -0.0027 0.0031 0.0089 -
0.0155 
GSK257997A 0.0035 -0.0055 -0.0229 0.0029 0.0016 -0.0015 0.0314 -
0.0108 
SB-211743 -0.0026 0.0017 -0.0357 0.0011 0.0005 0.0093 0.0291 -
0.0088 
SB-282975-A 0.0043 0.0105 -0.0276 0.0016 -0.0008 0.0079 0.1219 0.0029 
SB-633825 -0.0036 -0.0009 -0.0324 -0.0064 -0.0007 0.0084 -0.0766 -
0.0035 
GSK180736A -0.0239 0.0107 -0.004 0.0104 0.0035 -0.0068 0.1289 0.0041 
GSK300014A -0.0054 0.0263 -0.0123 0.0067 -0.0016 -0.0174 0.0067 -
0.0005 
SB-390526 0.0016 -0.0286 0.0107 0.0067 -0.0002 0.0064 0.0095 0.0024 
GSK1379706A -0.008 -0.0121 -0.0186 -0.0032 -0.0002 -0.019 0.0056 0.0002 
GSK1379742A -0.0138 -0.0113 0.0072 -0.0008 -0.0063 -0.0185 -0.0004 0.0029 
GSK1379717A -0.0007 -0.0188 -0.0068 0.0023 0.0074 -0.0146 0.0441 0.0124 
SB-341528 -0.0077 -0.0119 -0.0222 -0.0051 0.0029 0.0129 0.0019 0.0002 
SKF-97623 0.0045 0.0136 0.0189 0.0011 0.0105 0.0136 0.0034 -
0.0014 
GW743024X -0.0033 0.0221 -0.0088 0.0007 0.0006 -0.0193 -0.0077 -0.005 
GW843682X -0.0356 -0.002 0.006 -0.0019 -0.0027 -0.0058 -0.0079 0.0104 
GSK1379745A -0.0264 -0.0126 -0.0079 -0.0009 -0.0033 -0.0106 -0.0004 0.0028 
GW693917X -0.0113 -0.0108 -0.0023 -0.0058 0.0044 0.0054 0.0089 -
0.0052 
GW829874X -0.0122 -0.011 -0.0094 0.0001 0.0044 0.0105 0.0105 -
0.0064 
GW631581B -0.0156 -0.0114 -0.0142 -0.0024 -0.0003 -0.0009 0.0274 -
0.0033 
GW830365A -0.0179 -0.0122 -0.0294 -0.0052 -0.0031 0.0018 0.0142 0.0112 
GW852849X -0.0438 0.0011 0.0012 0.0079 -0.005 0.0043 0.0414 0.0139 
GSK292658A 0.0008 -0.0185 -0.0012 -0.0063 0.0036 -0.0116 0.0077 0.0086 
GSK346294A -0.0024 -0.0141 -0.006 -0.0042 0.0039 0.0115 0.0636 0.0063 
GW709199X 0.0033 -0.0197 -0.0071 -0.0013 0.0001 0.0071 0.0012 0.0028 
GW828206X 0.0015 -0.017 -0.0009 1E-04 -0.0049 -0.0041 0.0036 -0.002 
GW867588X 0.0023 0.0126 -0.0047 0.004 0.0016 0.0023 0.0168 -
0.0006 
SB-361058 -0.0364 0.0081 -0.0083 0.0113 0.0003 -0.0048 0.0475 0.0009 
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SB-711237 0.0002 0.0148 -0.0157 0.0046 -0.0044 -0.009 0.0075 0.0082 
SB-759335-B -0.0016 -0.0119 -0.0002 -0.0021 -0.0014 0.0096 0.0151 0.0053 
GSK1379741A -0.0012 0.0055 -0.0131 -0.002 -0.0043 -0.0153 -0.0065 -0.005 
GSK1379724A 0.0009 -0.0018 0.0195 1E-04 0.0117 0.0177 0.0304 0.0022 
GSK2213727A -0.0065 -0.0087 0.0089 -0.0061 0.0035 0.0202 0.0604 0.0057 
GSK2186269A 0.0034 -0.0026 0.0011 0.0101 0.0096 0.0133 0.0116 -
0.0046 
GW642125X -0.0069 0.006 -0.0175 0.0102 -0.0055 0.0052 0.0504 -
0.0012 
GW695874X -0.0021 0.0035 -0.0271 0.0056 -0.0052 -0.0056 0.0749 0 
GW679410X -0.0234 -0.0001 -0.0114 -0.0067 -0.0002 0.0141 0.0867 -
0.0062 
SB-735465 -0.0277 -0.0067 -0.0158 -0.0041 0.0107 0.0127 0.0671 0.0003 
SB-738482 -0.023 -0.0023 -0.0251 -0.0041 -0.0054 0.0006 0.0886 -0.001 
GI261656A 0.0023 -0.006 -0.0187 0.0026 0.0049 -0.0125 0.0184 -
0.0003 
GSK1379800A -0.003 -0.006 0.0243 0.0081 0.0123 -0.0079 0.0904 0.0119 
GSK1398463A 0.0093 -0.0011 0.015 -0.004 -0.0055 0.0148 0.0169 -
0.0006 
GSK429286A -0.009 -0.0002 0.0193 0.0042 0.0117 0.0083 0.0159 0.0031 
GW869979X 0.007 0.0033 -0.0418 -0.0022 0.0106 0.0199 0.0168 -
0.0041 
SB-249175 -0.0006 -0.0084 0.0154 0.0024 0.0156 -0.0067 0.0601 -
0.0073 
GSK361065A -0.0083 0.0093 -0.0024 0.0045 -0.0103 -0.007 -0.0137 0.0069 
GSK938890A 0.0061 0.0006 -0.0573 0.0087 0.0122 -0.001 0.0269 -
0.0021 
GW580496A 0.0064 0.0052 -0.007 0.0111 0.0048 -0.0227 0.0044 0.0026 
GW622055X -0.0054 0.006 -0.0075 0.0062 0.0021 -0.0154 0.056 0.0035 
GW641155B 0.0017 0.0055 0.0044 -0.0006 0.0056 -0.0241 0.0084 0.0081 
GW795486X 0.0063 0.0009 0.0017 0.0091 0.0084 -0.0137 0.0124 0.0058 
GW809897X -0.0018 0.0116 -0.0077 0.0006 0.0008 -0.0206 0.0012 -
0.0069 
GW785404X 0.0029 0.0006 -0.0064 0.0089 -0.0043 0.0175 0.0148 0.0079 
SB-693162 -0.0104 -0.0093 0.0089 0.0089 0.0005 0.0152 0.0263 -
0.0037 
GSK718429A 0.0047 0.0004 -0.0029 0.0013 0.0031 -0.0085 0.0202 0.0072 
GW569530A -0.0005 -0.0064 0.0181 0.0003 0.003 -0.0029 0.0134 0.0045 
GW775608X -0.0005 -0.0067 0.0206 -0.0054 0.0003 -0.0061 0.0163 0.0095 
SB-210313 0.0032 0.0027 0.01 -0.0035 -0.0044 -0.0047 0.0449 0.0017 
SB-220455 -0.0019 -0.0002 -0.0153 0.0023 -0.0038 -0.0014 0.0578 0.0141 
GSK1379712A -0.0044 -0.0002 -0.0142 0.014 -0.0046 -0.0075 0.0049 0.0049 
GSK1379721A -0.0118 -0.0057 -0.0282 -0.0046 -0.0016 -0.0052 0.0072 0.0132 
GSK1379722A -0.0062 -0.0005 -0.0305 -0.0003 -0.0019 -0.0052 0.027 0.0005 
GW589961A -0.0079 -0.0009 -0.0007 -0.0061 0.0075 0.006 0.0142 -
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0.0064 
SB-742864 -0.0124 -0.0096 -0.0146 -0.0043 0.0004 0.0041 0.0512 0.0045 
GW459057A -0.0003 0.0031 -0.021 0.0009 0.0003 0.0098 0.0004 -
0.0069 
GW819077X 0.004 0.0032 -0.0203 0.0093 -0.0019 0.004 -0.004 -
0.0034 
SB-347804 0.0111 0.0011 -0.0248 0.0027 0.0027 0.0081 -0.0112 0.0043 
SB-409513 0.002 0.0003 -0.0267 -0.0002 -0.0041 0.0026 0.0025 -
0.0032 
SB-734117 -0.0087 0.0009 -0.0546 0.0041 -0.0004 0.0043 0.0655 -
0.0002 
GW809885X -0.0063 -0.0032 -0.0094 -0.0038 -0.001 0.0061 0.0234 0.0026 
GW440146A 0.0059 -0.0037 -0.003 -0.0022 0.0038 0.0028 0.005 0.006 
GW514786X 0.0077 -0.007 -0.0202 0.0032 0.0035 -0.0035 0.0117 0.0144 
SB-376715 -0.0113 -0.0053 -0.0168 0.0038 0.0048 -0.0015 0.0018 0.0029 
AH5015X 0.0068 -0.0104 -0.0132 0.0033 0.0034 0.0051 0.0611 -
0.0046 
GSK2372690A 0.0005 -0.0073 0.0156 0.0009 0.0058 0.0009 -0.0266 0.0026 
GW681251X 0.0031 0.0084 0.0093 0.0029 0.0087 -0.0027 0.0371 0.004 
GW810578X 0.0024 -0.0076 0.015 -0.002 0.0084 -0.0021 0.0302 0.0043 
SB-390766 -0.017 -0.0029 0.0007 -0.0029 0.0057 0.0038 0.0879 0.0054 
SB-404290 -0.0001 -0.0049 0.011 -0.0037 0.0049 -1E-04 -0.0266 0 
GSK466317A -0.0172 0.0117 -0.0268 -0.0006 -0.0017 0.0027 0.0559 -
0.0068 
GSK483724A 0.0091 0.0073 -0.0255 -0.0041 -0.0003 -0.0017 0.0313 0.0084 
GW572738X 0.0109 0.0085 -0.0265 -0.0052 -0.0026 0.0024 -0.0033 -
0.0068 
GW583340C 0.0118 0.0079 -0.0136 0.0101 -0.0039 -0.0031 -0.001 -
0.0067 
GW812171X -0.0117 -0.0078 0.0185 0.0009 0.0019 -0.0009 0.0297 -
0.0036 
SB-431542-A -0.0106 0.0093 -0.0399 0.0129 0.0041 0.0065 0.0412 0.0049 
SB-733416 0.0021 -0.0008 0.0071 0.0041 0.0053 -0.0119 0.001 0.0005 
SB-736302 0.0066 0.0082 -0.0259 -0.0065 0.0014 -0.0003 0.001 -
0.0027 
GW701427A -0.0107 -0.0023 -0.0127 0.0004 0.0048 -0.0058 -0.0251 0.0134 
GW829055X -0.0025 0.006 0.0063 0.0006 0.0029 -0.0068 0.0389 0.0047 
GSK248233B 0.0055 -0.0091 0.0038 0.0011 -0.0005 0.0105 0.0054 0.0096 
SB-738561 0.0006 -0.0035 -0.0152 0.0116 0.0041 0.0108 0.0391 0.0041 
GW276655X 0.0026 -0.0032 0.0065 -0.0009 0.0002 -0.0053 0.0009 0.0012 
GW278681X -0.0041 -0.0008 -0.0219 -0.0094 -0.0057 0.0096 0.0178 0.0101 
GW279320X -0.0037 -0.0038 -0.0135 0.0038 -0.0032 0.0107 -0.0008 0.007 
GW282974X -0.0051 -0.0037 0.0047 -0.0053 0.0017 0.0034 0.0242 0.0113 
GW300657X -0.0038 -0.0022 0.0059 -0.0036 0.0043 -0.0004 0.0233 0.0154 
GW432441X -0.0168 0.0052 -0.0175 0.0075 0.0006 0.009 -0.1791 0.031 
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GW513184X -0.0115 -0.0026 -0.0237 0.0054 -0.0096 -0.0007 -0.0468 0.0077 
GW549034X -0.009 0.0042 0.0051 -0.001 -0.0044 -0.0018 0.0161 0.0045 
GW618013X -0.0157 -0.0017 -0.0569 0.0003 -0.0087 0.0084 0.082 0.02 
GW644007X -0.0859 -0.0011 -0.0583 0.0028 -0.0151 -0.0181 0.0822 -
0.0015 
GW679410X -0.013 0.0061 -0.0119 -0.0036 -0.0013 0.0051 0.069 0.0054 
GW708336X -0.008 0.005 -0.0286 -0.002 -0.0039 -0.0113 0.0056 0.0103 
GW784684X -0.0113 0.0012 0.0101 -0.0059 -0.0026 -0.001 0.0133 0.0058 
GW804482X -0.0158 0.0036 0.0064 0.0087 -0.0086 -0.0111 0.1298 0.0238 
GW810372X -0.001 0.0072 0.0177 0.0017 -0.0034 0.0177 0.0082 0.0135 
GW827396X -0.0068 -0.0046 -0.0105 0.008 -0.0032 -0.0032 0.0256 0.0324 
SB-264865 -0.0291 0.0076 -0.0003 -0.0027 0.0032 0.0156 125.244 -0.056 
SB-747651-A -0.0017 0.0112 -0.039 0.0044 0.0009 0.0042 0.022 0.012 		
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Chapter	5. Protein-Observed	Fluorine	NMR	is	a	Complementary	Ligand	
Discovery	Method	to	1H	CPMG	Ligand-Observed	NMR	
 
Reproduced with permission from “Protein-Observed Fluorine NMR is a Complementary 
Ligand Discovery Method to 1H CPMG Ligand-Observed NMR,” A. K. Urick, L. P. 
Calle, J. F. Espinosa, H. Hu, W. C. K. Pomerantz, ACS Chemical Biology 2016, 3154-
3164. Copyright 2016 American Chemical Society. 
 
Motivation: We compared the newly developed 1D protein-observed fluorine NMR 
(PrOF NMR) screening method with the well-characterized ligand-observed 1H CPMG 
NMR screen to evaluate its potential as a ligand discovery tool. We selected the first 
bromodomain of Brd4 as a model system to benchmark PrOF NMR because of the high 
ligandability of Brd4 and the need for small molecule inhibitors of related epigenetic 
regulatory proteins. We compare the two methods’ hit sensitivity, triaging ability, 
experiment speed, material consumption, and the potential for false positives and 
negatives. 
5.1 Introduction 
Fragment based ligand discovery (FBLD) and fragment based drug design 
(FBDD) have been rapidly gaining traction in the chemical probe development and drug 
discovery process for difficult targets such as RNA,178 transcription factors,179 and 
epigenetic regulatory proteins.118,180 Using molecules with lower molecular weight and 
lower functional group density than molecules found in traditional high throughput 
screening libraries, fragment screens seek to sample chemical space more efficiently. 
With vemurafenib55 and venetoclax56 as approved drugs that originated from FBDD and 
several other drug candidates in Phase III clinical trials that also started as fragments, 
FBDD is becoming a validated technique for drug discovery. These success stories 
highlight the impact that new methods can have in the drug discovery process. 
Fragment screening facilitates drug/chemical probe development at the earliest 
stages of the discovery process. However, because of their small size (molecular weight 
typically less than 300 g/mol), fragments are likely to bind with low affinity, 
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necessitating sensitive methods to detect protein-ligand interactions during a screen. 
Among these techniques are thermal shift analysis,79 surface plasmon resonance,181 X-ray 
crystallography,77 and NMR techniques such as saturation transfer difference (STD),182 
Carr-Purcel-Meiboom-Gill (CPMG),70 WaterLOGSY,183 and HSQC NMR67. 
Remarkably, some studies show little overlap in hits detected by different screening 
methods.184–186 With the potential for low overlap, it is prudent and common practice to 
use an orthogonal biophysical method to verify an active.187 Using protein-observed and 
ligand-observed NMR experiments allows sensitive follow-up with different assays that 
utilize similar conditions. The goal of this study is to compare the effectiveness of a new 
protein-observed 19F NMR (PrOF NMR) screening method with an established ligand-
observed 1H CPMG screen to provide insight on the appropriate way to implement PrOF 
NMR in a ligand discovery setting as a complimentary assay. 
Nuclear magnetic resonance spectroscopy has been used, among other techniques, 
as a way to conduct fragment screens. NMR screens can be conducted by ligand-
observed techniques or protein-observed techniques, both of which have inherent 
advantages over the other. Ligand-observed NMR techniques take advantage of protein-
specific properties (relaxation rates, diffusion coefficients, nuclear Overhauser effects) 
being transferred to bound small molecules. The ligand-observed 1H CPMG method used 
here detects ligand-binding interactions as a function of a drop in signal intensity due to a 
transfer of the protein’s short transverse relaxation time (T2) properties to the ligand. 19F 
CPMG or 1H CPMG are most common due to the high gyromagnetic ratios of 19F and 1H 
nuclei and thus lead to readily acquired spectra. 19F CPMG is widely used and effective 
due to the large chemical shift range exhibited by fluorine, the reduced spectral overlap 
due to its much simplified spectra, and the absence of background signals. However, 
because we wanted to assess a wide array of compounds without being limited to ligands 
containing fluorine, we used 1H CPMG as the ligand-observed experiment for our 
benchmark study. 
Protein-observed NMR experiments monitor perturbations to protein resonances. 
These protein resonances provide an in situ quality control since protein aggregation or 
precipitation events are readily detected by reduced intensity of the NMR resonances. 
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Because different regions of the protein give rise to unique NMR resonances, protein-
observed experiments also provide information on changes in the chemical environment 
on the protein surface which can be used to characterize ligand binding sites and binding-
induced conformational changes. Typically, these experiments monitor the amide 
backbone in the case of 1H-15N HSQC NMR or through selective side-chain labeling for 
1H-13C HSQC NMR, but this approach can be material-intensive, time-consuming, and 
expensive due to the need for isotopic labeling.67,188 The fluorine nucleus, as an 
alternative, is highly responsive to changes in the chemical environment. 19F is 83% as 
sensitive as 1H and 100% isotopically abundant (thus inexpensive,119 e.g., at $52 per 
gram, 5-fluoroindole is over 10-20 fold cheaper for either 13C or 15N-labeled indole)  
facilitating detection of 19F at low concentrations (40-50 µM) for small and medium-sized 
proteins.85  
Although, alternative protein-observed NMR methods are available, PrOF NMR 
benefits from both a simplified NMR spectrum as well as being a sensitive reporter of 
weak binding interactions. As such, 19F NMR has been used in ligand discovery for both 
ligand-observed and protein-observed experiments.32,99,127,131,162,189–193 In some cases, 
protein-observed 19F NMR has proven advantageous when used in conjunction with other 
protein-observed NMR methods.  In studying Equinatoxin II, Anderluh et al. found that 
1H-13C HSQC NMR resulted in longer experiment times and lower response than 19F 
NMR.194  Harner et al. reported a 7-minute experiment using SOFAST 1H-15N HSQC on 
a comparable bromodomain at 70 µM protein, compared with the 2-minute PrOF NMR 
experiments reported here at 50 µM protein.68 Additionally, Richards et al. reported in 
studies with Δ-somatostatin that 19F NMR offered improved Kd precision due to higher 
spectrum resolution and greater chemical environment sensitivity.195  
  169 
As an alternative to 2D-NMR methods, chemical shift perturbation experiments using 1D 
protein-observed NMR can be valuable using an unlabeled protein.196 For the protein 
under study here, we found that chemical shift response from the 1H of the N-H of 
tryptophan196 to be 6-20x less responsive than the equivalent PrOF NMR shift with 
acetaminophen and two compounds uncovered in this screen which will be described 
below (Figure 5.1, 	
Figure 5.2). We have previously applied PrOF NMR for fragment-based 
screening of over 500 small molecules and characterized the bromodomains Brd4, BrdT, 
and BPTF using fluorine-labeled aromatic amino acids 3-fluorotyrosine and 5-
fluorotryptophan (5FW).131 Using this method, we reported the first molecule selective 
for BPTF over Brd4 using a simultaneous dual protein screening approach.32 However, 
due to a reduced surface coverage from labeling only a few side chains, the potential for 
false negatives was a concern which we sought to evaluate in this study.	
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Figure 5.1 Comparison of the perturbations induced upon the W81 PrOF NMR 
resonance and the assumed W81 indole resonance with various binders.	
 
	
Figure 5.2 The area of the 1H NMR spectrum corresponding to the N-H tryptophan 
resonances.	
 
 
 
  171 
The first bromodomain of Brd4 represents an important model protein because of 
its high ligandability and the need for small molecule inhibitors of other bromodomains 
due to a growing understanding of their importance in regulation of disease. 
Bromodomains are epigenetic regulatory proteins, recognizing acetylated lysine residues 
present on histone tails. Of the 61 human bromodomains, Brd4 in particular has been 
shown to be involved in cancer,13 inflammation,17 and heart disease.197 However, many 
other bromodomains lack specific chemical probes for evaluating the pharmacological 
inhibition effects on their biology. In this study we sought to compare PrOF NMR with 
the well-established 1H CPMG NMR method to evaluate the effectiveness of this 
technique as a screening method, as well as the complementarity between ligand-
observed and protein-observed NMR techniques. 1H CPMG was chosen because it is 
frequently used as a screening technique,198 and we found it to be robust for this protein 
system. We sought to compare assay speed, hit overlap, and the potential for false 
negatives and false positives with PrOF NMR. To this end, we screened 930 fragments 
against Brd4 using each method and discuss our findings regarding the potential 
advantages and limitations of the two methods. 
 
5.2 Results 
5.2.1 PrOF NMR Results 
In the PrOF NMR screen, 930 fragments were tested in mixtures of five; induced 
chemical shift perturbations and resonance broadening were used to rank-order hits. The 
PrOF NMR screen was performed in the presence of 2% DMSO, and because DMSO is a 
known bromodomain ligand that affects fluorine chemical shifts,131 all PrOF NMR 
screening experiments are compared with a 2% DMSO control sample. For assessing the 
speed and reproducibility of the experiment the screen was conducted twice with 
different numbers of scans leading to a thirteen- and two-minute NMR experiment time. 
The comparison of resonance perturbations between the long and short PrOF NMR 
experiments indicates that two minutes is a sufficient experiment time for acquiring 
screening data under these conditions (Figure 5.3, Figure 5.4). Chemical shift 
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perturbations from fragment binding between the thirteen- and two-minute experiments 
were very similar, with modest concordance for the linewidth broadening between the 
two screening times (Figure 5.3). In shorter experiments resulting in lower signal-to-
noise ratios (S/N = 7:1), the ability to accurately measure linewidth and integration values 
of resonances is diminished, while the induced chemical shift is still readily interpreted. 
When chemical shift is used as the primary indicator of a binding interaction, as is the 
case for this study, S/N ≥ 7:1 are sufficient. 
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Figure 5.3 A comparison of the data in the 13-minute PrOF NMR experiment and 
the 2-minute PrOF NMR experiment. 
Comparing the percentage of mixtures perturbing W81 greater than a specific chemical 
shift (top) or linewidth (bottom). The average difference in perturbation of chemical shift 
of W81 between the 13-minute experiment and the 2-minute experiment was 0.0049 
ppm, with a standard deviation in chemical shift perturbation average of 0.0055 ppm. 
Chemical shift perturbation is very robust even with low signal to noise, while linewidth 
is comparable after the widths are greater than 0.03 ppm. The average difference in 
linewidth between the 13-minute and 2-minute experiment is 0.0116 ppm, with a 
standard deviation of 0.0111 ppm. 
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Figure 5.4 A 2-minute PrOF NMR experiment (S/N: 7:1). 
The perturbation due to the binding interaction of 1 is clearly visible in this spectra as it 
was with the 13-minute PrOF NMR experiments. 
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Figure 5.5 PrOF NMR spectrum of 5FW-Brd4 and 1. 
In the presence of 1, the resonance for W81 is significantly shifted upfield consistent with 
binding near the acetylated lysine interaction site of Brd4. 
 
Perturbation of chemical shift is used as the initial indicator of a binding 
interaction because we expect most of the active fragments to be relatively weak ligands. 
Weak ligand interactions (Kd > 100 µM) typically fall into the fast exchange regime on 
the NMR time scale, with highly reproducible chemical shifts. Broadening of a resonance 
is also an indication of a binding event, potentially in the intermediate exchange regime, 
and was used as a secondary measure. The first bromodomain of Brd4 has three 
tryptophan residues: W81 (11 Å from N140, a conserved residue in bromodomains) is at 
the binding site, W75 is 18 Å from N140, and W120 is on the opposite end of the protein, 
36 Å from N140 (Figure 5.6).199–201 Because of the distance of W120 from the binding 
site, it is assumed that W120 is not perturbed by ligands during the screen. Thus, when 
the 19F resonances corresponding to W81 or W75 are perturbed more than the greatest 
observed perturbation of W120, we conclude that a binding interaction is taking place. To 
capture as many potential binding interactions as possible for the analysis, we take a 
perturbation of 0.03 ppm for either W75 or W81 to be the cut-off value indicating the 
lowest limit for a binding interaction because this was the highest perturbation observed 
for W120 (Figure 5.7). In this screen 59.1% of mixtures yielded a perturbation of W81 
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greater than 0.03 ppm. As an example of seeking a more stringent hit-rate, the percentage 
of detected hits drops to 21% with a cut-off perturbation of 0.14 ppm as illustrated in 
Figure 5.7. 
 
Figure 5.6 First bromodomain of Brd4 with all three tryptophan residues displayed 
and labeled by residue number. 
Spheres indicate the acetylated lysine binding site (generated by SiteMap). PDB ID: 
3UVW. 
 
Because PrOF NMR is a protein-observed technique, it cannot be determined 
which compound is binding to the protein in the mixture of five without further 
deconvolution in which each compound is tested individually. Because of the high hit-
rate with Brd4, 20% of the mixtures were deconvoluted in order to reduce protein 
consumption while assessing a large representative sample of the hits in the screen. 10% 
of the mixtures in the screen were selected to be deconvoluted due to broadening of the 
W81 resonance in their corresponding PrOF NMR spectra, and an additional 10% were 
chosen to span a range of PrOF NMR chemical shift perturbations (0.03 ppm – 0.31 ppm) 
so as to capture both low- and high-affinity interactions, as well as assess five mixtures 
causing global loss of protein signals, potentially indicating the presence of aggregators. 
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Figure 5.7 Analysis of the chemical shifts of the three resonances of 5FW-Brd4, 
comparing the percentage of mixtures perturbing the chemical shift of a particular 
resonance. 
Left) With a chemical shift change of 0.01 ppm or higher W120 is perturbed in over 30% 
of mixtures, but with a 0.03 ppm cutoff W120 is not perturbed. Thus, 0.03 ppm 
perturbations of either W75 or W81, which are closer to the binding site, are used as the 
hit cutoff for PrOF NMR. Right) A 0.03 ppm linewidth change for the resonances for 
W75 and W81 were also considered a hit cutoff. 
 
A valuable strength of protein-observed NMR methods is their ability to quantify 
ligand affinities by titration. While chemical shift perturbation is a standard method for 
detecting ligand interactions, the magnitude of the perturbation also varies due to local 
chemical environment so a larger shift does not necessarily correspond to a stronger 
interaction. To quickly rank-order hits from the PrOF NMR screen, we took 22 ligands 
(11 of which are publically available) and titrated each ligand into a single NMR tube 
containing 5-fluorotryptophan-labeled Brd4 (5FW-Brd4) (Figure 5.8, Figure 5.9). Using 
a single tube reduces protein consumption, but results in error propagation from pipetting, 
does not control for the effect of DMSO (a known bromodomain ligand) or protein 
dilution. Additionally, the concentration of the ligands was not verified by quantitative 
NMR. We term these values Δδ50, whereas we ascribe dissociation constants to titrations 
that use distinct NMR samples for each titration point to keep the DMSO concentration 
consistent, from fresh ligand stocks with a concentration verified by quantitative NMR. 
Using the more rigorous titration method, we obtained dissociation constants for five 
actives found in the screen.  
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Figure 5.8 Selected molecules that were hits in the PrOF NMR screen. 
The Δδ50 was measured by PrOF NMR titration. Percent reduction in signal in the 1H 
CPMG experiment is indicated by percent drop, and the change in chemical shift upon 
the addition of ligand at 400 µM is indicated with Δδ. 
 
 
 
 
 
 
 
 
 
 
  179 
 
 
Figure 5.9 Fitting graphs for selected compounds for Δδ50 determination using PrOF 
NMR titrations. 
The data was fitted to the following equation using SigmaPlot (Systat Software Inc., San 
Jose, California, USA): 	
 
 
 
5.2.2 1H CPMG Results 
In the 1H CPMG screen, the same 930 compounds were screened in the same 
mixtures of five. Some of the more potent compounds showed a 100% signal intensity 
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reduction (Figure 5.10). Due to the signal-to-noise from using 100 µM ligand, for a 
reliable measurement we assume the limit of detection for change in resonance signal 
intensity is 10%. A hit was thus defined by a 20% reduction in ligand signal intensity 
upon addition of the protein to allow for a competition experiment. For the 1H CPMG 
screen, a competition step with a known potent ligand can significantly reduce false 
positive rates and at the same time provide valuable information on the inferred binding 
site for the hit. For this reason, we performed the competition step using (+)-JQ1 as the 
competitor, and a competitive hit required a 50% recovery of the signal intensity upon the 
addition of (+)-JQ1 (i.e., a 10% reduction of the original signal intensity in the limiting 
case).13 Of the 930 compounds screened, 230 of the compounds were identified as hits 
(24.7%) with Brd4 and 190 (20.4%) compounds were competitive hits against (+)-JQ1. 
 
Figure 5.10 A 1H CPMG experiment of 1 and Brd4. 
Upon the addition of Brd4, the 1H resonances of fragment 1 signal intensity are reduced 
up to 100% in the top spectrum. Examples of reduced resonances are indicated by the 
dashed lines. 
 
5.2.3 Comparison of Results 
Due to the high hit-rate in the PrOF NMR screen that is in part ascribed to the 
conservative chemical shift cut-off, not every mixture which contained a hit was 
deconvoluted. Because the same mixtures were used for both the PrOF NMR and 1H 
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CPMG screens, we offer a comparison of the data as mixtures as well as the 190 
compounds individually tested by PrOF NMR. When comparing the fragment mixture 
results between 1H CPMG and PrOF NMR, the two assays are 77% similar when using a 
competition 1H CPMG experiment (74% when results from the competition step are 
omitted). From the data for the 190 individual compounds deconvoluted by PrOF NMR 
(38 mixtures), there was 85% similarity between the two assays when using a 
competition 1H CPMG experiment (80% when omitting the competition experiments) 
(Figure 5.11). After deconvolution, nearly every mixture that was a hit by PrOF NMR 
contained at least one individual compound that bound, with 17 of the 33 mixtures 
containing more than one hit. The only mixture that was a hit by PrOF NMR that did not 
identify a small molecule binder after deconvolution of the mixture had an initial W81 
chemical shift perturbation of 0.033 ppm, barely above the cut-off of what is considered a 
hit in this screen. 
 
Figure 5.11 Comparison of hit data between PrOF NMR and 1H CPMG from the 
fragment mixture data (A,B) as well as the individual deconvoluted compounds 
(C,D). 
 
While both assays have a large overlap in detected hits, we analyzed 
disagreements between the two screens to identify sources of potential false positives and 
negatives. For weak binding ligands, there were 10 discrepancies exhibiting only minor 
perturbation in one assay (i.e. chemical shift changes of 0.03 ppm - 0.05 ppm in PrOF 
NMR; or signal intensity drop of 20 - 30% in 1H CPMG) and no perturbation in the other. 
In this case, the discrepancies can be explained by the weakest binders being missed by 
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one of the two assays as the sensitivity limits of these assays are approached. In the case 
of stronger binding compounds, there were 13 cases where there was a moderate to 
strong perturbation in one assay that was a non-binder by the other assay (Table 5.1, 0.05 
- 0.2 ppm, PrOF NMR; 30 – 100% signal drop, 1H CPMG). In the case of 1H CPMG, 
seven ligands were detected as competitive hits but not detected by PrOF NMR, though 
only two of those exhibit a signal drop of greater than 50%. These two compounds may 
bind deeply in the binding site, or at an allosterically-coupled location, such that PrOF 
NMR may not have a fluorine probe close enough to detect the binding event, and could 
thus be false negatives in the context of PrOF NMR. Additionally, there were two PrOF 
NMR hits that were non-competitive hits by 1H CPMG, indicating that the ligands bound 
but were not competitive at the acetylated lysine binding site. These molecules may be 
consistent with either non-specific binders or binding to a second site on the protein. By 
PrOF NMR both of these hits perturbed W81 as well as W75, but because there are more 
than 10 fragments that perturbed both W81 and W75 in the PrOF NMR screen that were 
competitive hits by 1H CPMG it is unlikely that W75 could be used to ascertain 
differential binding. From this analysis we conclude that although a small fraction of 
false positives and negatives were identified between the two methods, the majority of 
compounds that were missed by one of the two screening methods correspond to low- to 
moderate-affinity fragments. Importantly, only two fragments (1% of competitive 1H 
CPMG hits, 0.2% of total molecules in the screen) that scored as strong and competitive 
hits by 1H CPMG are potential false negatives by PrOF NMR (Table 5.1). 
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Table 5.1 A list of discrepancies between hits identified by PrOF NMR and 1H 
CPMG 
Compound 
No. 
Δδ W81 
(ppm) 
ΔlinewidthW81 
(ppm) 
Δδ 
W75 
(ppm) 
% Drop 
(CPMG) 
% 
recovery 
(CPMG) 
13 0.264 0.0738 -0.0058 <10% N/A 
14	 -0.2107 0.0123 -0.0021 14.4% 50.6% 
15 0.0878 0.0123 -0.0772 <10% N/A 
16 -0.0763 0.0246 -0.0168 <10% N/A 
17 -0.062 0.0123 -0.0176 <10% N/A 
18 -0.0443 0 -0.0007 <10% N/A 
19 0.0389 0.0123 -0.0039 <10% N/A 
20 0.0313 0 0.0001 10.4% 258.5% 
21 0.0271 0 -0.0187 100.0% 29.2% 
22 0.0262 0.0123 -0.0291 90.2% 119.4% 
23 0.02 0 0.0014 28.5% -34.0% 
24 0.0198 0.0123 -0.0191 41.6% 82.1% 
25 0.0171 0 -0.0181 22.3% 35.5% 
26 0.0168 0.0123 -0.0236 61.7% 26.6% 
27 0.0159 0.0123 -0.0042 23.4% 102.9% 
28 -0.0113 0 -0.0193 43.6% 160.2% 
29 -0.008 0 -0.0167 20.2% 33.3% 
30 0.0074 0 -0.0199 36.8% 130.0% 
31 0.007 0 -0.0242 100.0% 40.0% 
32 -0.0034 0 -0.0165 65.8% 119.7% 
33 0.0028 0 -0.0088 41.2% 14.8% 
34 -0.0014 0 -0.0111 69.0% 5.3% 
35 0.0013 0 -0.0068 56.1% -4.5% 
36 -0.0011 0.0123 -0.0054 20.4% -20.6% 
37 -0.0009 0 -0.0144 43.4% 10.9% 
38 0.0005 0.0123 -0.0275 28.6% 32.6% 
39 -0.0005 0 0.0015 30.9% -77.5% 
40 0.0001 0 -0.0247 28.7% 134.8% 
 
 
Small molecule-induced protein aggregation is a common artifact in many 
screens202 and can be a significant cause of false positives. Therefore, we also evaluated 
this effect in our study. In our screen, there were five mixtures where the resonances in 
the PrOF NMR spectrum were no longer visible, and these five mixtures were 
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deconvoluted to reveal one compound from each mixture responsible for the signal 
suppression, potentially acting as protein aggregators (Figure 5.12). These molecules 
were not detected as 1H CPMG hits because of insufficient signal-to-noise ratios to 
analyze the data. However, if a competitive ligand-observed experiment were conducted 
detecting the displacement of a “spy molecule”,70 these aggregators could result in false 
positives. Adding detergents to the screening buffer can be one way to reduce such 
effects. Due to the absence of fluorine in many commercial detergents, they are 
compatible with 19F-based ligand-observed and protein-observed experiments, although 
they were not used in our current study. 
    
                                                                 Aggregator 1            Aggregator 2 
 
Figure 5.12 Potential protein aggregators found by PrOF NMR. 
In the bottom spectrum is the protein in the absence of the small molecule mixture.  In the 
top spectrum all resonances for the protein disappear indicating that the small molecule 
mixture induces the formation of a large protein aggregate, or the protein has crashed out 
of solution. Two such compounds that resulted in this spectrum are shown on the right, 
and are similar to known PAINs compound categories (Baell, J. & Walters, M., Nature, 
2014, 481-483.)  
 
Prioritizing compounds based on affinity is important for carrying compounds 
forward in the lead discovery process. This is particularly true in cases of high hit-rates in 
a fragment screen, such as described here. From our screening data and follow-up affinity 
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determination, we found that both methods are fairly effective at triaging hits from the 
screening data. We used PrOF NMR titrations to determine the Δδ50 for 22 compounds. 
We then compared several parameters with Δδ50, and found that chemical shift 
perturbation in PrOF NMR and signal intensity reduction in 1H CPMG correlate but only 
modestly with Δδ50 measured by PrOF NMR (Figure 5.13). Despite broadening being 
related to chemical exchange kinetics in PrOF NMR, there is a poor correlation between 
broadening and Δδ50 with Brd4. Interpretation of broadening in terms of relative affinity 
is complicated by the differences in chemical shifts between bound and unbound state 
which varies between ligands, as well as additional protein dynamics such as restricted 
mobility of side-chains due to binding interactions. Additionally, with higher affinity 
fragments there are cases where the W81 resonance is sharpening out of the baseline, 
approaching a fully bound state. This can result in situations where a broader resonance 
does not necessarily indicate a tighter binder. Thus, resonance broadening was not an 
effective method for ranking compounds in this PrOF NMR screen. However, when 
screening proteins with a lower ligandability, broadening of resonances in PrOF NMR 
could potentially be a useful parameter for rank-ordering compounds as well. 
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Figure 5.13 A comparison of 20 different hits ranked by Δδ50 by PrOF NMR and 
different assay data. 
 A). Signal reduction in 1H CPMG in panel A or PrOF NMR chemical shift perturbation 
in panel B). A correlation is noticeable between Δδ50 and 1H CPMG signal drop, as well 
as Δδ50 and W81 chemical shift perturbation. While one could expect broadening of 
W81 to also correlate well, with Brd4 this is not the case. Using a protein with a lower 
ligandability could result in better rank-ordering with broadening, but with Brd4 many of 
the tighter binders are already coalescing at 400 µM ligand. 
 
As further support for the successful identification of true bromodomain binders, 
several of the compounds identified in this screen have similar pharmacophores to known 
bromodomain inhibitors: isoxazoles,31 triazoles,13,17 amidines,32 and ureas32,33 have all 
been previously reported.180 Additionally, we identified several ligands containing 
ketones, potentially acting as acetylated lysine mimetics. We thus conclude, that the 
conditions for screening fragments against Brd4 by both PrOF NMR and 1H CPMG were 
effective for uncovering new ligands.  
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5.2.4 Dissociation Constant Determination 
Protein-observed NMR techniques, including PrOF NMR, have been utilized to 
quantify dissociation constants via ligand titration at a fixed protein concentration. These 
derived dissociation constants rely on chemical shift perturbations from a titration 
experiment. While titrations can be performed with 1H CPMG ligand-observed 
experiments, these experiments require rigorous controls to present off-setting effects 
from convoluting the measured dissociation constants, and can also be time 
consuming.190,203 These titrations are easily accomplished with PrOF NMR and can be 
used to prioritize compounds based on affinity and/or ligand efficiency. The dissociation 
constants obtained by this method were used to establish ligand affinities described above 
for comparing with resonance perturbations. Original affinity estimates were obtained by 
titrating a small molecule from the library stock directly into the protein solution, which 
can introduce errors as described above. To verify the rank ordering and more accurately 
measure the dissociation constants, the affinities of the top five compounds (molecules 1, 
2, 3, 4, and 12) were determined by PrOF NMR (Figure 5.14, Figure 5.15, Figure 5.16, 
Figure 5.17, Figure 5.18). The affinities shown in Table 5.2 ranged from 6.2 to 256 µM 
and were consistent with the rank ordering by Δδ50. Using the same samples a 1D 
protein-observed experiment was conducted monitoring the protein indole N-H 
resonances, however due to the lack of significant chemical shift upon ligand binding 
only two of five Kd values could be obtained but were in agreement with PrOF NMR 
values (32 vs 39 µM for 1, and 148 vs 142 µM for 2). 
  188 
To	higher molar	ratio1H-NMR 19F-NMR
FREE
FREETo	higher molar	ratio
KD=	39	± 2	µMKD=	32	± 2	µM
 
Figure 5.14 A titration of 5FW-Brd4 (40 µM active protein) with 1 monitored by 
both PrOF NMR and 1H NMR of the N-H tryptophan resonance (2% DMSO). 
 
 
To	higher molar	ratio
1H-NMR 19F-NMR
FREE
FREETo	higher molar	ratio
KD=	142	± 3	µMKD=	148	± 6	µM
 
Figure 5.15 A titration of 5FW-Brd4 (40 µM active protein) with 2 monitored by 
both PrOF NMR and 1H NMR of the N-H tryptophan resonance (2% DMSO). 
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1H-NMR
FREE
At	higher molar	ratio
To	higher molar	ratio
19F-NMR
FREE
Monitoring 1H-NMR of the N-H
tryptophan resonances no significant
chemical shift changes were recorded
even at the highest molar ratio. KD=	123	± 7	µM
 
Figure 5.16 A titration of 5FW-Brd4 (40 µM active protein) with 3 monitored by 
both PrOF NMR and 1H NMR of the N-H tryptophan resonance (2% DMSO). 
 
 
 
To	higher molar	ratio
19F-NMR
FREE
1H-NMR
FREE
At	higher molar	ratio
Monitoring 1H-NMR of the N-H
tryptophan resonances no significant
chemical shift changes were recorded
even at the highest molar ratio.
KD=	256	± 10	µM
 
Figure 5.17 A titration of 5FW-Brd4 (40 µM active protein) with 4 monitored by 
both PrOF NMR and 1H NMR of the N-H tryptophan resonance (2% DMSO). 
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To	higher molar	ratio
1H-NMR 19F-NMR
FREE
FREE
At	higher molar	ratio
Monitoring 1H-NMR of the N-H
tryptophan resonances no significant
chemical shift changes were recorded
even at the highest molar ratio.
KD=	6.2	± 0.4	µM
 
Figure 5.18 A titration of 5FW-Brd4 (40 µM active protein) with 12 monitored by 
both PrOF NMR and 1H NMR of the N-H tryptophan resonance (2% DMSO). 
 
 
To verify the rank-ordering of NMR hits by additional methods, we measured the 
top eight fragments by Δδ50 with thermal shift analysis (TSA) and isothermal titration 
calorimetry (ITC) with unlabeled Brd4. All eight showed an increased melting 
temperature of Brd4 by 0.5 °C or greater by TSA (Figure 5.19), and five led to 
quantifiable dissociation constants by ITC (Figure 5.20, Figure 5.21, Figure 5.22). Two 
of the molecules for which we were unable to quantify the affinities showed an 
incomplete binding isotherm trend, consistent with weak binding. One of the fragments 
that showed incomplete binding was 9. Seeking to verify binding measurements by 
another method, we attempted to measure the Ki of 9 and 1 by fluorescence anisotropy. 
While 1 resulted in a Ki of 10.8 µM (comparable to ITC measurements), the fluorescence 
anisotropy experiments with 9 still led to an incomplete binding curve supporting a weak 
binding affinity (Figure 5.23). In summary of these results, the rank-ordering of the hits 
by ITC and TSA matches the rank-ordering of hits by PrOF NMR Δδ50 determined by the 
initial titrations. 
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Figure 5.19 Differential scanning fluorimetry of apo-form of Brd4 and three 
different binders. 
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Figure 5.20 ITC results of the highest affinity fragments which were identified by 
PrOF NMR experiments. 
These ITC experiments were performed with Brd4 wild-type in the presence of DMSO 
(0.5% DMSO). 
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Figure 5.21 ITC results of the highest affinity fragments which were identified by 
PrOF NMR experiments. 
These ITC experiments were performed with 5FW-Brd4 in the presence of DMSO (0.5% 
DMSO). 
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Figure 5.22 ITC results of the other fragments which were identified by PrOF NMR 
experiments. 
These ITC experiments were performed with Brd4 in the presence of DMSO (0.5% 
DMSO). 
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Figure 5.23 Fluorescence anisotropy competitive inhibition measurement of 1 and 9, 
displacing a fluorescently labeled ligand, BI-BODIPY. 
The isotherm for 9 shows incomplete binding, consistent with a low affinity ligand. 
 
Table 5.2 Comparison of biophysical affinities obtained by different methods 
Compound ITC - Kd (µM) 
(Ligand 
Efficiency) 
5FW-Brd4 
ITC (µM) 
PrOF 
NMR Kd 
(µM) 
1H NMR 
Kd (µM) 
Δδ50 PrOF 
NMR 
(µM) 
Thermal 
Shift 
(Δ °C) 
12 3.4 (LE: 0.53) 2.8 6.2 b <1 4.53 
1 18.6 (LE: 0.46) 14.7 39 32 <1 2.23 
2 37.4 (LE: 0.42) a 142 148 3.6 0.77 
3 42.1 (LE: 0.40) a 132 b 3.6 1.1 
4 54.6 (LE: 0.41) a 256 b 6.4 0.72 
5 a a a a 9.9 a  
6 b a a a 7.6 1.4 
7 a a a a 14 a  
8 b a a a 9.1 1.3 
9 b a a a 9.6 0.57 
10 a a a a 21.3 a  
11 a a a a 24.3 a  
a Values not determined 
b Results inconclusive 
 
In comparison of Kd values from PrOF NMR titration and ITC variations of 1.8 to 
4.7-fold were observed. To determine the effect of fluorine incorporation on binding to 
Brd4, the dissociation constants of the two strongest binders, 1 and 12, were measured by 
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ITC with 5FW-Brd4 (Figure 5.20, Figure 5.21). In this case, the Kd values by ITC were 
similar (12: 3.4 vs. 2.8 µM, 1: 18.6 vs. 14.7 µM). Besides error in fitting the data for the 
weak binding fragments, additional origins of these effects may be the 4-fold higher 
concentration of DMSO used in the PrOF NMR experiment (2% versus 0.5%) which can 
attenuate ligand binding.	 Comparison	 of	 the	 affinities	 obtained	 for	 the	 fluorinated	proteins	by	PrOF	NMR	and	ITC,	suggest	this	could	exert	a	2.2	to	2.6-fold	effect.	The	4.7-fold	difference	supports	an	added	perturbation	in	binding	beyond	differences	in	experimental	 conditions.	Therefore, we conclude in the small sample of molecules 
studied that binding interactions seem to be minimally to modestly perturbed by fluorine 
incorporation (). These results are consistent with our prior studies.131 
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5.3 Discussion 
 
Table 5.3 A general comparison of PrOF NMR with 1H CPMG as screening 
methods 
1H CPMG PrOF NMR 
Difficult to optimize without known ligand 
 
Does not require reference compound for 
optimization of experimental conditions 
 
More prone to false positives without competition 
experiments 
 
Less prone to false positives 
 
Low concentration of unlabeled protein (2-10 
µM) needed 
 
Requires moderate concentration of fluorinated 
protein (≤ 40 µM) 
 
Low concentration of ligand needed (low to mid 
µM), solubility of ligands can be observed by 
resonance height 
High concentration of ligand needed (high µM 
to mM), no information on solubility of ligands 
is provided 
No experimental deconvolution needed, but data 
analysis is time consuming 
 
Data analysis can be readily automated, but 
experimental deconvolution required 
 
Faster with larger proteins, no theoretical upper 
bound size limitation 
 
Faster with smaller to medium proteins, 
approaches a size limitation (<65 kDa for 
aromatic amino acid labeling)137 
 
NMR time for this 1H CPMG screen (15 kDa 
protein, three 10 minute NMR experiments): 93 
hours 
NMR time for this PrOF NMR screen (15 kDa 
protein, 2 minute NMR experiment): 29 hours 
(23 hours of which would be used to 
deconvolute 140 mixtures. Note: only 38 
mixtures were deconvoluted to conserve 
protein) 
 Facile Kd determination with titration 
experiment 
 
Because 1H CPMG is a ligand-observed technique, the method can report on 
ligand solubility as well as ligand binding interactions. However, ligand-observed 
methods can suffer substantially when there are no known ligands for the desired target 
for optimizing the experiment. The known ligand allows the tuning of screening 
parameters, such as ligand and protein concentration, as well as the CPMG filter length. 
Acetaminophen was used as a test compound for this screen, which we previously 
determined to bind to Brd4 with a Kd between 230 and 290 µM. With unoptimized 
parameters the signal change upon binding was negligible, but optimized ligand 
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concentration (100 µM) and CPMG filter length (800 ms) resulted in a nearly 30% drop 
in signal intensity (Figure 5.24). Without a reference compound, one could screen an 
entire library while unknowingly using poorly optimized conditions. With protein-
observed techniques, once the labeled protein has been obtained the NMR parameters can 
all be optimized using only the protein. The effects of different ligand concentrations are 
more straightforward with protein-observed techniques (greater ligand concentration 
results in greater response) and can be initially estimated based on protein ligandability 
prediction. Importantly, a high-affinity reference ligand allows for competition CPMG 
experiments, which could help to avoid false positives resulting from non-specific 
binding or protein denaturants. This highlights the utility of broad spectrum inhibitors for 
a class of proteins, such as bromosporine for bromodomains.53 As an alternative to a 
competition experiment to eliminate non-specific binding with ligand-observed NMR 
experiments, an STD NMR method exists that tests for specific binding by epitope 
mapping.73 
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400 µM Acetaminophen, 10 µM Brd4, 400 ms 
 
400 uM Acetaminophen, 10 µM Brd4, 800 ms 
 
100 µM Acetaminophen, 10 µM Brd4, 400 ms 
 
100 µM Acetaminophen, 10 µM Brd4, 800 ms 
 
	
 
Figure 5.24 A comparison of the different CPMG parameters. 
Rear NMR spectra are just ligand, while front NMR spectra are ligand + protein. Both 
concentration of ligand and CPMG filter length are varied, with 100 µM acetaminophen 
and an 800 ms filter length resulting in a greater signal drop upon protein addition than 
400 µM acetaminophen with a 400 ms filter length. 
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A potential difficulty with using PrOF NMR is the ability to obtain fluorinated 
protein in sufficient yields, as well as the potential for the fluorinated protein to behave 
differently than the unlabeled protein, although neither of these have been problematic 
for bromodomains. Fluorine substitutions on aromatic rings tend to increase π-π stacking 
interactions by 0.5 kcal/mol per fluorine atom.204 Work by Dougherty et al. found that 
incorporation of 5-fluorotryptophan into proteins can reduce cation-π interactions by 0.6-
0.8 kcal/mol.205,206 These energetic differences result in a 4-fold change in binding 
affinity or less, and would only occur if the fluorinated amino acid is directly involved in 
the binding interaction. ITC studies with 1 and 12 indicate no significant change in 
binding affinities between Brd4 and 5FW-Brd4, consistent with prior studies using 
different ligands.131 However, the 4.7-fold difference in binding between the unlabeled 
protein and fluorine labeled protein for molecule 4 may reflect such a case. 
Because only certain amino acids are fluorinated for PrOF NMR, some structural 
information is useful to determine which amino acids are close to the binding site of 
interest. Acetaminophen binds weakly with Brd4, and has been crystallized with the 
highly homologous bromodomain of Brd2. Assuming a similar binding mode between 
Brd4 and Brd2, the fluorine of W81 is 6.1 Ǻ from the nearest heavy atom of 
acetaminophen (Figure 5.25). However, with Brd4 bound to (+)-JQ1, W75 is also slightly 
affected (0.13 ppm) with the fluorine atom 11.3 Ǻ away from the nearest heavy atom of 
(+)-JQ1. This latter effect may occur from a subtle conformational change not observed 
in the x-ray structure. Several other ligands in the PrOF NMR screen perturb both W81 
and W75, so the distance dependence of the fluorine atom can vary. Aromatic amino 
acids tend to be enriched at protein-protein interfaces,100 and with bromodomains we 
found high conservation of aromatic amino acids near the binding site.131 Therefore, for 
these type of interactions it is highly likely at least one aromatic amino acid will be close 
by to monitor. 
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Figure 5.25 An overlay of Brd4 and Brd2 where Brd2 is crystallized with 
acetaminophen. 
Assuming a similar binding mode, this places the nearest heavy atom of acetaminophen 
6.1 Ǻ away from the fluorine of W81 in 5FW-Brd4. 
 
 
Protein size will play a large role in the speed with which spectra can be acquired. 
A smaller protein results in rapid PrOF NMR experiments with lengthy 1H CPMG 
experiments, while for larger proteins the ligand-observed becomes the faster of the two 
methods. At this protein size, a PrOF NMR screen is substantially faster than a 1H CPMG 
screen (2 minutes vs. 20-30 minutes for a single experiment, though experimental 
deconvolution is necessary by PrOF NMR), but as protein-size increases PrOF NMR will 
require longer experiment times due to a longer rotational correlation time leading to 
resonance broadening. Rule et al. has shown a 65 kDa protein labeled with 5-
fluorotryptophan can lead to broad but resolved resonances.137 In this case, experiment 
times would be significantly longer unless a more dynamic side chain is labeled.89,156 
Because CPMG exploits the differences in rotational correlation between small ligand 
and large protein, it exhibits the opposite trend, i.e., the sensitivity of CPMG increases 
with larger proteins. With larger proteins higher concentrations of ligand can be used, 
dramatically reducing experiment time. One difficulty with 1H CPMG that could be 
6.1 Ǻ 
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resolved with software is the ability to work up screening data. Because of the potential 
for overlapping resonances, and the need to correlate resonances from the screen with 
baseline spectra of the individual ligands, automated data processing can greatly expedite 
the process.207  
Finally, protein-observed techniques are inherently less prone to false positives as 
long as more than one resonance is present. Because there are NMR resonances in a 
specific pattern due to the local chemical environment of each observed nucleus, the 
spectrum will reveal whether or not a protein is in solution and well-folded. If the protein 
is denatured or degraded, the resonances coalesce, disappear, or sharpen. This is 
essentially an in situ quality control for every protein-observed experiment, reducing 
potential false positives. Additionally, because there are multiple resonances 
corresponding to amino acids at different positions on the protein, the perturbed 
resonances frequently correlate with the rough identification of the ligand binding site, 
although as with all protein-observed NMR experiments that rely on chemical shift 
perturbations, conformational effects cannot be ruled out. However, we have found that 
the chemical shift perturbations for bromodomains tend to localize to residues near the 
binding site.131 This type of analysis is useful if there are multiple binding sites on a 
protein construct where only one is the desired target. Gee et al. previously showed this 
in the context of the protein KIX which possesses two binding sites.127 Additionally, 
because multiple labels are present which may be outside known binding sites, there is 
the potential for serendipitously uncovering a cryptic binding site. 
In conclusion, in this study we have benchmarked PrOF NMR as having 
comparable sensitivity to 1H CPMG with 85% assay overlap when an additional 
competition experiment is employed in the 1H CPMG NMR experiment in the context of 
bromodomain screening. Without a competitor the agreement between the two assays 
dropped to 80%. The similar hit-rate of PrOF NMR with the well-utilized 1H CPMG 
further validates PrOF NMR as a screening method for ligand discovery for similar 
proteins. Because the detection abilities of both methods were so similar, the decision of 
which biophysical screen to use as a primary screen is protein dependent, and the 
complementary nature of the data supports conducting both ligand and protein-based 
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experiments. Factors that can influence this decision are the availability of reference 
compounds, the ability to express protein in sufficient yields, protein size, and presence 
of multiple binding sites. One advantage of 1H CPMG over PrOF NMR is the ability to 
avoid a time consuming deconvolution step for the fragment mixtures. We found an 85% 
similarity between PrOF NMR of a represented set of deconvoluted mixtures and 1H 
CPMG, similar to the mixture data which was 77% similar between methods, as such no 
further deconvolution pursued. Due to the similarities in assay conditions, the 
possibilities of doing a sequential ligand-observed and PrOF NMR experiment during the 
same NMR screen may prove beneficial eliminating the need for deconvolution.  
5.4 Future directions 
Three dimensional fragments are low molecular weight compounds that have 
some degree of shape. The utility of 3D fragments is underexplored, despite drug-like 
compounds having more sp3 or 3D character.208 Statistical analysis of drug-like 
compounds has shown that during each phase of the drug development process, 
successful compounds tend to have a significant amount of Fsp3 character, as well as at 
least one stereocenter.208 Additionally, compounds that are less aromatic and have more 
3D character tend to be more water soluble,209 an important quality for use in vivo and in 
biophysical assays. Therefore, 3D-enriched fragment screens could produce higher 
quality drug-like hits than traditional 2D-enriched screens. 
To evaluate the effectiveness of 3D-enriched fragments, five hundred 3D-
enriched fragments were screened against Brd4, a model protein, using 1H CPMG. The 
active-rate will be compared with the 2D library presented in the preceding text. These 
compounds will be further elaborated to ascertain the quality of 3D-fragment hits. 
5.5 Materials and Methods 
Preparation of fragment library: 
The fragments in the screening library were initially analyzed by 1H NMR, and 
any compounds with low resonance intensity from low solubility or aggregation 
propensity were removed from the set. The fragments were then combined into mixtures 
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of five in such a way to maximize the diversity of compounds in each mixture, while 
avoiding mixing reactive functional groups. Although the fragment library consists of a 
majority of commercial fragments, several fragments are proprietary compounds of Eli 
Lilly & Company. 12 was one such compound, whose structure has been omitted. 
 
Expression of 5FW-Brd4 (42−168): 
Unlabeled and 5FW-labeled Brd4 were expressed based on established 
methods32,131 using E. coli Bl21(DE3) + pRARE strains. To express the labeled protein, 
the secondary culture in LB media was grown until an OD600 of 0.6 was reached followed 
by harvesting. Cells were resuspended in defined media of Muchmore et al.110 containing 
5-fluoroindole (60 mg/L) in place of tryptophan.96 The resuspended E. coli were 
incubated at 37 °C while shaking for 1.5 h followed by cooling to 20 °C and media 
temperature equilibration for 30 min. Protein expression was induced with 1 mM IPTG 
overnight (14−16 h) at 20 °C. The cells were harvested and stored at −20 °C. Cell pellets 
were thawed at room temperature followed by the addition of lysis buffer (50 mM 
Phosphate pH 7.4, 300 mM NaCl) containing protease inhibitor PMSF (5 mM) as well as 
the Halt protease inhibitor and purified according to methods described in the appendix 
using Ni-affinity chromatography. Yields following purification are 120 mg/L 5FW-Brd4 
(>94% fluorine incorporation assessed by mass spectrometry). Purity of proteins was 
assessed by SDS-PAGE. Fluorinated amino acid incorporation efficiency in proteins was 
measured by mass spectrometry as described in the appendix. Concentration was 
determined via absorbance at 280 nm.177 
 
Protein-observed fluorine (PrOF) NMR: 
1D 19F NMR Parameters: 19F NMR spectra were acquired at 565 MHz on a 
Bruker Avance III spectrometer equipped with a quadruple resonance HFCN CryoProbe 
without proton decoupling, unless otherwise specified. Samples for binding assays 
contained 50 µM 5FW-Brd4 and 5 fragments each at 400 µM in 50 mM Tris, 100 mM 
NaCl, and 5% D2O, pH 7.4. Spectra were referenced to trifluoroacetate (−76.55 ppm). 
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Measurement parameters included a relaxation delay time of 0.7 s and a 58° pulse flip 
angle (based on the Ernst angle from T1 determination). An acquisition time of 0.05 s 
and a spectral width of 10 ppm were used for all experiments. Thirteen-minute screening 
experiments used 1000 scans while two-minute screening experiments used 160 scans. 
Small molecules were titrated into the protein solution from concentrated stock solutions 
of DMSO (100 mM). Final DMSO concentrations were kept at or below 2%. Proton 
decoupling was not used because it results in a reduction in signal intensity due to the 
negative nuclear Overhauser effect with large molecules. Additionally, the increased 
NMR linewidth from large biomolecules obscures couplings. 
 
1H CPMG: 
1H NMR spectra were first collected on all compounds in the fragment library to 
be used as reference spectra for deconvoluting screening data. Samples were prepared 
with 100 µM each of fragment, and a 1H CPMG spectrum acquired of each mixture (with 
a CPMG filter length of 1.2 s and an interpulse delay of 2.5 ms). In a second step, a 
concentrated protein stock solution was then added to each sample to a final 
concentration of 10 µM Brd4, and a 1H CPMG spectrum was recorded. Finally, known 
competitor (+)-JQ113 was added to a concentration of 20 µM, and competition was 
monitored by recovery of signal intensity. 
 
Fluorescence anisotropy: 
Fluorescence anisotropy was measured from an excitation wavelength of 485 nm 
and an emission wavelength of 535 nm on a Tecan Infinite 500 plate reader using low 
volume 384-well plates (Corning 4511). All experiments were carried out in 50 mM Tris, 
150 mM NaCl, and 4 mM CHAPS at pH 7.4. The fluorescently labeled tracer, BI-
BODIPY, was synthesized according to published methods.165 For both direct binding 
and competition experiments, 25 µM stocks of a BI-BODIPY stock solution in DMSO 
were diluted to a final concentration of 25 nM. For direct binding experiments, Brd4 was 
serially diluted from micromolar to subnanomolar concentrations. For competition 
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experiments, Brd4 was kept at a constant concentration of 156 nM, equivalent to 80% 
bound tracer as determined in direct binding experiments, and the concentration of 
competing ligand was serially diluted from micromolar to subnanomolar concentrations. 
Data were collected within 30 min after plating to minimize Brd4 binding to the plate 
surface. All experiments were carried out in triplicate. Acquired data were fit using 
GraphPad Prism. Kd values were determined by fitting to the following equation, which 
accounts for ligand depletion. In this equation, b and c are the maximal and minimal 
anisotropy values, respectively, a is the concentration of fluorescently labeled tracer, x is 
the protein concentration, and y is the observed anisotropy value. 
y = c+ (b− c) (Kd + a+ x)− (Kd + a+ x)
2 − 4ax
2a   
 
IC50 values were determined using GraphPad Prism’s log(inhibitor) vs response function. 
Ki values were obtained using a variant of the Cheng-Prussof equation from Huang et 
al.102 
 
Isothermal titration calorimetry: 
Experiments were carried out on a MicroCal Auto-iITC200 titration from 
Malvern with a cell volume of 200 µL and a 40 µL microsyringe. Experiments were 
carried out at 25 °C while stirring at 750 rpm, in ITC buffer (50 mM phosphate buffer at 
pH 7.4 and 150 mM NaCl). The microsyringe was loaded with a solution of ligands 
whose concentrations were accurately measured by quantitative NMR (ITC buffer with 
0.5% DMSO-d6), and was automatically inserted into the calorimetric cell which was 
filled with an amount of the protein, Brd4 and 5FW-Brd4 (200 µL, 30 µM in ITC buffer 
with 0.5% DMSO-d6). The system was first allowed to equilibrate until the cell 
temperature reached 25 °C and an additional delay of 60 s was applied. These first 
titrations were conducted using an initial control injection of 0.5 µL followed by 18 
identical injections of 2 µL with a duration of 4 s per injection and a spacing of 150 s 
between injections. Afterwards, a second titration was performed over this first titration 
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without cleaning the cell. This second titration was executed with Continue Injections as 
Automation Method in MicroCal Auto-iTC200. Second titrations were conducted using 
19 identical injections of 2 µL with duration of 4 s per injection and a spacing of 150 s 
between injections. The titration experiments were designed in such a fashion, as to 
ensure complete saturation of the protein before the final injection. The heat of dilution 
for the ligands was independent of ligand concentration and corresponded to the heat 
observed from the last injection, following saturation of protein binding, thus facilitating 
the estimation of the baseline of each titration from the last injection. The collected data 
were corrected for ligand heats of dilution, and deconvoluted using the MicroCal PEAQ-
ITC Analysis Software to yield enthalpy of binding (ΔH) and binding constant (Kd). 
Thermodynamic parameters were calculated using the basic equation of thermodynamics 
(ΔG = ΔH - TΔS = -RTlnKd, where ΔG, ΔH and ΔS are the changes in free energy, 
enthalpy and entropy of binding respectively). A single binding site model was employed 
by MicroCal PEAQ-ITC Analysis Software.  
 
Thermal shift assays: 
Thermal shift assay (TSA) measures the thermal stability of the Brd4 wild-type, 
and the comparison between the melting temperature of apo-protein and melting 
temperatures in the presence of different compounds. Previous exploratory phase was 
performed to determine optimal experimental conditions for this assay in the same buffer 
as ITC (50 mM phosphate buffer at pH 7.4 and 150 mM NaCl). In 96-well PCR plate 
with a sample of 20 µL in each well (2.5% DMSO) Brd4 was at 26 µM, fragments were 
assayed at 250 µM, and Protein Thermal ShiftTM Dye was utilized at 2X (Protein Thermal 
ShiftTM Dye Kit from ThermoFisher Scientific). Fluorescence data was collected on an 
Applied Biosystems 7500 FAST RealTime PCR System with an excitation range of 580 
± 10 nm. The fluorescence emission signal at 623 ± 14 nm was used for data analysis. 
Samples were preheated for 2 minutes at 25 °C, then the temperature was continuously 
increased 2 °C/min from 24 to 99 °C, and finally samples were maintained for 2 minutes 
at 99 °C. 
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Protein Expression and Molecular Biology Materials:  
For E. coli growth, LB agar, LB media, defined media components including 
unlabeled amino acids, uracil, thiamine-HCl, nicotinic acid, biotin and buffer components 
were purchased from RPI corp. Thymine, cytosine, guanosine were purchased from Alfa 
Aesar. Magnesium chloride, manganese sulfate, succinic acid, calcium chloride and 5-
fluoroindole were purchased from Sigma-Aldrich. Miniprep plasmid purification kit was 
purchased from Clontech.  
	
Unlabeled Brd4 Protein Expression:  
The pNIC28-BSA4 plasmid containing the first bromodomain of Brd4 genes were 
kind gifts from the laboratory of Stefan Knapp. For protein expression, either the E. coli 
Rosetta (DE3) strain (Novagen) was first transformed with the respective expression 
plasmid or the BL21(DE3) strain was cotransformed along with the pRARE (Novagen) 
plasmid and plated onto agar plates containing kanamycin (100 mg/L) and 
chloramphenicol (35 mg/L). Following overnight incubation at 37 °C, a single colony 
was selected from the agar plate and inoculated in 50 mL of LB media containing 
kanamycin (100 mg/L) and chloramphenicol (35 mg/L). The primary culture was grown 
overnight at 25 °C while shaking at 250 rpm. For secondary culture growth, 1 L of LB 
media containing kanamycin (100 mg/L) was inoculated with the primary culture and 
cultured at 37 °C while shaking at 250 rpm. When the O.D. of culture at 600 nm reached 
0.6, the shaker temperature was reduced to 20 °C. After 30 minutes, the expression was 
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induced with 1 mM IPTG overnight for 12-16 h. Cells were harvested by centrifugation 
and stored at -20 °C.  
 
Bromodomain Purification:  
To purify fluorinated and unlabeled Brd4, the cell pellet was thawed at room 
temperature followed by the addition of lysis buffer (50 mM Phosphate pH 7.4, 300 mM 
NaCl) containing protease inhibitor PMSF (5 mM) as well as the Halt protease inhibitor. 
Cells were lysed by sonication and the cell lysate was centrifuged at 7500 g for 30 
minutes followed by supernatant filtration over Whatman filter paper. Filtrate containing 
the histidine-tagged Brd4 was loaded on to a nickel-NTA affinity column and eluted with 
an imidazole gradient on an AKTA FPLC system monitoring the O.D. at 280 nm. 
Imidazole was removed from the buffer using a HiPrep column (GE) for buffer exchange 
into 50 mM Tris pH 7.4, 100 mM NaCl. Purified and buffer exchanged protein was 
treated with TEV protease for either 2 hours at room temperature or alternatively at 4 °C 
overnight on a rotating carrousel. The cleaved His-tag, TEV protease and uncleaved Brd4 
were removed using nickel-NTA affinity resin.  
 
Protein Mass Spectral Analysis: 
Product molecular weight was confirmed by electrospray ionization mass 
spectrometry (ESI-MS) using a Waters Acquity UPLC/Synapt G2 QTOF LC-MS. To 
determine the percent incorporation for fluorinated proteins the integration values of the 
different deconvoluted mass peaks are entered into the following equation to determine 
the relative incorporation e.g, FWBrd4:  
 * 100 	
0FWBrd4 is 5FWBrd4 with no fluorine substitutions, 1FWBrd4 is 5FW-Brd4 
with one fluorine substitution, 2FWBrd4 has two fluorine atoms substituted and FWBrd4 
has 3 fluorine atoms substituted. Below is an example mass spectrum of 5FW-Brd4 
(expected mass of triply fluorinated 5FW-Brd4, 15137 m/z). 
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Figure 5.26 Protein mass spectrum of 5FW-Brd4. 
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Chapter	6. Prediction	of	19F	NMR	chemical	shifts	in	labeled	proteins	
 
Reproduced with permission from “Prediction of 19F NMR Chemical Shifts in Labeled 
Proteins: Computational Protocol and Case Study,” W. C. Isley III, A. K. Urick, W. C. K. 
Pomerantz, C. J. Cramer, Molecular Pharmaceutics 2016, 2376-2386. Copyright 2016 
American Chemical Society. 
 
Note: The following was largely the work of Dr. William C. Isley III, and is also present 
in Chapter 2 of his dissertation “Factors Affecting Recognition and Chemical Reactivity 
at the Macromolecular Scale”. To place my contributions to this work in context, the 
entire study has been reproduced below. 
 
Motivation: Resonance assignment of the protein’s 19F NMR spectrum is necessary for 
structural analysis, but can be challenging. Here, a quantum chemical method has been 
developed as an initial approach to facilitate the assignment of a fluorinated protein’s 19F 
NMR spectrum. The epigenetic “reader” domain of protein Brd4 was taken as a case 
study to assess the strengths and limitations of the method. 
6.1 Introduction 
Epigenetic proteins regulate the expression of genetic information through 
addition, removal, or molecular recognition of posttranslational modifications of DNA or 
DNA associated proteins. Bromodomains are epigenetic protein modules that bind to N-
ε-acetyl groups on lysine side-chains including those of acetylated histone proteins. Small 
molecule chemical probes for these proteins are in high demand for their potential 
therapeutic regulation of disease.210 Since the first reports13,17 in 2010 of two nanomolar 
inhibitors for BET bromodomains Brd2, 3, 4 and T, eighteen clinical trials have been 
initiated to test the efficacy of BET bromodomain inhibition in the areas of cancer and 
inflammation.158,210 There are many other bromodomains, however, which lack specific 
chemical probes to evaluate their role in both health and disease.180  
We recently reported a protein-based NMR method for bromodomain ligand 
discovery, using fluorine-labeled aromatic amino acids.127,131 Since inception, this 
method has been used for screening libraries of low-complexity, small molecules termed 
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fragments,99,127,128,193 as well as higher complexity molecules based on kinase inhibitor 
scaffolds.32 In these experiments, proteins are expressed in the presence of fluorine-
labeled amino acids (e.g., 3-fluorotyrosine, or 3FY) resulting in global replacement of the 
non-fluorine labeled aromatic amino acid. A feature of this method is the sensitivity of 
the 19F nucleus to different chemical environments, typically leading to rapidly obtained 
and well-resolved 1D 19F NMR spectra. In the case of the first bromodomain of Brd4, we 
replaced all seven tyrosine residues with 3FY resulting in dispersed resonances spanning 
over 12 ppm (Figure 6.1).131  
A notable challenge when conducting protein-observed 19F NMR experiments (or 
PrOF NMR), is the initial assignment of the NMR resonances. This is most often 
facilitated by site directed mutagenesis experiments.106 In these experiments a particular 
amino acid that is labeled with fluorine is mutated to a different amino acid, and the 19F 
NMR spectrum of the mutant protein compared to the wild type protein. The absence of a 
single resonance is then used to assign the NMR spectrum. However, this method is not 
generally applicable as not all mutant proteins may express well, or multiple resonances 
may be perturbed in the NMR spectrum. In the case of 3FY-labeled Brd4, several of the 
mutant proteins expressed at low levels and some were more susceptible to degradation, 
thus complicating the NMR analysis particularly for the 3FY resonances for Y118 and 
Y119.131  To help overcome challenges of mutagenic protein expression, we reasoned 
that a computational approach to NMR chemical shift prediction would function as a 
useful tool in facilitating the 19F NMR assignment motivating this study. Protein based 
NMR ensemble (NMRE) simulations for 1H, 13C, and 14N have been able to utilize the 
wealth of available NMR data in the literature to create a predictive protocol from 
machine learning algorithms; however, the database on 19F NMR in proteins is 
significantly smaller.211 Sampling of the protein’s conformational ensemble has been 
shown to significantly improve prediction accuracy over simply using the X-ray crystal 
structure.212,213  
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Figure 6.1 Measured 19F NMR spectrum of 3FY-labeled Brd4. 
So that the resonance width can be observed unmodified, no line broadening has been 
applied to this spectrum. However, modest application of line broadening will increase 
both S/N and reproducibility of chemical shift. 
 
Chemical shift predictions for fluorinated proteins have highlighted several 
challenges for theory. Using the 5-fluorotryptophan-labeled galactose binding protein, 
Pearson et al. predicted the 19F NMR spectrum with reasonable agreement with 
experimental data.214 Additionally, Sternberg et al.215 developed a semi-empirical 
protocol for prediction of fluorotryptophan 19F NMR for a solid state membrane bound 
protein gramicidin A that gave reasonable agreement with more rigorous levels of theory. 
Conversely, despite systematic analysis of local electrostatic effects and short range 
contacts, Lau and Gerig were unable to reliably predict the 19F NMR spectrum of the 
more dynamic 6-fluorotryptophan-labeled dihydrofolate reductase.216 These mixed results 
for fluorotryptophan illustrate the challenges associated with making accurate 
predictions.  The challenge is enhanced by the even more narrow spectral range of ≈ 2 
ppm for 5-fluortryptophan-labeled Brd4. Recent work by Kasireddy et al.217 demonstrates 
the challenges and potential utility of 19F NMR predictions on fluorohistidine molecules. 
By contrast, the prediction of the chemical shifts within 3FY-substituted proteins has not 
been previously attempted.  
In this report, we propose that the wider spectral range of 3FY provides a novel 
and significantly more accessible platform to predictively assign the full 19F NMR 
spectrum of a 3FY-labeled bromodomain, Brd4. The enhanced utility of 3FY as a 
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predictive platform is more challenging than other fluorinated aromatics (4-phenylalanine 
or fluorotryptophan) given the increased conformational flexibility and additional 
hydrogen bonding interactions provided by the phenol and asymmetric substitution.  We 
also demonstrate that automation of spectral predictions for 19F NMR in bromodomain-
containing proteins is feasible, and that a cluster based method for prediction of 19F NMR 
chemical shifts shows great promise for further development. While traditional 
predictions of protein-based 1H NMR involve dynamic simulations to sample the large 
ensemble of configurations, the relative rigidity and availability of X-ray crystal 
structures for bromodomains, and the limited number of side-chain resonances requiring 
assignment, render an exploratory cluster-based model feasible. Due to the high 
conservation of aromatic amino acids in the majority of the 61 bromodomains,131 this 
method may find general utility for these proteins.  
6.2 Theoretical Methods 
In this section, we summarize our overall protocol to arrive at 19F chemical shift 
predictions starting from a Protein Data Bank (PDB) file for an unlabeled protein. The 
solution of the crystal structure of 3FY-labeled Brd4 (PDB 4QZS) was shown to have 
minimal structural perturbation (RMSD 0.089 Å) vs the unlabeled protein (PDB 
3MXF).13,131 We include full details of file manipulation and software employed; scripts 
developed for process automation are also publically available. This work utilizes the 
overall scheme below, with details described in the following sections. 
1. The protein structure is taken from the PDB file.  
2. To obtain an initial solvation environment around the target residues, a 
molecular dynamic optimization of water molecules on a frozen protein is 
performed. 
3. From the solvated protein, clusters are excised around each 3FY. The NMR ab 
initio calculations of the full protein are prohibitively expensive, so protein 
fragments are used. 
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4. Geometries sampling the fluorine and phenol conformers are generated, and 
the target 3FY is optimized within a frozen protein fragment using density 
functional theory.  
5. NMR chemical shifts are predicted using a Boltzmann average over the 
cluster conformers.  
6.2.1 Hydration of Protein and Optimized H-atom Positions 
We used the online Molecular Dynamics on Web (MDWeb) toolset,218 initially 
going through the following steps for a given protein structure:   
Select action “Prepare Structure Topology for AMBER ParmFF99SB* (Hornak & 
Simmerling, including Best & Hummer psi modification)”219,220  
Select action for structural optimization of 50 or more exterior water molecules 
using the Classical Molecular Interaction Potentials (CMIP)221  
Select action to energetically minimize hydrogen atom positions using NAMD222 
Select action to export PDB structure 
File I/O: The resulting PDB exported from MDWeb lacks the column at the end 
of a regularly formatted PDB file that specifies the actual atom designation for each 
ATOM type. Opening the PDB file in OpenBabel223, and choosing to convert PDB -> 
PDB fixes this issue.  
6.2.2 Cluster Generation 
The final, properly formatted PDB file serves as input to the cluster generation 
script. Additional input includes specification of a target residue number and a cutoff 
radius to be used for cluster generation. Waters solvating the exterior of the protein are 
optimized with the AMBER force field during step 3, which samples the solvation 
configurational space rapidly and serves as a platform for cluster exploration.  
The script generates a local cluster by identifying other protein residues within the 
cutoff radius of the target residues’ non-hydrogen atoms. Once all such surrounding 
residues have been found, the script keeps them in position, caps all open backbone 
termini with acetyl- (N terminus) or N-methylamino- (C terminus) groups, and eliminates 
all remaining atoms. Note that any crystallographically conserved water molecules, 
counter ions, or small molecules in the PDB file are removed during the prepare topology 
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step—water molecules are added back to the structure, however, in the next step. The 
interior water molecules are added during cluster generation, and are manually inserted 
so as to match the phenol-water distance determined from X-ray diffraction, along with 
the oxygen atom oriented at same angle from the aromatic plane as in the XRD. The 
orientations of the hydrogen atoms on the water relative to the phenol (not available from 
XRD) are chosen so that the water can participate in hydrogen bonding (either as a donor 
or acceptor depending on orientation and nearby side chain functionality). 3FY residues 
exposed to the protein surface are solvated with one to three water moieties. The 
coordinates of these waters are allowed to relax, as discussed further below. Once a 
cluster (with no fluorine atoms) has been generated, four conformers are created 
manually, corresponding to the four relative orientations of fluorine and the phenolic 
proton (Figure 6.3). 
6.2.3 Optimization 
The geometry of the target residue is then optimized with Density Functional 
Theory, within a frozen cluster, i.e. only the fluorinated residue is optimized within its 
otherwise fixed cluster framework. This step employs the M06-L224 density functional 
and the def2-SVP  basis set225 on all atoms. The aqueous SMD226 continuum solvation 
model is also employed, as early surveys of gas-phase results were found to give poor 
structures and also to suffer from convergence difficulties in clusters having local charge 
separations. 
6.2.4 19F NMR Chemical Shift Prediction 
Following restrained optimization of the cluster, the 19F NMR chemical shift is 
predicted. Trifluoroacetate (δexp = -76.55 ppm) is employed to compute a reference 
chemical shielding (σref), with computations of 3FY chemical shifts δpred then being 
determined as  
 δpred = (σref + δexp)  – σpred   
where σpred is the shielding predicted for 3FY in the cluster. All chemical shifts are 
reported relative to CFCl3 (set to 0.0 ppm). To predict chemical shifts most accurately, a 
linear regression of predicted values on experimental measurements is common practice. 
We benchmarked several computational protocols on a training set of 14 molecules 
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containing aryl-fluorine bonds (Table 6.1) evaluating such model parameters as 1) gas 
phase vs SMD implicit solvation, 2) density functional choice (B3LYP vs PBE0), and 3) 
basis set size (double-zeta vs triple-zeta quality). Most protocols performed well over the 
benchmark set, PBE0 with implicit solvation provided the highest accuracy for prediction 
of the chemical shift of 3-fluorotyrosine. We adopted PBE0/SMD with the EPR-II basis 
set as our recommended protocol, as it offers an optimal combination of accuracy and 
computational efficiency. The corresponding linear regression to be used with chemical 
shifts predicted from this level of theory is 
   
Additional analysis is provided below in Results and Discussion. 
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Table 6.1 Performance of 19F δ Prediction Protocols in Comparison to 
Experiment. 
  
 19F δ (ppm) a 
   Exp SMD Implicit Solvation 
   
 
PBE0 B3LYP HF 
Molecule  
 
EPR-II EPR-III EPR-II EPR-III EPR-III 
2-fluorophenol 1 b 1 -141.9 -144.4 -136.6 -147.0 -146.8 -152.0 
2,6-difluorophenol 2 b 2 -139.1 -140.2 -133.5 -143.2 -144.0 -146.2 
2-fluoro-p- 
hydroquinone 1 b 
3 
-138.7 -140.3 -132.6 -143.1 -143.1 -145.7 
3-fluorotyrosine b 4 -137.6 -142.6 -135.8 -145.2 -146.3 -151.8 
5-fluoroindole 3 
5 -
126.55 -135.2 -129.1 -138.7 -140.1 -144.2 
6-fluoroindole 3 
6 -
121.83 -131.5 -125.3 -135.2 -136.4 -137.9 
5-fluorotryptophan 3 
7 -
126.15 -134.6 -128.7 -138.1 -139.9 -143.7 
6-fluorotryptophan 3 
8 -
122.85 -131.1 -125.5 -134.8 -136.8 -138.4 
fluorobenzene 
9 -
113.15 -121.3 -113.8 -125.2 -124.7 -136.3 
hexafluorobenzene 10 -164.9 -166.7 -163.9 -168.1 -173.5 -130.8 
4-fluorophenylalanine 11 -116.7 -125.8 -119.2 -129.7 -130.4 -148.5 
Pentafluoro- 
benzene (1,5F) 
12 
-139.9 -143.0 -138.5 -145.3 -148.5 -172.5 
Pentafluoro- 
benzene (2,4F) 
13 
-162.1 -167.0 -163.9 -168.6 -173.7 -161.8 
Pentafluoro- 
benzene (3F) 
14 
-153.5 -158.5 -154.6 -160.4 -164.6 -169.3 
Statistics  
      Slope  
 
0.860 0.930 0.808 0.897 0.204 
Intercept  
 
-24.55 -9.22 -34.40 -24.25 -109.69 
R**2  
 
0.9737 0.9541 0.9695 0.9477 0.0683 
a Chemical shifts reported relative to CFCl3 at 0.00 ppm and trifluoroacetate at -76.55 
ppm b These molecules have one explicit water molecule to accuarely model effect of 
hydrogen bonding to phenol on 19F chemical shifts.  
 
In many instances, a 3FY residue can adopt multiple poses within its associated 
cluster, and the phenol group leads further to multiple possible rotamers. To account for 
an equilibrium distribution of structures, Boltzmann weighted chemical shifts were 
computed as 
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where G is a relative solvated electronic energy for conformer ci. 
Software. All optimization and chemical shift computations were accomplished 
using the Gaussian09 Rev D.01 suite of electronic structure programs.  
6.3 Results and Discussion 
No benchmarking study for the accuracy of 19F NMR chemical shift predictions 
for biomolecular moieties at the density functional (DFT) or Hartree Fock (HF) level of 
theory was available. To validate our own protocol, we explored various options over a 
14-molecule training set as outlined in the theoretical methods. This protocol was 
employed to predict composite 19F chemical shifts using local clusters and accounting for 
conformational flexibility. We next address the modeling challenges associated with our 
protocol and the physical insights into the effects of chemical environment on 19F NMR 
shifts in proteins that it provides.  
6.3.1 Optimizing 19F NMR Prediction Protocol 
Prior to cluster generation, a method to predict the 19F NMR of aryl fluorine 
resonances in a training set of different fluorinated aromatic rings spanning about the 
same spectral frequency range as 3FY (-125 to -145 ppm) was optimized.131 The training 
set and experimental NMR data are reported in Table 6.1; data for a subset are shown in 
Figure 6.3. The phenols in the training set all include one explicit water molecule acting 
as a hydrogen bond acceptor to represent the solvation shell. Addition of water to 3FY 
shifts δpred downfield by 8 ppm, from -150 ppm to -142 ppm. The protocols tested include 
molecular optimization with M06-L/def2-SVP in either the gas phase or with an aqueous 
SMD solvation model. After these structures were obtained, NMR predictions were 
performed using either the PBE0227 or B3LYP228 density functionals in combination with 
either the EPR-II or EPR-III basis sets. Additionally, NMR predictions were made at the 
Hartree Fock level of theory using the 6-311++G(2d,2p)229,230 basis set and the aqueous 
SMD solvation model.  
Results for selected regressions of computed training set 19F NMR data on 
experimental measurements are shown in Table 6.2. Plotted in Figure 6.2, the correlation 
between experiment and theory selected for further use was found for the protocol 
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combining the aqueous SMD solvation model,226 the PBE0 density functional,227 and the 
EPR-II basis set. A similar statistical performance was obtained with the larger basis 
PBE0/EPR-III/SMD model, but we chose to continue with PBE0/EPR-II/SMD based on 
its lesser computational expense. B3LYP methods offered similar levels of accuracy 
across the set. PBE0 was selected given its better performance for 3FY (Table 6.1). 
Although some prior research suggested that 19F chemical shifts for fluorobenzenes were 
accurately predicted at the Hartree Fock level of theory,231 we found density functional 
methods to be much more accurate over our biologically motivated training set. 19F NMR 
has been found to be more sensitive to changes in the electrostatic potential232 and it has 
been shown that including exact Hartree-Fock exchange in hybrid density functionals 
increasingly degrades the prediction of nuclear shieldings as nuclei become heavier.233 
Compared to 1H and 13C nuclei, modeling of 19F NMR chemical shifts in other systems 
has found greater errors for HF predictions than for those at the DFT or MP2 levels.232–234  
Table 6.2: Performance of 19F δ Prediction Protocols Compared to Experiment After 
Linear Regression.a  
Protocol Intercept Slope Adj. R2 
PBE0   /EPR-II -24.6 ±  5.4 0.860 ± 0.039 0.974 
PBE0   /EPR-III -9.2 ±  7.7 0.930 ± 0.057 0.954 
B3LYP/EPR-II -34.4 ±  5.4 0.809 ± 0.040 0.969 
B3LYP/EPR-III -24.3 ±  8.0 0.897 ± 0.058 0.948 
HF      /6-311++G(2d,2p) -109.7 ± 27.9 0.285 ± 0.204 0.068 
a All models employed aqueous SMD continuum solvation. 
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Figure 6.2 All molecules from the training set are shown, as well as predicted 19F δ 
from PBE0/EPR-II/SMD vs. experiment for the full training set. 
6.3.2 Cluster Radial Convergence 
Accurate modeling of the fluorine-19 isotope’s magnetic behavior requires that 
cluster models reproduce the local environment derived from the full protein. The 
fluorinated resonance of Y65 (3FY65) of the apo form of the Brd4 bromodomain (PDB 
ID: 4IOR) was selected to evaluate the convergence of predicted chemical shift with 
respect to cluster size. Residue 3FY65 serves as a sensitive test case since it is a solvent-
exposed amino acid which might be expected to sample quite different environments in 
different rotamer states (e.g., protein interior vs exterior directed fluorine). The relative 
energies and chemical shifts for each conformer are included in Table 6.3. During cluster 
generation, a radial cutoff of at least 2.75 Å is required in order to include the residue 
having a carbonyl group that can serve as a hydrogen bond acceptor for the phenol. A 
cutoff of 3.25 Å is required to encompass surrounding water molecules since hydrogen 
atoms are not used in cluster generation. After these previously absent possible phenolic 
hydrogen bond acceptors (and/or donors, although 3FY is generally a better acid than a 
base in this regard) have been included, the convergence of the predicted fluorine NMR 
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chemical shift improves. However, the relative stability of each conformer as a function 
of cluster size is not as well converged. Taking into consideration the computational 
expense of the chemical shift prediction step, clusters generated with a radial cutoff of 
greater than 4.00 Å were found to be too large to be conveniently employed in the 
chemical shift calculation step. In general, to balance computational efficiency and 
accuracy in modeling the local environment, we recommend employing a cutoff distance 
between 3.25 Å and 4.00 Å. Unless otherwise noted, results reported below are for a 
cutoff distance of 4.00 Å. 
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Table 6.3: Convergence of 3FY65 19F NMR δ (ppm) as a Function of Cutoff 
Distance.a  
   
ΔE(s-cis-
in) 
ΔE(s-
trans-ex) 
ΔE(s-cis-
ex) 
19F NMR δfit (ppm)d 
R 
(Å) 
# 
AAb 
# 
PPc 
kcal/mol kcal/mol kcal/mol 
s-
trans-
in. 
s-cis-
in 
s-
trans-
ex 
s-cis-
ex. 
δpred 
(ppm) 
2.00 2 1 -2.85 0.06 -2.65 -133.8 -153.3 -133.5 -152.2 -152.5 
2.25 2 1 -- -- -- -- -- -- -- -- 
2.50 5 1 -2.63 -2.26 -3.92 -137.0 -156.3 -136.1 -153.8 -155.0 
2.75 6 2 
0.00 -0.46 3.97 
N/A 
-130.9 
e 
-146.7 
e -149.6 -141.7 
3.00 8 3 
0.01 -1.57 6.32 
N/A 
-132.1 
e 
-136.5 
e -145.8 -136.2 
3.25 11 2 
-2.96 -4.33 -2.26 
-121.0 f 
-122.5 
e 
-129.4 
e 
-133.9 
f -129.6 
3.50 11 2 -- -- -- -- -- -- -- -- 
3.75 14 3 
-3.56 -4.97 -2.59 
-121.0 f 
-127.9 
e 
-132.4 
e 
-136.6 
f 
 -
132.1 
4.00 14 3 -- -- -- -- -- -- -- -- 
EXP -- -- -- -- -- -- -- -- -- -137.4 
a The isomeric environments are separated into interior (in.) vs exterior (ex.) and s-cis vs s-trans. Energy 
differences are reported relative to the s-trans-in conformer. b AA is the number of residues kept with side 
chains intact (does not include caps). c PP is the number of disconnected peptide chains. d δfit is the 
Boltzmann weighted 19F NMR chemical shift e Includes a hydrogen bond to the carbonyl oxygen of an 
adjacent peptide. f Includes a hydrogen bond to external water. 
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6.3.3 3-Fluorotyrosine Conformer Weights 
One challenge from a chemical modeling standpoint is the accurate sampling of 
all thermodynamically relevant conformers. For the 3FY systems considered here, there 
are nearly always four relevant conformers (Figure 6.3Error! Reference source not 
found.). These conformers account for the internal orientation of the phenol hydrogen 
relative to the fluorine, and the relative orientation of the fluorine to the protein tertiary 
structure. The number of accessible conformers can increase if additional phenol 
hydrogen-bond acceptors are present (non-hydrogen bonded conformers are generally 
much higher in energy). These different conformers expose the sensitive fluorine probes 
to different magnetic environments.  
   
Figure 6.3 Nomenclature of tyrosine conformations. 
a) s-cis vs s-trans conformers. b) s-trans 3-fluorotyrosine shown in interior (in) vs exterior 
(ex) locations for the fluorine atom.  For residues at the surface, the exterior orientation 
effectively places the fluorine into the solvent, while for more buried residues it simply 
denotes an “outward” vs and “inward” rotation. *In the case of an entirely interior 
residue, “exterior” implies the environment closest to the surface. 
 
Considering the phenol’s conformational effects on the 19F chemical shift, there 
are two key observations. In the absence of other external groups, s-cis (H,F) conformers 
are slightly lower in energy than s-trans conformers, which reflects the expected 
favorable electrostatic interaction expected in the absence of alternative hydrogen-
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bonding opportunities, e.g., with coordinating water molecules. There is a large 
difference in the chemical shifts for the two fluorine-hydrogen orientations: s-trans 
conformers have  ≈ -130 ppm, whereas the lower-energy s-cis conformers have 
 ≈ -150 ppm. A strong upfield shift is consistent with significantly higher nuclear 
shielding from a dipolar interaction with the hydroxyl group. This result is also consistent 
with computations and experimental results from Dalvit et al. who identify highly 
shielded fluorine nuclei in close proximity to hydrogen-bond donors.235 If external 
hydrogen-bond acceptors for the hydroxyl group are present, however, this disparity in 
chemical shifts is substantially reduced. These various effects are manifest in Figure 6.4 
for residue 3FY65, for which there are indeed four accessible conformers and for which 
two phenolic hydrogen-bond acceptors are observed, (1) external water, and (2) an 
interior peptide backbone carbonyl. In the case of 3FY65, as predictions converge with 
increasing cluster size, it is apparent that the most favorable conformer involves 
externally oriented fluorine, with the s-trans phenolic proton hydrogen-bonded to the 
interior peptide carbonyl. In effort to experimentally assess predicted conformer 
weighting PrOF NMR spectra of 3FY-Brd4 were acquired at 15 °C, 25 °C, and 35 °C to 
see if our model could accurately replicate the spectra at different temperatures. 
However, because the small changes in chemical shift from different temperatures (Avg. 
change = 0.13 ppm) are much lower than the current error in our method we were unable 
to draw conclusions from these experiments (Table 6.4). 
 
Table 6.4 Temperature Effect on 3FY-Brd4 19F Chemical Shifts 
Residue δ at 25 °C (ppm) Δδ at 15 °C (ppm) 
Y97  -140.1 -0.26 
Y118  -138.0 -0.11 
Y65  -137.4 -0.21 
Y98  -136.6 -0.06 
Y139  -136.6 -0.06 
Y137  -134.0 +0.05 
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Y119  -128.0 -0.16 
 
6.3.4 Accurately Modeling the Phenolic Environment 
Accurate modeling of the phenolic proton environment is a critical challenge for the 
accurate prediction of the 3FY 19F NMR, as a phenolic hydrogen-bond acceptor has a 
significant impact on the 19F chemical shift. Furthermore, inclusion of only the 
hydrogen-bond acceptor can be problematic if the acceptor itself is involved in additional 
strong interactions, e.g., a charged residue interacting with adjacent ionic residues. This 
happens in clusters where the target 3FY has a phenolic hydrogen bond to a negatively 
charged aspartate or glutamate. The anionic hydrogen-bond acceptor, in the absence of a 
positive counter-ion, over-delocalizes electronic density onto fluorine leading to an 
erroneous upfield shift. For example, a cluster of 3FY118 with a cutoff radius of 3.00 Å 
involves a hydrogen bond to a glutamate carboxylate and leads to a chemical shift 
prediction of -148.5 ppm. An increased cluster size, however, ultimately includes ion-
pairing of the glutamate’s carboxylate with the guanidinium group of arginine 113 
(Figure 6.4), and the predicted chemical shift becomes -140.8 ppm (Table 6.7), i.e., 
substantially reduced in magnitude.  
  
Figure 6.4 Brd4 (4IOR) Residue 118 with hydrogen bond to glutamate 49. 
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Note that within the right circle is glutamate 49’s counter ion, arginine 113, which is only 
included in clusters with a cut off radius larger than 3.00 Å. The right pane shows a 
slightly rotated orientation to facilitate visualization. 
6.3.5 Assessing Physical Contributions to Chemical Shifts 
While it would be difficult to partition contributions from chemically intuitive 
sources such as van der Waals forces, electrostatic charges, and hydrogen bonds from the 
19F chemical shift in the full protein environment, we have performed a series of 
calculations designed better to assess them in appropriate model systems. In particular, 
we have predicted the 19F chemical shift and fluorine Mulliken population in 
fluorobenzene as an argon atom, a sodium cation, a fluoride anion, and a water molecule 
are adjusted along the C-F axis over a range of lengths (with continuum aqueous 
solvation; Figure 6.5). These four probes interact predominantly through dispersion, 
positive charge, negative charge, and hydrogen bonding, respectively. Ar and F–- have a 
very similar effect on the chemical shift; a significant deshielding effect is predicted at 
smaller distances. The effect is as large as 21 ppm at a distance of 2.5 Å, but reduces to 2 
ppm by 3.5 Å. The behavior with respect to Ar is consistent with 1H deshielding observed 
in sterically compressed organic complexes.236 We note that Ar does not affect the 
population density on fluorine. The effect of fluoride is further discussed below. Explicit 
hydrogen bonding from a water molecule to the fluorine atom results in a smaller 
increase in deshielding, ranging from 11 ppm at 2.5 Å (O–F distance, somewhat shorter 
than expected for a typical hydrogen bond) to 0 ppm at 3.5 Å. In evaluating hydrogen 
bonding effects on the fluorine chemical shift, Dalvit and Vulpetti found that fluorines 
participating in hydrogen bonds exhibit a range of shieldings but are typically more 
shielded than those in hydrophobic environments.235 One difference in our model is that 
we have found that our models require explicit water to obtain the best match with 
experimental measurements. Although we do not observe a strong shielding effect nor a 
large accumulation charge on fluorine via water interactions, the net shielding and 
increased charge accumulation relative to fluoride or argon are consistent with the 
findings of Dalvit and Vulpetti. The sodium cation has the opposite effect on the 19F 
chemical shift, significantly shielding the fluorine atom, with the effect ranging from 18 
ppm at 2.5 Å to 2.5 ppm at 3.5 Å. These results do not show the same behavior exhibited 
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by alkali metal fluoride materials.237 Population analysis of the fluorine atom’s effective 
charge shows that the amount of electronic density localized onto the fluorine tracks with 
the trends in both fluoride and sodium. Table 6.5 shows that as the sodium cation gets 
closer, the amount of electrons on fluorine increases; the opposite trend is seen for 
fluoride. The increased (or decreased) shielding can be explained by an induced dipole 
moment on the fluorobenzene ring in response to the electrostatic charge getting closer.  
Table 6.5 Mulliken population analysis. 
Mulliken populations are taken from computations at the PBE0/SMD level of theory with 
EPR-II basis sets on C, H, F, and O atoms and def2-TZVPP on Ar and Na atoms. 
 Mulliken Population on Fluorine 
Distance Na+ Ar F- O(H2) 
2.50 -0.155 -0.166 -0.105 -0.194 
2.75 -0.133 -0.172 -0.117 -0.194 
3.00 -0.125 -0.172 -0.129 -0.186 
3.25 -0.122 -0.171 -0.139 -0.178 
3.50 -0.123 -0.1710 -0.146 -0.178 
 
 
Figure 6.5 Changes in fluorobenzene 19F NMR chemical shift (ppm) vs distances 
between the fluorine atom and various probe atoms (O for water). 
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6.3.6 19F NMR Predictions for 3-fluorotyrosine mutant BRD4 
Using a cutoff distance of 4.0 Å, we predicted the 19F NMR spectrum for the 
entire fluorinated mutant protein (Table 6.6). First we considered optimizing only each 
target residue within a rigid surrounding framework. We found this protocol to be 
sufficient for a subset of residues, namely 3FY98 and 3FY118, but not to be sufficient for 
the entire protein.  Closer examination of clusters with large discrepancies revealed that 
explicit water molecules directly interact with the 3FY phenol group in other instances. 
Even though the water positions are optimized during the classical molecular dynamics 
portion of the cluster generation protocol, the sensitivity of the 19F chemical shifts in the 
training set to local solvation led us to hypothesize that further optimization of adjacent 
water molecule positions might improve our chemical shift predictions. Data when 
nearby water molecules are included in the partial geometry optimization step are shown 
in Table 6.6. 
 
Figure 6.6 Performance of 19F δ for 3FY in Comparison to Experiment. 
Points selected are the chemicals shifts of the best fitting shift to experiment. 
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Table 6.6: NMR predictions for 3FY residues in BRD4.a  
Residues 
ΔE(s-
cis-in) 
ΔE(s-
trans-ex) 
ΔE(s-cis-
ex) 
19F NMR δfit (ppm)d EXP 
AA 
#AAb 
kcal/mol kcal/mol kcal/mol 
s-
trans-
in 
s-cis-in s-
trans-
ex 
s-cis-
ex 
δtot 
 
Y97  13 
5.10 6.69 2.32 
-
137.4 
-145.4 -126.5 -129.2 
-
137.3 
-
140.1 
Y118  12 
 -- 0.00e 4.39 
-- -- -140.8 -140.6 
-
140.8 
-
138.0 
Y65  14 
-3.56 -4.97 -2.59 
-
121.0 
-127.9 -132.4 -136.6 
-
132.1 
-
137.4 
Y98  14 
-0.13 9.52 10.15 
-
121.6 
-120.1 -121.1 -129.0 
-
120.8 
-
136.6 
Y139  10 
-9.41 -13.28 -4.43 
-
119.0 
-117.3 -143.0 -148.9 
-
142.9 
-
136.6 
Y137  11 
10.00 6.79 -3.49 
-
116.3 
-119.4 -136.7 -140.8 
-
140.7 
-
134.0 
Y119  14 
11.18 --  -0.31 
-
119.4 
-121.0 -- -122.6 
-
122.0 
-
128.0 
a Only the fluorinated tyrosine residue is optimized for these models. b The number of residues (# AA) 
describes the number of residues kept with side chains intact (does not include caps). c The number of 
disconnected peptide chains (#PP) is denoted by the number of chains. d δfit is the Boltzmann weighted 19F 
NMR chemical shift for 3-fluorotyrosine. e The isomeric environments are separated into interior (in.) vs 
exterior (ex.) and s-cis vs s-trans,energy differences are reported relative to the s-trans-in conformer except 
for 3FY118, for which no s-trans-in configuration exists, so the s-trans-ex configuration is taken as the zero 
of energy. 
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Table 6.7: Hydration effects on NMR predictions for 3FY residues in BRD4.a 
Residues 
ΔE(s-cis-
in) 
ΔE(s-
trans-ex) 
ΔE(s-cis-
ex) 
19F NMR δfit (ppm)e EXP 
AA #H2Od kcal/mol kcal/mol kcal/mol 
s-
trans-
in. 
s-cis-
in 
s-
trans-
ex 
s-cis-
ex. 
δtot 
 
Y97  3 
-2.18 -0.29 6.65 
-
137.5 
-
138.6 
-
133.7 
-
131.9 
-
138.3 
-
140.1 
Y118  1 
-- 0.00e 4.97 
-- -- 
-
137.4 
-
112.7 
-
137.4 
-
138.0 
Y65  2 
-6.32 -8.51 -2.85 
-
121.5 
-
129.7 
-
135.5 
-
136.5 
-
135.4 
-
137.4 
Y98  1 
-0.02 7.90 9.97 
-
120.4 
-
120.2 
-
120.8 
-
127.5 
-
120.4 
-
136.6 
Y139  2 
-9.31 -16.65 -5.28 
-
116.6 
-
115.3 
-
125.2 
-
137.9 
-
125.2 
-
136.6 
Y137  2 
-23.08 -28.25 -3.49 
-
114.1 
-
115.1 
-
129.6 
-
134.1 
-
129.6 
-
134.0 
Y119  1* 
11.26 -- -1.81 
-
119.4 
-
121.2 
-- 
-
124.4 
-
124.4 
-
128.0 
a Only the fluorinated tyrosine residue and water molecules are optimized for these models. b-e See 
footnotes to Table 6.6. 
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Figure 6.7 Lowest energy configurations of 3-fluorotyrosine clusters. 
3FY65 shows the s-cis-ex, 3FY97 shows the s-trans-ex, 3FY98 shows the s-trans-ex, 
3FY118 shows the s-cis-in, 3FY119 shows the s-cis-ex, 3FY137 shows the s-trans-ex, 
3FY139 shows the s-trans-ex. 
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3FY65 has two water molecules directly participating in hydrogen bonding 
interactions. We see that optimization of water has a 3 ppm shift on the low-energy s-
trans-ex conformation (-132.5 vs -135.5 ppm), and dramatically improves agreement of 
the Boltzmann weighted δtot with experiment. We also note that for the solvent-optimized 
protocol, both exterior fluorine orientations predict quite chemical shifts quite similar to 
one another (  = -135.5 and  = -136.6 ppm) and to experiment (δexp = -
137.4 ppm), while interior fluorine conformers are likely not to contribute (  = -
121.5 and  = -129.7 ppm).  
3FY97 has the strongest upfield shift measured at δexp = -140.1 ppm. We note that 
this moiety is on the exterior of the protein and has three water molecules that directly 
participate in hydrogen bonding with the phenol and fluorine. The predicted chemical 
shift for the s-cis-in conformer (Figure 6.7) has the most upfield shift we predict at  
= -138.6 ppm and matches quite closely with experimental measurements. 
3FY98 has one water molecule participating in a hydrogen bond with the phenol. 
Models for 3FY98 exhibit different behavior than experimental measurements. For a 
cutoff radius of 4.0 Å, only one water molecule is found near the residue, compared to 
the protein x-ray crystal structure where a cluster of six waters is adjacent (only one 
being < 3.5 Å away, see Figure 6.8). Given the possibility of an extended hydrogen 
bonding network, further exploration was performed on 3FY98 with additional water 
moieties. Results showed negligible change from H2O·3FY98. The phenoxide form of 
3FY would provide an insufficient shift in neutral conditions with a pKa over 8.4, which 
is not enough to account for the discrepancy in magnitude or population.238 Given that an 
extended solvation sphere does not account for the difference, we postulate that the 
discrepancy could be due to a dynamic change in configuration that is not taken into 
account by our modeling protocol. Consistent with this hypothesis, we note that the 
carbonyl backbone hydrogen acceptor K102 is very flexible, as measured by its b-factor. 
Any structural perturbations on the carbonyl backbone would not be taken into account 
by this protocol.  
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Figure 6.8 Hydration environment of Y98 in 4IOR x-ray structure of bromodomain 
Brd4. 
 
3FY118 has one water molecule directly participating in a hydrogen bond with the 
phenol. This hydrogen bond slightly reduces the upfield shift by accepting additional 
negative charge density. As the second further upfield shift measured at δexp = -138.0 
ppm, we see qualitative and quantitative agreement for the chemical shift predicted at 
 = -137.4 ppm. We note that 3FY118 does not have an “interior” fluorine 
configuration as the interior fluorine clashes directly with carboxylate side chain resulting 
in an extremely high energy configuration. 
3FY119 is measured to have the furthest downfield chemical shift, and is largely 
shielded from the protein surface by two adjacent alpha helix coils. We find 3FY119 
participates in a hydrogen bond with an adjacent carboxylate of aspartate 127. This 
carboxylate has an ion pair with arginine 122 and has one hydrogen bound water 
molecule (which does not participate in hydrogen bonding with the 3FY119). The s-cis-ex 
configuration is predicted to have a chemical shift of = -124.4 ppm, and with the 
exception of previously mentioned 3FY98, is the most downfield residue. We note that the 
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s-trans-ex configuration has no hydrogen acceptor for the phenolic proton, and with a 
low barrier for rotation of the phenol all initial guesses converge to s-cis-ex (Figure 6.7).  
3FY137 and 3FY139 are both solvent accessible residues on the exterior of the 
protein. We find that during molecular dynamic optimization, 3FY137 has one sodium ion 
and two waters directly interacting with the phenol. Given the close proximity of sodium 
to the residue, and the high mobility of sodium cations, sodium was also relaxed during 
solvent optimization. The s-cis-ex configuration is the only configuration that results in a 
chemical shift in the typical range for an external residue at -134.1 ppm as compared to -
134.0 ppm. 3FY139 has two waters and a sodium atom near the residue with water 
participating in hydrogen bonding to the phenol. Similar behavior is noted here where the 
s-cis-ex configuration predicts a chemical shift at -137.9 as compared to a measured 
chemical shift at -136.6 ppm. We note for both 3FY137 and 3FY139, DFT optimization of 
solvent waters were critical to improve the accuracy of the NMR predictions with 
changes between 6 to 10 ppm.  
The predicted most stable configurations for each residue are shown in Figure 6.7. 
If we examine this set of residues, we see that the s-trans-ex conformer is predicted to be 
the most stable conformer for all residues except 3FY97 and 3FY98, where the s-cis-in 
conformer is more stable. However, if we compare the predicted chemical shifts to their 
respective measured values, we notice that the s-cis isomers show a much smaller 
deviation than s-trans isomers for five out of seven residues. The residues where water 
does not act as the phenolic hydrogen bond acceptor (3FY97, 3FY118, 3FY119) have the 
most reliable predictions compared to measured values (MSE 2 ppm). In applying this 
protocol to future systems, we note that the assignment of new resonances can be eased 
by eliminating conformers that have predicted chemical shifts well downfield of observed 
3FY chemical shifts. Secondly, the resonances where the phenol directly interacts with a 
well conserved carboxylate residue are most reliable.  
We then examined the effect that optimizing water has on the chemical shift of 
the fluorinated tyrosine. If 3FY98 is excluded, which shows not fully understood divergent 
behavior, the protocol for the best match exclusive target residue relaxation has a mean 
unsigned deviation (MUD) from experimental data of 3.5 ppm (Table 6.8). Including 
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optimized water networks with the target residue leads to improvements in the protocol 
when the residue is directly solvated by water. When explicit water solvent is optimized, 
the MUD for the same protocol improves to 1.3 ppm. This demonstrates that explicit 
solvent optimization dramatically improves predictions of the fluorine environment in the 
bromodomain containing-proteins. Future work should likely focus further on the 
accurate prediction of relative conformer energetics as they influence averaged chemical 
shifts. 
Table 6.8 Performance of 19F δ for 3FY in Comparison to Experiment 
 
AA 97 118 65 98 139 137 119 MSE MUE 
 
δexp 
-
140.1 -138 -137.4 -136.6 -136.6 -134 -128 
All -
98 
All -
98 
Hydrated 
3FY 
δfit 
(Best) 
-
138.6 -137.4 -136.5 -127.5 -137.9 
-
134.1 -124.4     
Δδfit 1.5 0.6 0.9 9.1 -1.3 -0.1 3.6 0.9 1.3 
δfit 
(GS) 
-
138.6 -137.4 -135.5 -120.2 -125.2 
-
129.6 -124.4     
Δδfit 1.5 0.6 1.9 16.4 11.4 4.4 3.6 3.9 3.9 
δtot 
-
138.3 -137.4 -135.4 -120.4 -125.2 
-
129.6 -124.4     
Δδtot 1.8 0.6 2 16.2 11.4 4.4 3.6 4.0 4.0 
Only 
3FY 
δfit 
(Best) 
-
137.4 -140.8 -136.6 -129 -143 
-
136.7 -122.6     
Δδfit 2.7 -2.8 0.8 7.6 -6.4 -2.7 5.4 -0.5 3.5 
δfit 
(GS) 
-
137.4 -140.8 -127.9 -120.1 -143 
-
140.8 -122.6     
Δδfit 2.7 -2.8 9.5 16.5 -6.4 -6.8 5.4 0.3 5.6 
δtot 
-
137.3 -140.8 -132.1 -120.8 -142.9 
-
140.7 -122     
Δδtot 2.8 -2.8 5.3 15.8 -6.3 -6.7 6 -0.3 5.0 
 
6.4 Conclusions 
This work has taken a first step toward automated prediction of 19F NMR spectra 
for bromodomains. The machinery has been built and tested on Brd4 to take the protein 
crystal structure, extract clusters based on target residues and desired cluster sizes, and 
predict chemical shifts. We have shown that water plays a significant role in the 
prediction of the 19F chemical shifts of 3FY residues, and that models must take account 
of water’s influence on the tyrosine phenol group in order to accurately predict chemical 
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shifts. This makes 3FY much more challenging to model than 4-fluorophenylalanine 
labeled proteins, but can provide significant insight into the local structure of hydrogen 
bonding networks. Further work on accurately sampling the thermodynamically 
accessible ensemble of configurations, e.g., through sampling of molecular dynamics 
(MD) trajectories as evaluated by Lehtivarjo et al.,213 could improve this first-generation 
protocol, albeit at a considerably higher computational cost associated with performing 
MD simulations. As a reasonable first approximation to this challenge of thermodynamic 
sampling, our first generation model uses simply the four conformers associated with the 
orientation of the phenolic proton and the fluorine atom. Further consideration of more 
sophisticated techniques for ensemble averaging is warranted in future studies. Based on 
results from BRD4, this method should be able to predict accurate chemical shifts for 3-
fluorotyrosine residues where water does not directly participate as a hydrogen bonding 
partner; for microsolvated residues, further attention to alternative possibilities may be 
necessary. This protocol shows promise as a tool to facilitate assignment of challenging 
19F NMR spectra in labeled proteins. 
6.5 Future directions 
Continuation of this work will include increasing the accuracy of the predictions, as 
well as expansion to other amino acids. Initial work has been performed to predict 
the chemical shifts of 5-fluorotryptophan incorporated into Brd4 in a halgonase. 
Though convergence of the initial minimization step has proven challenging for 
Brd4, the lack of available rotomers could simplify the prediction process. 
 
 
Labeled Protein Expression: 
3FY-Brd4 was expressed based on established methods using E. coli DL39(DE3) 
+ pRARE strains. To express the labeled protein, the secondary culture in LB media was 
grown until an O.D. at 600 nm of 0.6 was reached followed by harvesting. Cells were 
resuspended in defined media of Muchmore et al.4 containing 3-fluorotyrosine (80 mg/L) 
in place of tyrosine. The resuspended E. coli were incubated at 37 °C while shaking for 
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1.5 h followed by cooling to 20 °C and media temperature equilibration for 30 min. 
Protein expression was induced with 1 mM IPTG overnight (14−16 h) at 20 °C. The cells 
were harvested and stored at −20 °C. The cell pellet was thawed at room temperature 
followed by the addition of lysis buffer (50 mM Phosphate pH 7.4, 300 mM NaCl) 
containing protease inhibitor PMSF (5 mM) as well as the Halt protease inhibitor. Cells 
were lysed by sonication and the cell lysate was centrifuged at 7500 g for 30 minutes 
followed by supernatant filtration through Whatman filter paper. Filtrate containing the 
histidine-tagged Brd4 was loaded on to a nickel-NTA affinity column and eluted with an 
imidazole gradient on an AKTA FPLC system monitoring the absorbance at 280 nm. 
Imidazole was removed from the buffer using a HiPrep column (GE) for buffer exchange 
into 50 mM Tris pH 7.5, 100 mM NaCl. Purified and buffer exchanged protein was 
treated with TEV protease at 4 °C overnight on a rotating carrousel. The cleaved His-tag, 
TEV protease and uncleaved Brd4 were removed using nickel-NTA affinity resin. 
 
1D 19F NMR Parameters: 
19F NMR spectra were acquired at 470 MHz on a Bruker 500 spectrometer with a 
5 mm Prodigy TCI Cryoprobe without proton decoupling. Samples containing 60 µM 
3FY-Brd4 in 50 mM TRIS, 100 mM NaCl, 10% D2O, pH 7.5 were used for NMR 
experiments. Measurement parameters include a relaxation delay of 0.3 s for 3FY-Brd4 
containing a 30° flip angle, an acquisition time of 0.1 s, and a spectral width of 18 ppm. 
A 20 Hz line-broadening was applied after 3000 transients. 
 
Discussion of effective dispersion and relative line width of 19F NMR spectra: 
It is worth discussing the effective dispersion associated with the experimental 
chemical shift measurements based on the line width of broad protein resonances.  The 
linewidths of 3FY-Brd4 are indeed broad and vary between 0.09 ppm and 0.14 ppm at 
half-height. The median error in the chemical shift prediction is 1.3 ppm, so differences 
due to linewidth should be a minimal source of error at this point. Despite the larger 
linewidth the chemical shift of 19F resonances is very reproducible with a standard 
deviation of 0.03 ppm or less being common.5 Based on the reproducibility in chemical 
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shifts, the average resonance line-width, and the average error in the theoretical 
measurements, as a conservative estimate we anticipate the uncertainties would be minor 
and only contribute ~11% error in the event that accurate chemical shifts were difficult to 
measure. 
 
Variable Temperature Chemical Shifts: 
To assess the effect of temperature on chemical shift, additional 19F NMR spectra 
of 3FY-Brd4 were acquired at 15 °C and 35 °C. At 35 °C we observed substantial signal 
reduction, indicating reduced stability of the protein. However, we were able to acquire 
an NMR spectrum at 15 °C. In most instances the difference in chemical shift between 15 
°C and 25 °C is less than the linewidth at half-height of the resonances. To eliminate 
variable chemical shifts from trifluoroacetate at different temperatures, the spectra 
provided for the variable temperature experiments are unreferenced.  
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